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ABSTRACT  
Methicillin-Resistant Staphylococcus aureus (MRSA) infections increase the cost and 
consequences of patient care within hospitals. Patients can be tested for MRSA using the 
Conventional Culture Method or new rapid Polymerase Chain Reaction (PCR) tests, such as 
the Xpert MRSA test. International studies have compared the costs and consequent 
management pathways for these two methods of MRSA testing. However, in the South 
African context where socio-economic status and access to healthcare may contribute 
different influences, no such models exist. Therefore, the aim of this study was to investigate 
the costs of the management pathways associated with using the current Conventional 
Culture Method for MRSA testing, to construct decision-tree-analytic models and compare 
them to the new PCR testing, in order to inform decision-making.  
 
TreeAge decision-tree-analytic models were developed to depict the current pathways, and 
associated costs, incurred by patients with a suspected MRSA infection in an orthopaedic 
and vascular ward at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in South 
Africa in 2013. These models were then compared to theoretical pathways including 
implementing the Xpert MRSA. The models were populated with input parameters from 
observations conducted in the two wards, the microbiology laboratory and the main 
dispensary, and costs were calculated using the retrospective utilization reviews formulated 
from the antibiotics administered and laboratory tests that isolated MRSA in the study 
population. Sensitivity analyses were performed to evaluate the effect of the variables on the 
models.  
 
The average total cost of antibiotics and MRSA laboratory tests utilised per patient in the 
orthopaedic and vascular wards were R3 846.82 and R2 964.39 respectively. Based on 
ethnographic observations and retrospective utilization reviews, three pathways for a patient 
with a suspected infection were identified: Empiric Antibiotics followed by Microscopy, 
Culture and Sensitivity (MCS); MCS followed by Empiric Antibiotics; Empiric Antibiotics and 
MCS concurrently. The fourth pathway included implementing the Xpert MRSA test. Analysis 
of these pathways revealed that implementation of the Xpert MRSA would be the optimal 
strategy in the orthopaedic ward, but the most expensive strategy in the vascular ward.  
 
In conclusion, these costs and pathways highlight the utilization of scarce resources. Thus, it 
is suggested that, before new methods of MRSA testing are introduced, the current practices 
and pathways for patients with a suspected MRSA infection should be further evaluated and 
improved.   
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1. INTRODUCTION  
 
1.1 Background to Research 
Hospital-Acquired Infections (HAIs) are a prevalent problem in hospitals worldwide. In South 
Africa, it is predicted that one in seven patients are at a high risk of HAIs (Brink et al., 2006). 
Infection due to MRSA is amongst the most common HAIs and ranges from an asymptomatic 
infection to one that can be fatal (Cunningham et al., 2007).   
 
HAIs increase patient mortality and morbidity as well as increase the cost of patient care, 
therefore, infection control policies are established to prevent and reduce these infections. 
However, within South African hospitals, these policies are not always strictly adhered to  
(Brink et al., 2006). Infection control policies can consist of routine contact precaution, 
isolation, decolonization, screening and surveillance (Girou et al., 1998; Rebmann et al., 
2011). Screening and testing for HAIs can be performed using various methods. 
 
The Conventional Culture Method is commonly used when an MRSA infection is suspected. 
However, in using this method, it can take between one and five days to confirm an MRSA 
infection. The range in waiting time is due to the required methodology of the Conventional 
Culture Method, in which microscopy is first performed to identify Gram-positive cocci, 
followed by incubation for 24 and 48 hours and thereafter, further incubation and antibiotic 
sensitivity tests (Huletsky et al., 2004; Brown et al., 2010). It is general practice to administer 
empiric antibiotics whilst Healthcare Professionals (HCP) are waiting for the patient’s test 
results. These are broad-spectrum antibiotics with the aim of targeting the most probable 
organisms causing the infection. Empiric antibiotics are often expensive and may lead to 
unnecessary antibiotic usage, which could then lead to further antibiotic resistance. Only 
once the test results are available can the HCP change the antibiotics to a narrow spectrum 
and targeted treatment, thus the prolonged waiting period for the test results causes a delay 
in optimum targeted patient therapy (Cunningham et al., 2007; Kluytmans, 2007).  
 
Although the Conventional Culture Method has been routinely used to identify suspected 
infections, alternative methods are being investigated due to having to wait for up to five days 
before the patient's confirmed tests results are available. One of the novel methods under 
consideration to identify MRSA is to use real-time PCR testing. These tests are becoming 
more favoured as the laboratory testing process is less labour-intensive and MRSA test 
results are available within two hours (Kluytmans, 2007). The tests therefore eliminate the 
need for empiric antibiotics and targeted therapy can be initiated sooner to eradicate the 
patient’s infection, thereby reducing further transmission of MRSA and ultimately decreasing 
morbidity and mortality due to MRSA (Wolk et al., 2009).  
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Despite the numerous benefits of the novel PCR testing for MRSA, cost is a disadvantage of 
the PCR tests, as this method is more expensive than the Conventional Culture Method. 
International studies comparing the costs of using the Conventional Culture Method to the 
PCR testing methods have demonstrated that the rapid PCR tests may be more cost-saving 
due to the benefits of the rapid release of PCR test results  (French, 2009; Li et al., 2012). 
Cost studies comparing the cost and treatment outcomes from the use of Conventional 
Culture Method to PCR tests for MRSA resistance have not yet been conducted in South 
Africa. The outcomes of such studies could greatly assist in decision-making when updating 
infection control policies to implement new screening or diagnostic methods that would be 
beneficial to both patients and healthcare institutions. 
 
There are published guidelines for the treatment of patients with MRSA in South African 
public sector hospitals (Department of Health, 2012). However, no detailed evidence could 
be found regarding the actual clinical management pathways, and associated costs, that 
follow in daily practice for these patients. Thus, to inform the decision-tree-analytic models, 
this study includes conducting observations to document the current clinical management of 
MRSA at a public hospital in South Africa.  
 
Decision-analytic modelling is a useful tool for assessing alternatives and therefore economic 
evaluations using decision-analytic modelling are becoming increasingly popular to inform 
decision-making in healthcare. Studies have developed decision-analytic models to compare 
the costs and management pathways that follow when using the Conventional Culture 
Method versus PCR testing for MRSA (Li et al., 2012; Tübbicke et al., 2012a).  
 
However, a search of the literature shows that, such decision-tree-analytic models have not 
yet been built for the South African healthcare context. It is important that these models are 
developed in relation to healthcare in South Africa as the country’s socio-economic status 
and access to healthcare may contribute different influences as compared with other 
countries (Ataguba et al., 2011).   
  
Therefore, there is a need for research to be conducted in the South African healthcare 
context to build decision-tree-analytic models comparing the costs and management 
pathways that follow depending on whether the Conventional Culture Method or PCR tests 
are used for MRSA to inform future decision-making. This research aims to create such 
models for use in varying healthcare situations in order to compare alternatives to aid in 
decision-making in any public hospital in South Africa.  
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1.2 Aim 
The aim of this study was to investigate the management pathways and associated costs of 
using the current Conventional Culture Method for MRSA testing, to construct decision-tree-
analytic models and compare them to the new PCR testing, in order to inform future 
decision-making. 
 
1.3 Objectives  
1. To conduct observations in selected hospital wards in order to document the clinical 
practices of HCPs regarding the current management of patients with suspected MRSA 
infection; to identify the current methods used to detect MRSA at the microbiology 
laboratory; and to document the process of dispensing antibiotics to inpatients at the 
antibiotics designated area of the main CMJAH dispensary.        
 
2. To carry out a retrospective utilization review of the different antibiotic regimes 
administered and laboratory tests conducted that isolated MRSA in the study population. 
 
3. To perform a cost analysis, using the utilization and costing data obtained, to determine 
the costs associated with the antibiotics administered and laboratory tests conducted that 
isolated MRSA in the study population.  
 
4. To develop decision-tree-analytic models to compare the current costs and management 
pathways associated with the Conventional Culture Method versus a theoretical scenario 
arising if the PCR tests for MRSA were to be implemented at CMJAH.  
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2. LITERATURE REVIEW  
 
2.1 Hospital-Acquired Infections 
2.1.1 Overview of Hospital-Acquired Infections  
Globally developing and developed countries are affected by HAIs. It is predicted that within 
South African hospitals, one in seven patients are at a high risk of HAIs (Brink et al., 2006). 
HAIs are not only a common occurrence but also a critical problem as they are a major 
cause of death, increased morbidity and additional costs within hospitals (Calfee, 2012; Kelly 
et al., 2012).   
 
HAIs, also known as nosocomial infections, are defined as, “An infection acquired in hospital 
by a patient who was admitted for a reason other than that infection”. If the infection was not 
incubating or present when the patient was admitted to hospital but develops 48 hours 
thereafter, it is classified as an HAI. Infections that occur within four weeks after hospital 
discharge are also termed HAIs. HAIs may also include visitors or hospital personnel that 
acquire infections (World Health Organization, 2002). 
 
2.1.2 Types of Hospital-Acquired Infections   
HAIs can be identified using definitions formulated from biological and clinical measures for 
specific infection sites. There are around 50 possible sites of infection, the most common of 
which are the urinary tract, respiratory tract, skin and soft tissue as well as surgical sites. 
There are also different routes of transmission for micro-organisms that cause infection in 
hospitalised patients. Bacteria can be transmitted by direct contact between patients and 
HCPs or by indirect contact from objects contaminated with micro-organisms, as well as via 
droplet or airborne spread. HAIs may also be caused by a disruption in the patient’s own 
flora or by bacterial resistance that develops due to commonly used antibiotics (World Health 
Organization, 2002; Brink et al., 2006).    
 
HAIs may be caused by various pathogens. Depending on the country, hospital environment, 
patient population and other factors, the type and frequency of pathogens may differ. 
However, most HAIs are caused by bacteria, such as Staphylococcus aureus, 
Enterobacteriaceae and Pseudomonas species. Data reported to the National Healthcare 
Safety Network between 2009 and 2010 regarding antimicrobial resistant pathogens 
accountable for HAIs revealed that of all the pathogens reported, 16% of the pathogens were 
due to Staphylococcus aureus, 14% due to Enterococcus species, 12% due to Escherichia 
coli, 11% due to coagulase-negative staphylococci, 9% due to Candida species, 8% due to 
Pseudomonas aeruginosa and 5% due to Enterobacter species. These HAIs include 
ventilator-associated pneumonia, catheter-associated urinary tract infections, surgical site 
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infections and central line–associated bloodstream infections. Amongst the reported 
pathogens responsible for all the HAIs, approximately 20% of the pathogens were multidrug-
resistant phenotypes and as such, MRSA accounted for 8.5%, vancomycin-resistant 
Enterococcus accounted for 3%, Escherichia coli, Enterobacter species and carbapenem-
resistant Pseudomonas aeruginosa each accounted for 2%. This was the second 
antimicrobial susceptibility report of data from the National Healthcare Safety Network and 
when comparing the resistance data of the first and second reports, the findings stated 
above were similar (Sievert et al., 2013).  
 
2.1.3 Factors that Promote Infection in Hospitalised Patients   
Patients staying in hospitals are vulnerable to acquiring infections. Factors that predispose 
these patients to infection include having a weakened immune system; undergoing medical 
procedures and the insertion of invasive medical devices; having open wounds; receiving 
glucocorticosteroid and antibiotic medication; and non-adherence to infection control policies 
(Yamakawa et al., 2011). Studies have established that within hospitals, the Intensive Care 
Unit (ICU), acute surgical and orthopaedic wards have the highest prevalence of HAIs (World 
Health Organization, 2002). 
 
2.1.4 Impact of Hospital-Acquired Infections 
HAIs hinder the patient, the hospital and the economy as these infections unnecessarily 
increase the morbidity and mortality rate and add to the cost of patient care within hospitals. 
Patients that are affected with HAIs are at a higher risk of medical complications and co-
morbidities that may last throughout their life (World Health Organization, 2002).  
 
A common consequence of HAIs is increased length of patient stay in hospital. Studies 
conducted show various results for prolonged length of stay due to different methods used to 
calculate these values as well as the type of HAIs and wards that were included in the study. 
One study found that increased length of stay and costs due to HAIs in patients with lower 
respiratory tract infections was 2.58 extra days in hospital, whereas a patient with a urinary 
tract infection would not have any additional days in hospital (Graves et al., 2007). This 
contrasts with a study conducted by Schulgen and co-authors, which used different 
approaches that reflected an increased length of stay due to HAIs, as the estimated number 
of extra days for patients with post-operative wound infection was 21, 11 and 10 to 12 days, 
and for patients with nosocomial pneumonia length of stay was 14, 8 and 3 to 4 extra days. 
The variation in the numbers reported is due to the different methods used to calculate the 
extra number of days spent in hospital due to HAIs (Schulgen et al., 2000). 
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Additional number of days spent in hospital due to HAIs greatly increases the cost of patient 
care. Other costs that are associated with HAIs are increased labour costs, administration of 
additional medication, further laboratory tests and extra infection control precautionary 
measures required. In a study that estimated the increase in healthcare costs due hospital-
acquired bloodstream infections, the additional costs attributable were: increased length of 
stay (58% of total costs); antibiotics and other pharmaceutical products (each 10% of total 
cost); billed medical procedures (15% of total cost); and laboratory tests (2.4% of total cost) 
(Vrijens et al., 2010). Another study reported that the costs for patients with HAIs are up to 
two and a half times higher than the costs for patients without HAIs (Glance et al., 2011). 
Thus it can be seen that these preventable HAIs unnecessarily use up scarce resources that 
are allocated to hospitals.  
 
This study focuses on MRSA, which is a bacterial pathogen that is resistant to commonly 
used antibiotics.   
 
2.2 Methicillin-Resistant Staphylococcus aureus  
2.2.1 Overview of MRSA 
Staphylococcus aureus is a Gram-positive facultative anaerobic bacterium. In humans it can 
be found in normal bacterial flora or it can present as pathogenic which causes infections. In 
the late 1950s, methicillin was developed and was used to treat Staphylococcus aureus. 
However, shortly thereafter in 1960, methicillin resistance emerged (Kelly et al., 2012). 
MRSA is a strain of Staphylococcus aureus which is resistant to commonly used beta-lactam 
antibiotics including methicillin, oxacillin, amoxicillin and penicillin (Gorwitz et al., 2008). 
MRSA is a leading cause of many HAIs but is also present in the community and amongst 
people with no known risk factors. However, this study focuses only on Hospital-Acquired 
MRSA.  
 
A literature review by Tübbicke and co-authors (2012b) provides an overview of the key 
factors that need to be taken into account when considering the burden and cost of MRSA as 
well as when deciding on which MRSA screening method to implement. These key factors 
include the prevalence and transmission rate of MRSA; the costs of each case of MRSA; and 
the performance characteristics, turn-around-time and cost of the various methods of 
screening for MRSA. Therefore, MRSA infections are a complex challenge within hospitals 
(Tübbicke et al., 2012b). 
 
2.2.2 Prevalence of MRSA  
The prevalence of Methicillin-Resistance amongst Staphylococcus aureus clinical isolates in 
Africa was evaluated in a literature review published in 2013. The data extracted in this 
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review indicates that from 2006 to 2011, the prevalence of MRSA among Staphylococcus 
aureus isolates decreased from 36% to 24% in South Africa. This is in contrast to data 
extracted for many other countries in Africa where the prevalence of MRSA seems to have 
increased since 2000 (Falagas et al., 2013). It is important to note that in these studies the 
rate of MRSA is expressed as the percentage of MRSA amongst Staphylococcus aureus 
isolates only and not as a percentage of all isolates obtained in that period.  
 
A retrospective study looking at patients with Staphylococcus aureus bacteraemia at Chris 
Hani Baragwanath Academic Hospital and at CMJAH between November 1999 and October 
2002 reported that the prevalence of MRSA was 23.4% (105 of 449 patients with 
Staphylococcus aureus bacteraemia) and that within a period of fourteen days there was a 
mortality rate of 33.3% in these patients suffering with MRSA bacteraemia (Perovic et al., 
2006).  
 
In comparison, a 26.9% MRSA rate was measured in a retrospective study carried out at 14 
provincial hospitals in KwaZulu-Natal from March to August 2001 and from October 2002 to 
August 2003. This study analysed 227 Staphylococcus aureus isolates and 61 of them were 
found to be resistant to oxacillin, methicillin and cefoxitin. It was also reported that resistance 
to six antibiotics classes was present amongst more than 40% of the MRSA isolates and 
resistance to a minimum of four antibiotic classes was identified in more than 80% of the 
MRSA isolates (Shittu et al., 2006).  
 
Furthermore, a 36% MRSA national incidence rate was revealed in a study investigating the 
antimicrobial susceptibility profiles of Staphylococcus aureus and other bacteraemic 
pathogens in South African private hospitals. This study used blood cultures isolated from 
patients in private hospitals in Johannesburg, Pretoria, Durban, Cape Town and 
Bloemfontein. Twelve laboratories were used to perform the antimicrobial susceptibility tests 
during the first six months of 2006. From the total of 25 524 blood culture isolates tested, 629 
were Staphylococcus aureus isolates and the average prevalence of oxacillin resistance was 
36%. This study also demonstrates that the demographic distribution of MRSA fluctuates 
from 29% to 46% within different private hospitals in South Africa (Brink et al., 2007).  
 
Currently, the latest available published data shows a 24% MRSA rate amongst 
Staphylococcus aureus isolates. This was found in a study conducted to determine the 
genetic basis of rifampicin resistance amongst isolates of MRSA in Cape Town hospitals. 
From July 2007 to June 2011, 13 746 Staphylococcus aureus isolates were obtained from 
the Groote Schuur Hospital NHLS Laboratory. Antimicrobial susceptibility tests were then 
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conducted and 3 298 (24%) of these isolates were found to be MRSA (Jansen van Rensburg 
et al., 2012).  
 
The different studies also used varying methods of identifying the isolates and in some cases 
the isolates were collected from private institutions as well. The methodology used in the 
studies needs to be taken into account in order to understand the implications of the 
percentage of MRSA expressed. However, despite the differences in the above studies, an 
overall decrease in the prevalence of MRSA in South Africa can be seen (33.3% in 1999; 
24% in 2011). Nonetheless, it is still important to research new methods of MRSA testing to 
further decrease this prevalence as well as to decrease the cost, mortality and morbidity 
currently associated with MRSA.  
 
2.2.3 Clinical Manifestation of MRSA 
It is important to be familiar with the manner in which MRSA presents clinically in order to 
recognise a suspected MRSA infection based on the signs and symptoms of a patient. Once 
MRSA is suspected, a series of steps need to be taken.   
 
Unlike some HAIs, infections due to MRSA do not present clinically with clear defining 
characteristics. HA-MRSA can cause bacteraemia, urinary tract infections, gastroenteritis, 
endocarditis, pneumonia, osteomyelitis and skin infections such as abscess, necrotising 
fasciitis, cellulitis and surgical site infections. The type of infection caused by HA-MRSA is 
influenced by the site of inoculation, toxins produced and virulence factors.  Although MRSA 
infections are not defined by specific clinical features, there are certain risk factors that can 
assist when suspecting an MRSA infection. Risk factors include length of stay in hospital, 
being immunocompromised, previous infections, surgery and insertion of medical devices 
(Naimi et al., 2003; Kelly et al., 2012).  
 
To further guide the diagnosis of MRSA, the patient’s history, antibiotic prescriptions and 
surgical procedures should be considered as well as local epidemiological trends should be 
taken into account. As infections due to MRSA cannot easily be diagnosed by clinical 
manifestations, laboratory diagnostic tests have to be done to confirm MRSA infections. 
Once an infection due to MRSA is suspected, samples from the patient need to be sent to 
the microbiology laboratory for investigation, empiric antibiotics are initiated and increased 
contact precaution measures should be implemented to prevent contamination and 
transmission of MRSA to other patients in the ward as well as to HCPs and visitors 
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2.2.4 Transmission and Colonization of MRSA 
HA-MRSA can be transmitted in the same manner in which other HAIs are transmitted, such 
as through droplet spread, contaminated objects and infected patients. Additionally, 
Staphylococcus aureus is a colonizer of various sites in humans, the nose being the most 
common, as 20% to 30% of the general population are nasal carriers of Staphylococcus 
aureus. Medical procedures often disturb patients’ natural barriers and thus may lead to 
infection. Therefore, there is controversy over whether eradication of Staphylococcus aureus 
in carriers decreases the risk of pathogenic infection due to Staphylococcus aureus and 
whether there is an increased risk of infection due to Staphylococcus aureus in patients that 
are nasal carriers of Staphylococcus aureus (Wertheim et al., 2005).  
 
As most carriers of Staphylococcus aureus present asymptomatically and have an increased 
risk of acquiring an infection while in hospital, many infection control programmes include 
nasal surveillance of Staphylococcus aureus upon hospital admission and decolonization 
with a topical antibiotic (Nelson et al., 2010).  
 
2.3 Preventing and Managing MRSA  
2.3.1 Infection Control 
Due to the nature and consequences of infection with MRSA, healthcare institutions try to 
prevent the emergence and subsequent spread of this pathogen along with many other 
nosocomial pathogens by devising and implementing strategies commonly referred to as 
Infection Control Policies. Infection control policies consist of various mandatory protocols for 
HCPs to act in a certain manner when performing their routine tasks. The contents and 
inclusion of protocols differs between various areas of the hospital as well as between 
different healthcare institutions. Common infection control practices are: routine contact 
precaution or barrier nursing such as hand hygiene practices; decontamination of equipment 
and surroundings; pre-emptive isolation of suspected MRSA-infected patients and isolation 
of MRSA-positive patients; decolonization of patients; and surveillance including screening of 
patients for MRSA (Girou et al., 1998; Rebmann et al., 2011). 
 
Within healthcare institutions, MRSA infection control policies can be divided into two broad 
strategies: surveillance and contact precaution measures. Each strategy consists of many 
programmes which may be used and the types of programmes chosen vary widely between 
institutions. Various studies have been conducted to evaluate the effectiveness of these 
programmes within hospitals in an attempt to formulate optimal guidelines to implement. The 
alternative programmes in each strategy are explained below. 
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Surveillance can take place in the form of universal surveillance or targeted surveillance. The 
classification and definitions of the types of surveillance vary. Universal surveillance is when 
all patients admitted to a hospital are screened for all types of pathogens, whereas targeted 
surveillance is restricted to screening only those patients that are seen as high risk patients, 
or to certain areas of the hospital (Tübbicke et al., 2012a). Targeted surveillance, also known 
as active surveillance, can include screening all patients when they are admitted to hospital, 
but it is screening for a specific pathogen such as MRSA only. Specimens collected based 
on patient’s presenting with signs and symptoms of infection are part of passive or clinical 
surveillance (Rebmann et al., 2011; Edmond et al., 2013). Certain hospitals focus on 
selective screening of MRSA nasal carriers on admission as they are at risk of developing 
into subsequent infections (Girou et al., 1998). In large hospitals and when resources are 
limited it is not feasible to screen all patients that are admitted, therefore it is important to be 
able to identify the risk factors in patients and high risk areas within the hospital. 
 
Contact precaution measures need to be initiated for patients that have been identified as 
MRSA-positive or are suspected to be infected with MRSA, in order to prevent the 
transmission of the pathogen. The World Health Organization (WHO) has formulated a list of 
precautions that should be implemented to prevent the spread of MRSA and certain 
countries have developed their own infection control organizations which have produced 
specific guidelines for their hospitals to follow. However, most of the guidelines include the 
following steps: early detection of infection; isolating infected or colonised patients either in 
an isolation ward or pre-emptive isolation of patients with suspected MRSA infection; 
decreased ward transfers and vigilance of patients from other hospitals; skin decolonization 
using chlorhexidine or mupirocin for nasal carriers; hand hygiene campaigns and using an 
alcohol-based disinfectant frequently; barrier precaution of wearing gloves, masks and 
aprons when interacting with MRSA infected patients or equipment; decontamination of 
medical devices and the environment as well as proper disposal of medical waste. (World 
Health Organization, 2002; Huang et al., 2006; Rebmann et al., 2011; Moody et al., 2013).. 
 
It is evident that there are numerous methods available to prevent the transmission of MRSA. 
Unfortunately, these policies are not always strictly adhered to and are practised to a variable 
extent amongst different hospitals and HCPs. Therefore, it is important to evaluate these 
policies and understand why certain of them are not carried out correctly in order to enhance 
the current policies and develop novel methods within these policies (Moody et al., 2013). In 
order to develop successful MRSA infection control policy, all members in the healthcare 
institution need to be incorporated and support from hospital management is essential 
(Rebmann et al., 2011). When deciding which programmes would be most suitable to 
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implement in a healthcare institution, various factors need to be taken into account: cost and 
access to resources are commonly an important consideration. 
 
2.3.2 Infection Control in South Africa  
Around the world, countries are developing, improving and implementing infection control 
policies to reduce the number of infections within healthcare institutions due to the negative 
impact of these infections. The Department of Health in South Africa developed The National 
Infection Prevention and Control Policy and Strategy 2007, in order to support the WHO 
Global Patient Safety drive. The purpose stated in this policy is, “to set minimum national 
standards for the effective prevention and management of health care associated infections”. 
This document outlines the roles and responsibilities of the various HCPs in healthcare 
institutions, provides a summary of the areas identified for improvement and includes other 
factors that need to be considered when developing a successful infection prevention and 
control policy (Department of Health, 2007).  
 
Although infection control policies are available globally, the South African public healthcare 
system faces numerous challenges such as: infection control policies are not well 
established and are practised inconsistently within different institutions; data is often under-
reported or not reported from all hospitals and laboratories; and standardised surveillance 
systems are not implemented in the majority of these institutions. Currently, inadequate 
infection control practices are also due to medical equipment not being disinfected correctly, 
transfer of colonised or infected patients between hospitals, overcrowding in healthcare 
facilities and administering parenteral fluids that are contaminated. Additional problems are 
staff shortages and overworked staff for the large amount of patients, inadequate training 
and supervision of staff and limited numbers of correctly qualified infection control 
practitioners (Dusé, 2005). It is important that effective infection control policies, surveillance 
systems and infection prevention and control training programmes are enforced in all South 
African healthcare institutions. Therefore, in 2005, The Guideline for the Management of 
Nosocomial Infections in South Africa was published, outlining the management of common 
nosocomial infections by providing their definition, microbiology, diagnosis, management, 
duration of treatment and prevention, as it aims to “provide recommendations for the initial 
choice of antimicrobial agents and the appropriate management of these infections” (Brink et 
al., 2006).    
 
2.3.3 Antibiotic Treatment Pathways 
Within South African public hospitals and clinics, The Standard Treatment Guidelines (STG) 
and Essential Medicines List are commonly used as a reference amongst HCPs when 
prescribing and administering medication. According to this guideline intravenous (IV) 
 12 
 
vancomycin at a dose of 20 mg/kg every 12 hours is administered to patients with MRSA 
infection. It is also recommended that after the third dose of vancomycin the patient’s trough 
levels should be monitored and the dose must then be adjusted accordingly to ensure that 
the trough level stays between 15–20 micromol/L (Department of Health, 2012).  
 
Although vancomycin can be seen as the current “gold standard” for the treatment of MRSA 
infections, alternative antimicrobials such as linezolid, trimethoprim-sulphamethoxazole, 
clindamycin, daptomycin, quinupristin/dalfopristin and tigecycline as well as novel agents 
may be considered for the treatment of MRSA infections due to the emergence and rise of 
vancomycin-resistant Staphylococcus aureus (Micek, 2007; Wasserman et al., 2011). It is 
therefore imperative that antibiotic programmes are executed in hospitals to decrease and 
prevent further antibiotic resistance.  
 
In an attempt to standardise, monitor and compare the utilization of medication, including 
antibiotics, the WHO has formulated the Anatomical Therapeutic Chemical (ATC)/Defined 
Daily Dose (DDD) system. The DDD is the “assumed average maintenance dose per day for 
a drug used for its main indication in adults” and is used as an international measurement 
unit for drug utilization research (World Health Organization Collaborating Centre for Drug 
Statistics Methodology, 2012). Due to the contribution of incorrect antibiotic use to increasing 
antibiotic resistance, studies have used the DDD to measure and compare antibiotic 
consumption in hospitals (Muller et al., 2006; Gagliotti et al., 2014).  
 
Antibiotics are commonly prescribed and administered inappropriately. Therefore, to further 
guide HCPs when prescribing and administering antibiotics, Antibiotic Stewardship 
programmes are devised and implemented in healthcare institutions to promote and ensure 
the proper use of antibiotics to try to decrease and prevent further resistance. South African 
Antibiotic Stewardship programmes include the MCC Conference on Antimicrobial 
Resistance, Global Antibiotic Resistance Partnership South Africa, South African Antibiotic 
Stewardship Programme (SAASP) and the Best Care…Always! Campaign (Dusé, 2005; 
Dusé, 2011). Recently, the South African Antimicrobial Resistance National Strategy 
Framework 2014-2024 was developed by the National Department of Health with aid of the 
SAASP and WHO. This framework consists of three pillars which are: Antimicrobial 
Stewardship; Antimicrobial Surveillance; Infection Prevention and Control. This framework 
also encourages research in diagnostic and therapeutic agents within South Africa 
(Mendelson et al., 2015).    
 
When managing a patient with an MRSA infection or suspected infection, various factors 
should be considered before simply prescribing the first line standard treatment available. 
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These factors include the source of the patient’s infection, for example, if it is a deep wound 
infection then antibiotics and a drainage system may be required. The results of the 
microbiology laboratory diagnostic tests are another factor that should be used to guide the 
choice of antibiotic treatment for the individual patient (Wasserman et al., 2011). However, 
while HCPs are waiting for these results from a patient suspected to be infected with MRSA, 
a common strategy is to administer empiric treatment to the patient. Empiric treatment 
includes administering a broad-spectrum antibiotic which would act against the most 
probable causes of infection. While this may seem effective, empiric antibiotics are usually 
expensive and may result in unnecessary use of antibiotics which could lead to further 
organism resistance (Cunningham et al., 2007; Kluytmans, 2007). Therefore, novel rapid 
ways of testing for MRSA are being investigated to decrease the problems encountered 
while waiting for current the microbiology diagnostic tests used.     
 
2.4 Laboratory Tests for MRSA   
2.4.1 Screening versus Diagnostic  
Methods for detecting MRSA and other pathogens can be used for screening as part of a 
surveillance programme or as diagnostic tests to guide a patient’s clinical diagnosis. Within a 
surveillance programme there are various forms of screening that can be performed, such as 
active screening (Muto et al., 2003), universal screening, routine screening (Huang et al., 
2006), selective screening (Girou et al., 1998) or a combination of these and other screening 
methods. Globally, many healthcare institutions screen their patients on admission to detect 
carriers for MRSA and/or other pathogens, as these carriers are at potential risk of 
developing and spreading infections. Therefore, this strategy is to rapidly identify carriers so 
that they can be decolonised and appropriate contact precaution can be implemented (Davis 
et al., 2004). Currently, there is much controversy regarding the effectiveness of such 
screening programmes (McGinigle et al., 2008; Edmond et al., 2013; Glick et al., 2014).  
However, not all healthcare institutions screen their patients on admission due to various 
reasons such as cost, limited resources and insufficient staff. These healthcare institutions 
would then only conduct diagnostic tests when a specific patient presents with clinical signs 
and symptoms of a suspected infection (Harbarth et al., 2011).  
 
There are various methods available to detect for MRSA and the same methods can be used 
for either screening or diagnostic tests. This study focuses on the Conventional Culture 
Method and the new PCR testing for MRSA infections.  
 
2.4.2 Conventional Culture Method 
Although the Conventional Culture Method is most commonly used to detect MRSA in 
patients, it takes a period of between one to five days before the results reflecting a patient’s 
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MRSA status are available. Even though this method is quite sensitive for detecting MRSA, 
the prolonged waiting time is problematic in many aspects. While waiting for the laboratory 
results from the Conventional Culture tests, empiric antibiotics are often prescribed and 
administered to patients with a suspected infection. The use of these empiric antibiotics 
needs to be investigated and strictly controlled as their misuse may lead to additional 
resistance, increased costs and unnecessary use of limited resources. The waiting period 
also delays the initiation of optimum targeted therapy for patients. Another problem that 
occurs while waiting for the culture results is that in settings where all suspected patients are 
isolated there is lengthy unnecessary isolation of patients, as only about 5% of these patients 
would actually be carriers of MRSA. In settings where patients are isolated only after culture 
results are available, there is an increased risk of transmission of MRSA as the MRSA 
infected patient would be amongst other patients during the waiting period (Cunningham et 
al., 2007; Kluytmans, 2007).   
 
The detection of organisms using the culture method in microbiology laboratories is a 
complex process that requires numerous equipment and sequential steps to be followed. 
Various studies have been conducted using alternative equipment and variations of the steps 
in the methodology in an attempt to increase the sensitivity and specificity of the tests as well 
as to decrease the turn-around-time for the culture results. Some studies have developed 
and used numerous types of different agar or media and are then compared with the results 
to determine which agar or media produced the best results (Malhotra-Kumar et al., 2010). It 
has also been shown that variations in the incubation time affect the results of the culture 
tests (van Hal et al., 2007). Alternative studies have compared different types of nasal swabs 
and how they respond to the various agars and incubation techniques to deduce the best 
combination (Safdar et al., 2003). The standard culture method used in certain laboratories is 
to plate directly on the agar media, while in other laboratories broth enrichment occurs before 
plating (Nonhoff et al., 2009; Harbarth et al., 2011; Marlowe et al., 2011). 
 
Thus the standard laboratory methods used for the detection of organisms by culture differ 
between laboratories and institutions. In South Africa, the NHLS is the public diagnostic 
pathology laboratory that provides services for more than 80% of the population (Bekker et 
al., 2014). The NHLS is a member of the Clinical Laboratory Standards Institute which has 
standard guidelines that should be followed when conducting laboratory tests. 
 
2.4.3 PCR Testing Method   
Due to the consequences of waiting for up to five days for the results of the Conventional 
Culture method, new rapid molecular nucleic acid methods for MRSA screening are being 
investigated. Real-time PCR testing for MRSA has emerged and is becoming popular as it 
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produces the patient’s MRSA results within two hours (Kluytmans, 2007). The rapid release 
of results from PCR testing leads to numerous benefits. For example, as the patient’s MRSA 
status will be available in less than two hours, the need for empiric treatment is eliminated 
and HCPs can immediately administer optimal targeted treatment that aids in the recovery of 
the patient and decreases the MRSA transmission, thereby decreasing the morbidity and 
mortality due to MRSA (Wolk et al., 2009). Rapid PCR testing may also reduce unnecessary 
and costly pre-emptive isolation and allows for prompt isolation and effective decolonization 
for known MRSA infected patients (Cunningham et al., 2007). 
 
In addition to the mentioned benefits associated with the PCR tests ability to rapidly release 
the patients' results, the PCR tests are simpler to use and require less hands-on time as 
compared to the Conventional Culture Method. Certain PCR systems can also be installed 
directly in the hospital wards. This allows for the PCR tests to be conducted and the results 
made available directly in the ward, thus decreasing the time delay normally caused by 
transportation of specimens to the microbiology laboratory and communication between the 
laboratory and the ward, therefore enabling faster access to MRSA results (Brenwald et al., 
2010).  
 
When comparing the cost of the Conventional Culture Method and the new rapid PCR tests, 
the PCR tests are more expensive. However, international studies have shown that despite 
the higher cost, the rapid PCR tests may be cost-saving as the test results are available 
within two hours, which leads to a reduction in empiric antibiotic treatment cost, a decrease 
in isolation cost, a decline in further MRSA transmission and severity of infections, as well as 
an increase in targeted optimal healthcare (French, 2009; Li et al., 2012). The results 
obtained from these studies can positively influence hospital management decisions to 
implement the method that would be most beneficial to both the patients and the institution.  
  
Studies comparing the cost and treatment outcomes from the use of Conventional Culture 
Method versus PCR tests for MRSA have not yet been conducted in South Africa. The 
outcomes of such a study would assist hospitals in South Africa to make decisions on 
managing MRSA infections, particularly in environments where reducing costs are important 
due to limited finances.   
 
There are various types of PCR tests for identifying MRSA that are being created and 
compared. The Xpert MRSA system from Cepheid, the LightCycler MRSA from Roche. and 
the BD GeneOhm from BD Diagnostics are examples of PCR tests that are approved by the 
FDA (Marlowe et al., 2011). This study focuses on Cepheid’s PCR tests for MRSA. Cepheid 
is a manufacturing company that has developed and markets novel PCR tests to screen for 
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Staphylococcus aureus and MRSA in approximately an hour from nasal swabs, blood culture 
or skin and soft tissue infections using the Cepheid Xpert MRSA, Xpert SA Nasal Complete, 
Xpert MRSA/SA BC or the Xpert MRSA/SA SSTI assay performed in the GeneXpert System.  
 
2.5 Ethnography in Healthcare 
Before a new method is implemented in a hospital, such as the Xpert MRSA testing method 
for MRSA, it is important to understand and evaluate the current methods and practices that 
are performed in the hospital setting. One of the manners in which to gain an overview of a 
healthcare system is to conduct research using both quantitative and qualitative approaches. 
Ethnography is a qualitative research method which can be defined as, “the study of social 
interactions, behaviours, and perceptions that occur within groups, teams, organisations, and 
communities” (Reeves et al., 2008). This definition lends itself well to a hospital setting as 
HCPs interact with patients and other HCPS, have their own perceptions and practices as 
well as work with other HCPs as team within the hospital to provide healthcare services to 
patients.  
 
Therefore, healthcare studies have been conducted which used ethnography to obtain 
information (Dixon-Woods et al., 2009).  A recent study used video-reflex ethnography in two 
wards within a hospital to make HCPs aware of their current infection control practices in 
order to identify risk areas and suggest methods of improvement to decrease HAIs (Iedema 
et al., 2015). Another study used meta-ethnography to analyse HCPs perspectives and 
practices of antibiotic prescribing in acute respiratory tract infections to determine the 
reasons that influence interventions to be successful or not (Tonkin-Crine et al., 2011).  
 
A key feature of ethnography is that it includes conducting observations in the natural setting 
that it being studied to achieve an understanding of the current setting and interactions that 
are generally not easily identified (Reeves et al., 2008). Ethnography is also used to gain an 
understanding of the healthcare system, HCPs and patients to assist decision-makers 
(Goodson et al., 2011).  
 
2.6 South African Healthcare System  
2.6.1 Private Sector versus the Public Sector 
Healthcare in South Africa is classified as a dual healthcare system as it consists of the 
private healthcare sector and the public healthcare sector. The private healthcare sector 
includes private hospitals and general practitioners. Whereas the public healthcare sector 
includes primary healthcare clinics and Community Health Centres in addition to different 
levels of hospitals: District (level 1), Regional (level 2) and Central or Tertiary (level 3) 
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(Coovadia et al., 2009). This study focuses on CMJAH which is an Academic Tertiary Level 
Hospital in the public healthcare sector in South Africa.    
 
The South African healthcare system is faced with inequalities in the distribution of resources 
and finances. For example, around 40% of the total health expenditure is used for the public 
healthcare system which caters for the majority of the population, as more than 60% of the 
population rely solely on the public healthcare system (Chopra et al., 2009; Coovadia et al., 
2009). Furthermore, human resources are also unequally distributed between the private and 
public healthcare systems as approximately 70% of the doctors in South Africa are full-time 
workers in the private healthcare system which provides healthcare to the minority of the 
population (Van Rensburg, 2004; Mayosi et al., 2014). To try and overcome these 
inequalities and improve the quality of healthcare in South Africa, National Health Insurance 
is being proposed.  
 
2.6.2 Costing System used in the Public Healthcare System    
Cost studies in the public sector are often limited due to a deficiency of uniform costing 
information and methodology (Oostenbrink et al., 2002). The public hospitals in South Africa 
use the User Guide for the Uniform Patient Fee Schedule (UPFS) as a common reference for 
billing patients. The UPFS acts as a simple guide for charging patients in the public hospital 
as it uses the “grouped fee approach” instead of the “itemised billing approach”. Thus, the 
UPFS has divided most tariffs into the two main categories of facility fee and professional fee 
(Department of Health, 2009). 
 
The UPFS has stipulated criteria that are used to classify patients as either being: full paying 
for patients receiving treatment from private HCPs or are funded externally; fully subsidised 
(H0) for patients that have been referred by Primary Healthcare facilities; or partially 
subsidised (H1 and H2) patients. The amount of subsidisation for partially subsidised 
depends on the patient’s income and the amount that needs to be paid is calculated as a 
percentage of the amount charged to patients that are full paying. The UPFS also has free 
services in which, irrespective of a patient’s classification, they do not have to pay for the 
service. The free services are only for designated circumstances and for patients that fulfil 
the conditions set out in the UPFS. For example, pregnant women are eligible for free 
healthcare services but if they are a member of a medical aid scheme, they will be exempt 
from the free service. It is important to note that that UPFS reflects the fees that the public 
hospital charges patients and it is not the amount that it costs the hospital to provide patients 
with healthcare (Department of Health, 2009).  
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Within the South African public healthcare sector, a medicines tender process is used in 
which the National Department of Health advertises tenders. Pharmaceutical companies then 
submit a bid to compete for these tenders and are then awarded the contract for the 
specified medication at the stipulated price for a period of two years. Therefore each 
medicine is normally supplied by only one company, or if the tender is split there will be more 
than one supplier (Gray, 2014). Previously the National Treasury was responsible for the 
management of medicine tender process, however, this responsibility has now been 
transferred to the National Department of Health and thus far has been successful in 
decreasing the cost and increasing the availability of various medicines (Pharasi et al., 
2013).  
 
Three sources are predominantly used to finance public healthcare in South Africa. Firstly, 
the national government distributes its funding amongst provinces using the equitable share 
formula and thereafter each provincial government decides on the amount to be spent on 
healthcare. Secondly, conditional grants that are received are once again distributed by the 
national government to the provincial health departments for use in specified spending areas 
which includes tertiary hospitals. Thirdly, revenue from each province is also used to pay for 
public healthcare in that province. Eight programmes are used to categorise provincial health 
expenditure and expenditure is disturbed differently amongst these programmes as required 
per province (Day et al., 2015).  
 
2.7 Economic Evaluations of Healthcare Programmes   
2.7.1 Economic Evaluations  
Economic evaluation can be defined as, “the comparative analysis of alternative courses of 
action in terms of both their costs and consequences” (Drummond et al., 2005). This 
definition highlights that the two key components of economic evaluations are costs and 
consequences and choices. The relationship between costs and consequences of an activity, 
which is also referred to as inputs and outputs, are used in decision-making. When in a 
situation where resources are scare, choices have to be made to decide how best to use 
these scare resources. When deciding whether to allocate scare resources to one activity or 
another, there are various benefits to performing an economic evaluation. Firstly, economic 
evaluations require that the current activities are measured and described in order for them 
to be correctly compared to the new activity as well as to evaluate whether the current 
activities are cost-effective. Secondly, economic evaluations consider the various viewpoints 
of a situation, such as the patient, the hospital, or the government. Thirdly, economic 
evaluations estimate and compare the opportunity cost of the alternative programmes' 
benefits by measuring the inputs and outputs to determine the value for money achieved 
(Drummond et al., 2005). 
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There are various techniques for conducting economic evaluations. The four common ones 
are Cost-Effectiveness Analysis, Cost-Utility Analysis, Cost-Benefit Analysis and Cost-
Minimisation Analysis. The question often arises as to which type of analysis is the best to 
perform. However, the type of analysis chosen must depend on the situation, the viewpoint of 
the analyst, as well as other factors (Drummond et al., 2005). Besides conducting the 
economic evaluation correctly, it is also important to be able to critically analyse the 
evaluation.  
 
2.7.2 Cost-Analysis   
Within all economic evaluations, cost-analyses are essential. When conducting a cost-
analysis in a healthcare environment, there are various factors that need to be kept in mind. 
Irrespective of the type of economic valuation being conducted, the comparative costs are 
commonly analysed when comparing treatment options or healthcare programmes. It is 
important to clearly identify the categories and the range of costs to be considered in the 
study. Thereafter, the quantities of the resources used in each category must be measured 
and a unit cost or price must be allocated to each category. When calculating costs in 
healthcare studies, the degree of accuracy and precision of the cost estimates depends on 
the method used to calculate these costs (Drummond et al., 2005).    
 
When conducting cost-analyses in a healthcare setting using patient data, researchers are 
faced with different obstacles such as missing data and inconsistency in costing 
methodology. As missing data is a common problem it is imperative that researchers are 
aware of the implications of missing data when calculating costs and the alternative methods 
of how to deal with missing data. When dealing with patient data, uncertainties may arise and 
there are also various ways to address them using statistical analysis (Drummond et al., 
2005).    
 
There are different approached that can be used to calculate costs in healthcare settings: the 
two common ones are the top-down approach and the bottom-up approach. The top-down 
approach, also referred to as gross costing or macro-costing, is ideally used in standardised 
settings and services as the total cost of a setting or service is divided by the number of 
patients treated by that service to obtain an estimation of the cost. The advantages of the 
top-down approach is that it is quick and simple to use in hospitals which keep detailed and 
accessible records of financial and utilization data. However, in hospitals where this data is 
not available and when settings or services are not standardised, the bottom-up approach 
should be used. The bottom-up approach, also known as ingredient-based or micro-costing, 
is when primary data collection is used to obtain information on the utilization of resources 
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per patient or service in order to calculate the unit cost per patient or service. Although the 
bottom-up approach may provide more accurate and detailed costs, disadvantages of this 
approach are that is it time-consuming, costly and the required information may be difficult to 
obtain. Due to the advantages and disadvantages of both approaches, a mixed approach 
can be used (Oostenbrink et al., 2002).    
 
There are several different ways to collect patient data for healthcare economic evaluations. 
Primary data can be collected and used by incorporating the economic evaluation with the 
randomised control trials for the approval of new products or primary data can be collected 
by designing new studies specific to economic evaluations of the product. Alternatively, 
secondary data can be used and analysed in economic evaluations by using decision-
analytic modelling. Each method has its own strengths and weaknesses. However, this study 
focuses on using decision-analytic modelling as a tool to compare the costs and 
management pathways that follow when using the Conventional Culture Method versus the 
new Xpert PCR tests for MRSA (Drummond et al., 2005).    
 
2.7.3 Decision-Analytic Modelling 
There has been a rise in the use of decision-analytic modelling to conduct economic 
evaluations to inform decision-making in healthcare settings. As stated by Philips and co-
authors (2006), “decision-analytic modelling represents an explicit approach to synthesising 
currently available evidence regarding the effectiveness and costs of alternative healthcare 
strategies” in order to aid in decision-making. Decision-analytic modelling has five essential 
characteristics that fulfil the objectives of economic evaluations. These are structure, 
evidence, evaluation, uncertainty and variability as well as future research (Drummond et al., 
2005). 
 
In situations where there are cases of uncertainty and decisions have to made, decision-
analytic models are often used. The two chief components that are common to all types of 
decision-analytic modelling are probabilities and expected values. When building a decision-
analytic model there are a series of steps that need to be followed. Different authors explain 
and separate these steps in various ways. However, the fundamental concepts are the same 
and include identifying and defining the decision problem; outlining the boundaries of the 
model; drawing the structure of the model; identifying and synthesising available data; 
specifying costs, outcomes and probabilities; conducting calculations and sensitivity analysis; 
dealing with uncertainty and variability; and applying the models to determine the importance 
of future research (Drummond et al., 2005; Rascati, 2013). 
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Unlike other healthcare studies, decision-analytic modelling uses and synthesises data 
collected from a wide variety of sources such as observations, clinical trials, retrospective 
patient records, surveys and claim databases (Weinstein et al., 2003). Within the healthcare 
context, decision-analytic modelling is used in numerous scenarios and is commonly used to 
compare new treatment alternatives or screening procedures (Werner et al., 2012). In 
healthcare settings where resources are scarce, such as the South African public healthcare 
setting, decision-analytic modelling should be frequently conducted to assess which 
alternatives would be best to implement, thus ensuring the optimal use of available 
resources.  
 
2.7.4 Economic Evaluations In the South African Healthcare Context  
The South African public healthcare setting faces many challenges. Along with its limited 
resources, there has been an overall increase in the cost of healthcare due to new advances 
in healthcare, a greater demand for healthcare products and services as well as higher 
standards of living and expectations. Despite the advantages that are associated with the 
advances in new pharmaceutical products and diagnostic techniques, they are often 
associated with a higher price as compared to older alternatives. There is now an increased 
awareness that decisions have to be made to decide how best to use limited resources, thus 
economic evaluations are being more frequently conducted in South Africa. With the 
increase in economic evaluation studies conducted in healthcare settings, it is important that 
HCPs contribute and cooperate with these studies as well as understand the implications of 
the outcomes. As established in several countries, South Africa is now also developing 
formal guidelines for healthcare economic evaluations of new pharmaceutical products 
(McGee, 2010; Dhamend, 2011). The South African Department of Health published The 
Guidelines for Pharmacoeconomic Submissions, December 2012 within the Medicines and 
Related Substances Act (Act 101 of 1965), under Regulations Relating To a Transparent 
Pricing System for Medicines and Scheduled Substances. The purpose of this publication is 
to provide guidelines for transparent and objective economic evaluations to assist decision-
making in the South African healthcare context. Although it is aimed at the private healthcare 
sector in South Africa, these guidelines are also applicable in the public healthcare sector 
(Department of Health, 2013).   
 
Economic evaluations are also beneficial in situations such as the South African healthcare 
context in which there is a public healthcare sector as well as where there is a developing 
National Health Insurance. When deciding on the items to include in the Standard Treatment 
Guidelines and Essential Drug List as well as in formularies for the public sector, the South 
African Department of Health is starting to include economic evaluations to guide their 
decisions. However, economic evaluations are also being used in the private sector in South 
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Africa due to the increasingly expensive cost of healthcare. The International Society for 
Pharmacoeconomics and Outcomes Research now also has a South African division, which 
discusses current health economic issues in respect of the South African context (McGee, 
2010). There are also other organizations that address health economics in South Africa 
such as The Health Economics and Epidemiology Research Office, which is associated with 
the Wits Health Consortium in Johannesburg and the University of Cape Town’s Health 
Economic Unit.   
 
Although health economic research can provide great value to the South African healthcare 
system, the quality of health economic research in South Africa is not well established. Thus, 
Gavaza and co-authors (2012) have conducted a systematic review entitled The State of 
Health Economic Research in South Africa. This review revealed that health economic 
research relating to South Africa was of fair or poor quality in contrast to a higher quality 
found in the health economic research relating to South Africa that was published overseas. 
This demonstrates that South Africa needs to improve the quality of health economic 
research conducted in order for such research to portray its true benefits. However, Gow and 
co-authors (2013), who are health economic researchers, have analysed and highlighted 
certain points of this systematic review such as that the title and the contents are misleading 
as they are not a completely objective review of the current economic situation in South 
Africa due to various reasons including that key South African researchers and economic 
organizations in the field have been omitted. It is commonly accepted, however, that there is 
a pressing need for further costing and health economic studies in the South African context 
to further inform decision-making.   
   
2.8 Building Decision-Tree-Analytic Models to Compare the Conventional Culture 
Method and PCR Testing for MRSA    
As decision-analytic modelling is a useful tool for assessing alternatives, studies have 
developed decision-analytic models to compare the costs of using the Conventional Culture 
Method versus the new PCR testing for MRSA (Li et al., 2012; Tübbicke et al., 2012a).  
 
With the introduction of the Xpert MRSA tests at a University Hospital in Norway, Li and co-
authors conducted a study to compare and calculate the cost-effectiveness of the new Xpert 
MRSA tests to the currently used culture tests by developing a decision-tree-analytic model 
in TreeAge. In addition, this study looked at two different strategies of the Xpert MRSA tests: 
the daytime strategy and the 24-hour strategy. The information for the model was obtained 
by conducting an actual trial study in the hospital on inpatients that were at a high risk of 
MRSA infection. It was found that overall not only were the Xpert MRSA tests less expensive 
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than the culture tests, but the Xpert tests were associated with additional positive outcomes 
such as decreased time of pre-emptive isolation (Li et al., 2012).   
 
The results found by Li and co-authors are in line with the results found by other studies that 
also developed decision-tree-analytic models. Although some of these studies used different 
types of information and measured different outcomes in their models, the results showed 
that the Xpert MRSA tests are preferred. A study conducted by Brown and Paladino, which 
developed a decision-tree-analytic model on TreeAge to assess the effects of using PCR 
tests, using information mainly from peer-reviewed literature, found the Xpert MRSA to be 
less expensive than the current strategies as well as possibly decreasing mortality rates in 
the European Union and the United Sates. (Brown et al., 2010).  
 
However, decision-tree-analytic models comparing the costs and management pathways that 
follow when testing for MRSA have not yet been built for the South African healthcare 
context. It is important that these studies are conducted and models are developed in relation 
to healthcare in South Africa due the country’s socio-economic status and access to 
healthcare being different as compared to other countries (Ataguba et al., 2011). Once these 
models are built, they can be used in different situations to compare MRSA diagnostic 
alternatives to aid in decision-making in South African hospitals.  
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3. METHODOLOGY  
 
3.1 Theoretical Framework  
This study aimed at conducting a cost-analysis to investigate the management pathways and 
associated costs of the current Conventional Culture Method versus new PCR testing for 
MRSA. However, from the outset of this study, it was found that research on this topic has 
not yet been conducted in the South African public healthcare context, nor was much 
information from the South African public healthcare context available on the separate 
aspects of this study. Therefore it was necessary for qualitative research to first be 
conducted to provide a background of the current practices in the chosen setting. The 
information acquired from the qualitative research guided and informed the quantitative 
research aspects of this study. 
  
The perspective used in this study was that of the South African public healthcare sector. 
Only the direct costs and utilization of antibiotics and laboratory tests that isolated MRSA in 
the study population were analysed in this study. All costs in this study are expressed in 
South African Rands (R).  
  
3.2 Study Design  
A mixed method research design was selected for this study as it consisted of both 
qualitative and quantitative methods to comprehensively answer the research question. 
Qualitative observations were conducted to provide an understanding of the current daily 
practices of HCPs in order to assist the collection and interpretation of retrospective patient 
records as well as to provide a more realistic approach when performing the cost analysis 
and developing the decision-tree-analytic models reflecting the patient management 
pathways.  
 
There are various methods in which qualitative and quantitative research could be 
conducted. In this study, Ethnography was chosen as the qualitative research method and 
Inductive Analysis was used to analyse the data collected. As this study did not include 
implementation of an intervention, it was a non-experimental study and thus the quantitative 
methods chosen were a secondary data analysis for the Retrospective Records Review and 
an economic evaluation for the Cost Analysis and Decision-Tree-Analytic Models.  
 
This study consisted of four methods. The first method involved conducting qualitative 
observations in the chosen hospital wards, the NHLS Microbiology Laboratory and the 
antibiotics section of the main dispensary at the CMJAH. The remaining three methods were 
quantitative and included a Retrospective Patient Records and Antibiotic Utilization Review, 
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a Costs Analysis and developing Decision-Tree-Analytic Models. Thus there was greater 
emphasis on the quantitative section of this study. Figure 1 represents the study design. The 
detailed study methodology will be further explained in Section 3.7 and 3.8.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study Design Showing Mixed Methods Research: Qualitative Methods used 
to Inform Quantitative Methods 
 
3.3 Study Site 
This study was conducted at CMJAH in Johannesburg, South Africa. CMJAH is a public 
sector hospital that provides secondary, tertiary and highly specialised services.  
 
Within the CMJAH the study sites included: 
- The Orthopaedic Ward  
- The Vascular Ward 
- The NHLS Microbiology Laboratory  
- The Hospital’s Medical Records Room  
- The Antibiotics Designated Area of the Main Dispensary  
 
3.4 Study Population 
To determine the study population, an application was submitted to the NHLS Information 
Systems to request details of all the patients at CMJAH that had been identified as MRSA- 
positive in 2013. From the data received from the NHLS Information Systems, there were 
702 samples that were MRSA-positive at CMJAH in 2013. These 702 samples were taken 
from 373 patients. The information received from the NHLS information system was sorted 
and filtered to reveal the wards that had the highest number of patients with MRSA during 
2013 as shown in Table 1.  
 
Qualitative 
Ethnographic Observations 
Quantitative 
Retrospective Records and 
Antibiotic Utilization Review 
Costs Analysis  
Decision-Tree-Analytic 
Models 
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Table 1: Number of Microbiology Laboratory Tests and Number of Patients that 
Isolated MRSA per Ward at CMJAH in 2013 
Number of 
Laboratory Tests 
Number of 
Patients 
Type of Ward 
104 42 Paediatric Surgery and Trauma  
60 25 Trauma ICU / Surgery 
57 36 Vascular  
49 36 Trauma Surgery 
47 18 Orthopaedic  
42 24 General ICU 
 
General Trauma and ICU wards were excluded due to the wide range of conditions affecting 
the patients in these wards thus making it difficult to follow treatment care pathways as well 
as due to the high turn-over of patients in these wards. The paediatric ward was also 
excluded as paediatric care differs from adult care and thus it would not be consistent for 
comparison purposes. Therefore, the study population consisted of inpatients that were 
diagnosed with MRSA in 2013 in the orthopaedic ward and the vascular ward at CMJAH as 
shown in Figure 2.  
 
A convenience sample was used in this study. The data received from the NHLS Information 
Systems contained the patient’s hospital number, ward number and other patient details as 
well as information about the laboratory tests of the patients that had MRSA in 2013. The 
data was filtered to find all the patients that were in the vascular and orthopaedic wards. The 
patient numbers of these patients were then used to access their retrospective medical 
records from the Hospital’s Medical Record Room. When accessing the retrospective patient 
records, patients whose records could not be found or did not contain 2013 information were 
excluded.  
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Figure 2: Breakdown of the Number of Samples and Patients that Isolated MRSA at 
CMJAH in 2013 to Determine the Study Population 
 
3.5 Study Duration  
The study was conducted between January 2013 and January 2015.                                      
 
Observations of clinical practice were conducted in the following areas: 
- Orthopaedic Ward during November 2013 
- Vascular Ward during April 2014 
- NHLS Microbiology Laboratory during February 2014 
- Antibiotics designated area of the main dispensary at CMJAH during September 2014 
  
Data was collected from the Hospital’s Medical Records Room: 
- For the patients in the Orthopaedic Ward  during February 2014 to  March 2014 
- For the patients in the Vascular Ward during May 2014 to June 2014 
 
 
 
373 
Number of patients with 
MRSA 
18 
Patients in the                         
Orthopaedic Ward  
16 
Patients with accessible 
retrospective records  
702 
Total number of MRSA 
samples 
36 
Patients in the                              
Vascular Surgery Ward 
29 
Patients with accessible 
retrospective records  
6 
Wards with more than 20 
patients with MRSA  
4 
Wards Excluded  
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3.6 Ethical Considerations  
An application was submitted to the Human Research Ethics Committee: (Medical) for 
Clearance of Research and ethical clearance for this study was approved in 2013 
(M130543).  
 
Written permission was then requested and granted from the CEO of CMJAH, Ms Bogoshi. 
Permission was also obtained from Professor Lukhele (head of the orthopaedic ward), 
Professor Veller (head of the vascular ward) and Dr Bosman from NHLS, as well as the 
Hospital’s Medical Records Room and the Responsible Pharmacist of the Dispensary at 
CMJAH. 
 
The Ethics Clearance Certificate and Letter of Research Permission for this study are in 
Appendix 1 and Appendix 2 respectively.  
 
3.7 Data Collection Procedures  
The data for this study was collected using four methodologies, the first being Qualitative 
Observation of Clinical Practice and the remaining three were Quantitative Retrospective 
Records Review, Cost Analysis and Decision-Tree-Analytic Models. 
 
3.7.1 Ethnographic Observations  
Ethnography includes conducting observations to obtain the required information by 
concentrating on the details to produce a thorough narrative account and understanding. 
Inductive Analysis is a systematic procedure in which the specific data collected is arranged 
into segments, codes and categories and then general patterns were recognised. A data 
segment is a single idea that can be understood on its own; these segments are then 
labelled by one or more codes. Similar codes are then grouped into categories depicting the 
main ideas of the data and the relationship between the categories are then described by 
patterns (McMillan et al., 2014).  
 
A special feature of ethnographic observations is that they are conducted within the natural 
setting of the study population, thus allowing for natural daily behaviour to be observed and 
documented (Reeves et al., 2008). This study used the stance of non-participant 
observations, in which the observer was a complete outsider who did not participate in the 
practices being observed nor offer any contribution to ensure the reliability and validity of the 
observations. This method consisted of ethnographic observations of the daily practices of 
HCPs at CMJAH.  
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3.7.1.1 Data Collection by Ethnographic Observations  
Ethnographic observations were used as a tool to gain an understanding of the naturally 
occurring practices at the study site and to ensure that the data collected included all the 
essential information (Reeves et al., 2008). It was not possible to collect all of the required 
information from the ethnographic observations that were performed, such as information 
regarding the criteria followed for placing a patient in isolation. Thus, HCPs involved in 
patient care in the current setting were approached to clarify issues verbally when more 
detail concerning policies or practices was required.  
 
Ethnographic observations were conducted in the orthopaedic and vascular wards as well as 
at the NHLS Microbiology Laboratory and the main dispensary at CMJAH. The general 
methodology for the ethnographic observations conducted is explained below. Thereafter, 
under the subsequent headings the specific methodology for the ethnographic observations 
conducted in each area is outlined.  
 
Once the study site was selected and permission in each of the study areas was obtained, 
general observations were first conducted to become familiar with the activities. This was 
followed by observations to document the details of the activities specific to the areas. During 
observations in the various areas, details were recorded regarding the general aspects of 
who was involved in the activities; what type of activities occurred; where and when the 
activity took place; and why the HCPs interacted in the observed manner. The specific 
factors that were observed and documented for each area are described in the following 
sections. 
 
The data obtained from the observations were documented as field notes and reflex records 
which were then analysed in the results section. Field notes contained the date, setting and 
data that were collected during the observations; reflex records were the notes written 
immediately after the observations to interpret the main activities and assess the data 
collected to identify information that was missing. 
 
3.7.1.1.1 Clinical Ward Observations  
Observations were conducted in the two wards to understand the clinical practices of HCPs 
regarding the current management of patients suspected of having an MRSA infection and 
the clinical pathways that followed, depending on whether the patient had MRSA or not. The 
purpose of the observations was to get a clear picture of what actually happens in daily 
practice. This was essential to ensure that appropriate data was collected for the CMJAH 
setting and to assist in understanding and interpreting the patient records when looking at the 
retrospective patient records.  
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The observations were conducted during the doctors' early morning ward rounds over seven 
days in each ward. Each observation lasted for the duration of the ward round (approximately 
30 minutes per ward). The observations did not interfere or have any impact on the ward 
rounds.  
 
During the observations in the wards, information was obtained and details were 
documented in the 8.3.1 Clinical Ward Observation Data Collection Sheet shown in 
Appendix 3. Particular attention was observed and documented for the following: 
- Doctor-Patient interaction  
- The use of antiseptic/disinfectant hand rub and hand washing   
- The use of Personal Protective Equipment (PPE)   
- Prescribing of antibiotics for suspected and confirmed infection  
- Request for and taking of specimens to be sent to the NHLS Microbiology Laboratory for 
suspected infections  
- Action taken while waiting for the patients results from the NHLS Microbiology Laboratory 
- Pre-operative, post-operative and wound care  
- Criteria and method of isolation of patients with suspected and confirmed infection  
 
3.7.1.1.2 NHLS Microbiology Laboratory Observations  
Observations were conducted in the NHLS Microbiology Laboratory at CMJAH to understand 
the current method of testing for a suspected MRSA infection. Observations were conducted 
at the bacteriology bench (“bact-bench”) in the microbiology laboratory. The purpose of the 
observation was to understand the current methods and get a clear picture of what happens 
in daily practice. This was essential to ensure that appropriate data was collected for the 
CMJAH setting and to assist in understanding and interpreting the patient records when 
looking at the retrospective patient records.  
 
The observations were conducted during the morning shift over five days. Each observation 
lasted for the duration of the first morning shift (time varied depending on the number of 
samples received each morning). The observations did not interfere or have any impact on 
the shift.  
 
During the observations in the microbiology laboratory, information was obtained and details 
were documented in the 8.3.2 Microbiology Laboratory Observation Data Collection Sheet 
presented in Appendix 3. Particular attention was observed and documented for the 
following: 
- The procedure from when a specimen for a suspected infection is received until a 
confirmed diagnosis is made.  
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- The steps involved during the different stages of Microscopy, Culture and Sensitivity. 
- The time taken and laboratory personnel involved in performing each of these steps. 
- Special attention was observed for the steps and procedure involved when a Gram-
positive Staphylococcus aureus and MRSA infection was suspected and detected in the 
laboratory. 
 
3.7.1.1.3 Antibiotic Dispensary Observations  
Information regarding the current antibiotic dispensing policies for inpatients at CMJAH was 
obtained from the antibiotics designated section of the dispensary at CMJAH. The 
information was obtained by basic observations and the pharmacist assisted by providing 
further information required to complete the field notes. The information obtained was 
recorded in the 8.3.3 Antibiotic Dispensary Observation Data Collection Sheet shown in 
Appendix 3.  
 
Particular information required regarding the common Empiric and MRSA-Specific Antibiotics 
used in each ward was: 
- The general policy used for dispensing antibiotics to inpatients.  
- Policy for antibiotics kept in ward stock versus antibiotics dispensed on a per-patient basis.  
- The antibiotics which require authorisation from consultants. 
- The antibiotics which require confirmation of infection from NHLS sensitivity results. 
- Additional policy for dispensing vancomycin, linezolid and carbapenems.   
- Current Antibiotic Stewardship practice in the hospital and dispensary. 
  
3.7.2 Retrospective Records and Antibiotic Utilization Review 
A retrospective records review was conducted by accessing the medical records of the 
patients in the study population from the Medical Records Room at CMJAH.  
 
3.7.2.1 Data Extraction Procedure  
The Hospital’s Medical Records Room has a manual system for storing and accessing 
patient records. However, the manual system is slowly being replaced by an electronic 
computerised system. The system used to retrieve the records was as follows: 
- The last digit of a patient’s hospital number was used as an indication of which area in the 
room to look. Example: all records ending in 0 were kept opposite the entrance of the 
room. Next to that were all records ending in 1 and so forth. 
- Once the area in the room was located, the mini filing drawers were labelled with the range 
of patient numbers that were within the drawer. 
- Within each drawer there were brown envelopes arranged in numerical order, each 
envelope had a hospital number on the front and was for an individual patient.  
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- Each envelope contained microfiche films of the individual's patient records.  
- A place holder was put in the place of the required patient number and the envelope was 
removed. 
- The microfilms were viewed through the microfiche viewer. 
- All patient records since June 2013 for patient numbers ending in 6, 7, 8 and 9 were on the 
electronic computer system. 
- These records were accessed by typing the patient’s hospital number into the computer 
program and the required document was opened as a PDF of the scanned patient records.     
 
Before extracting and recording data from the patients’ retrospective records, patient 
numbers (For example 369P01, 369P02) were allocated to each patient’s hospital number. 
The links between the allocated patient number and the patient’s hospital number were 
stored separately in a password-protected file. Therefore, when recording a patient’s 
information on a case report form, the allocated patient number was used and the patient’s 
actual hospital number, name, surname or any other patient-identifying data was not 
recorded. This was done in accordance with the ethics application in order to maintain 
patient confidentiality and anonymity.  
 
Patient records are not permitted to be photocopied, printed or transcribed directly onto a 
laptop, so all required information had to be handwritten in the Records Room and then 
transcribed in Excel spread sheets once outside the Records Room.  
  
3.7.2.2 Collection of Retrospective Patient Data  
Data was extracted from patient records and then recorded on individual patient case report 
forms, as in Appendix 4. Specific data that was extracted from the retrospective records was: 
- Age  
- Gender 
- Date of Admission 
- Date of Discharge  
- Diagnosis / ICD10 Codes  
- Operations and surgical procedures  
- Doctors notes regarding infection control; isolation; samples taken and sent for MCS for 
suspected infection; laboratory test information for suspected infections; antibiotics 
prescribed, administered, changed, or doses adjusted 
- NHLS laboratory results relating to infections 
- Antibiotic information (name, strength, dose, route, duration) on doctors’ prescription charts 
and nurses' administration charts  
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The data that was recorded on the individual patient case report forms was then entered into 
an Excel template created per ward. When entering the patients’ data collected from the 
retrospective records, there was missing information. Some of the missing information was 
obtained by consulting with various HCPs from the wards, the laboratory personnel at the 
NHLS Microbiology Laboratory and the pharmacist at the antibiotics designated area of the 
dispensary as well as by making assumptions which are stated in Section 5.9.   
  
3.7.3 Cost Analysis  
The costing methodology used in this study was the bottom-up approach. This approach was 
used as official databases containing the specific utilization and costing information were not 
found at CMJAH. Furthermore, although MRSA laboratory test utilization and costing 
information was obtained from the NHLS Information Systems, based on the observation at 
the wards, standardisation of clinical practice could not be deduced. Therefore, prior to 
performing the cost-analysis, primary data collection was conducted to obtain the utilization 
information of the antibiotics administered and MRSA laboratory tests conducted in the study 
population. 
 
3.7.3.1 Costing Information  
The antibiotic, NHLS laboratory test and Xpert MRSA costing information was obtained and 
filtered according to the utilization data collected from the retrospective patient records. The 
summarised databases formulated and used are in Appendix 5. 
  
3.7.3.1.1 Antibiotic Costing Information 
The costing information for the antibiotics was taken from the “Database Medsas-contract-
prices-INN-ATC 2013”. This was a 2013 database for the cost of antibiotics in public 
hospitals in South Africa. A list of all the antibiotics used in the study population was 
formulated for each ward and was allocated its respective cost from the database as shown 
in Appendix 5 (Table 29 and Table 30). These summarised databases were used when 
conducting the antibiotic cost calculations; the Average weighted price (contract) was used 
but when this was not available the Depot price Mar-13 (without mark-up) was used. 
 
3.7.3.1.2 NHLS Laboratory Test Costing Information   
The costing information for the NHLS laboratory tests that isolated MRSA was obtained from 
the costing information requested and received from the NHLS Information System. The 
costing data was then filtered to formulate a list of the different steps used in the laboratory 
tests that were conducted to detect MRSA in the study population for each ward. A list of the 
laboratory tests that isolated MRSA for each patient was then formulated for each ward and 
the respective costs were allocated to each test as listed in Appendix 5 (Table 31 and Table 
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32). These summarised databases were used when conducting the NHLS laboratory tests 
cost calculations. 
  
3.7.3.1.3 Xpert MRSA Costing information  
The price of the Xpert PCR kits for MRSA was obtained from a quote requested and received 
from Cepheid South Africa in May 2014 (QT1005SP). The information from the quote is 
summarised in Appendix 5 (Table 33).   
  
3.7.4 Decision-Tree-Analytic Models 
Decision-tree-analytic models were developed using TreeAge Pro 2013 Software and the 
TreeAge Pro 2013 User's Manual (TreeAge Software INC, 2013). The decision-tree-analytic 
models were populated with input parameters from the observations, retrospective records, 
cost analysis, experts’ opinions and the published literature. The plausibility of the models 
was assessed by varying the probabilities and costs of inputs for each branch (including the 
potential cost of the Xpert MRSA test). TreeAge Rankings, Sensitivity Analysis and Tornado 
Analysis were then performed to determine which pathway was most efficient and which 
variables were most sensitive. 
 
3.7.4.1 Patient Management Pathways  
Using the information obtained from the observations and retrospective records review, the 
various management pathways of a patient with a suspected infection were formulated as 
branches of a decision-tree-analytic model.  
 
A management pathway was formulated for each patient with a suspected MRSA infection to 
show the clinical pathways that followed regarding the administering of antibiotics and the 
collection of specimens for MCS as well as the steps taken while waiting for the laboratory 
test results and after the results were available. The management pathways were then 
grouped and used to formulate an ‘actual’ clinical decision-tree-analytic model per ward. 
Based on the clinical decision-tree-analytic models, a theoretical arm was added to the 
actual decision-tree-analytic model to represent possible scenarios of implementing the Xpert 
MRSA PCR tests.  
 
Each model started at the decision node with a patient with a suspected MRSA infection. The 
first set of branches after the decision node represents the various strategies used to 
manage patients with a suspected infection. The branches after the chance node represent 
the options within each strategy.  
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3.7.4.2 Decision-Tree-Analytic Model Structure  
For each ward a decision-tree-analytic model was developed to describe the current 
management of patients with a suspected and confirmed MRSA infection.  
 
Using the structure of the actual decision-tree-analytic model developed for each ward, a 
fourth arm was then added to evaluate effects and the clinical pathway that would follow if 
the Xpert MRSA PCR tests were to be implemented in the current clinical settings. The 
variable cost of the Xpert MRSA test was calculated from the quote received from Cepheid 
South Africa. 
 
3.7.4.2.1 Decision-Tree-Analytic Model Structure for the Orthopaedic Ward  
When a patient presented with a suspected infection in the orthopaedic ward, represented at 
the decision node, there was a range of clinical practices that could have been carried out as 
illustrated in Figure 3 and explained below. The branches from the decision node represent 
the alternative clinical practices that were performed for a patient that had a suspected 
infection: A patient would either first receive Empiric Antibiotics to try and treat the infection 
(first top branch); or a patient would have a specimen taken and sent for MCS to investigate 
the source of the infection (second branch); or a patient would have a specimen taken and 
sent for MCS and receive Empiric Antibiotics while waiting for the MCS results (third branch). 
The possible pathway that would follow if the Xpert MRSA test were to be implemented in the 
current clinical setting was represented by the fourth bottom branch. 
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Figure 3: Decision-Tree-Analytic Model Structure Showing the Management Pathways for a Patient with a Suspected Infection in the 
Orthopaedic Ward 
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Each of the four branches Figure 3 ends with chance nodes representing possible outcomes. 
The branches from the chance node either ended with another chance node representing 
further possible outcomes, or ended with a terminal node representing the endpoint, which 
has no further branches. Payoffs were assigned to the terminal node, representing the net 
value of that pathway.  
 
The first branch describes the pathway taken if a patient first received Empiric Antibiotics 
once an infection was suspected. Once the patient received the Empiric Antibiotics the first 
chance node describes the possible outcomes that either the patient had a specimen sent for 
MCS or that the patient did not have a specimen sent for MCS to investigate the source of 
infection. If the patient did not have a specimen sent for MCS, a terminal node and a payoff 
were assigned to that branch. If the patient had a specimen sent for MCS, a second chance 
node was added to that branch with the possible outcome of MRSA isolated or MRSA not 
isolated. If MRSA was not isolated, a terminal node and a payoff were assigned to that 
branch. If MRSA was isolated, a third chance node was assigned with the possible outcomes 
of either continue Empiric Antibiotics or Empiric Antibiotics stopped and changed to MRSA-
Specific Antibiotics. Both of these outcome branches were assigned terminal nodes and 
payoffs.  
 
The second branch describes the pathway taken if a specimen was first sent for MCS when 
an infection was suspected. Once a specimen was sent for MCS, there were two possible 
outcomes that were represented by a chance node. Either to start Empiric Antibiotics while 
waiting for the MCS results or to wait for the MCS results without starting Empiric Antibiotics. 
If Empiric Antibiotics were started while waiting for the MCS results, a second chance node 
was added to the branch with the outcomes of MRSA isolated or MRSA not isolated. If 
MRSA was not isolated, a terminal node and a payoff were assigned to that branch. If MRSA 
was isolated, a third chance node was assigned with the possible outcomes of either Empiric 
Antibiotics continued or Empiric Antibiotics stopped and changed to MRSA-Specific 
Antibiotics. Both of these outcome branches were assigned terminal nodes and payoffs. 
However, if after a specimen was sent for MCS, the outcome was to wait for the results, a 
chance node was added to this branch with the possible outcomes of MRSA isolated or 
MRSA not isolated. If MRSA was not isolated, a terminal node and a payoff were assigned to 
that branch. If MRSA was isolated, a third chance node was assigned with the possible 
outcomes of either MRSA-Specific Antibiotics administered or first Empiric Antibiotics and 
then MRSA-Specific Antibiotics administered. Both of these outcome branches were 
assigned terminal nodes and payoffs. 
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The third branch describes the pathway for when a Specimen For MCS was taken and at the 
same time Empiric Antibiotics were administered when an infection was suspected. The first 
chance node had the possible outcome of either MRSA isolated or MRSA not isolated. If 
MRSA was not isolated a terminal node and payoff were assigned to that branch. If MRSA 
was isolated a second chance node was allocated to that branch with the possible outcomes 
of either to continue Empiric Antibiotics or to stop Empiric Antibiotics and change to MRSA-
Specific Antibiotics. Both of these outcome branches were assigned terminal nodes and 
payoffs. 
 
The fourth branch represents the scenario of implementing the Xpert MRSA test in the 
current clinical setting which was to send a Specimen For Xpert MRSA testing when an 
infection was suspected. This branch ended with a chance node with the possible outcomes 
of MRSA isolated or MRSA not isolated. The branch of MRSA not isolated ended with a 
terminal node and a payoff. The branch of MRSA isolated ended with a chance node with 
two possible outcomes of either to immediately start MRSA-Specific Antibiotics or to first 
confirm the MRSA result by a culture and sensitivity test and administer Empiric Antibiotic 
while waiting for the culture and sensitivity results. The branch of start with MRSA-Specific 
Antibiotics ended with a chance node with the outcome of either to confirm the Xpert MRSA 
result by a culture and sensitivity test or not to confirm by a culture and sensitivity test. These 
two branches ended with a terminal node and a payoff. The alternative branch of to first 
confirm by culture and sensitivity tests and administer Empiric Antibiotics while waiting also 
ends with a chance node with the possible outcomes of continue Empiric Antibiotics or stop 
Empiric Antibiotics and start MRSA-Specific Antibiotics once the culture and sensitivity test 
results were available. These two branches ended with a terminal node and a payoff. 
 
3.7.4.2.2 Decision-Tree-Analytic Model Structure for the Vascular Ward 
When there was a patient with a suspected infection in the vascular ward, the branches from 
the decision node were the same as the branches from the decision node in the clinical 
practice decision-tree-analytic model Structure for the orthopaedic ward: First Branch of 
Empiric Antibiotics, Second Branch of Specimen For MCS and Third Branch of Empiric 
Antibiotic & Specimen For MCS. The possible pathway that would follow if the Xpert MRSA 
test were to be implemented in the current clinical setting was represented by the fourth 
bottom branch. The possible outcome branches from the chance nodes were slightly 
different as illustrated in Figure 4 and explained below. 
 
 
 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Decision-Tree Analytic Model Structure Showing the Management Pathways for a Patient with a Suspected Infection in the 
Vascular Ward 
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The first branch from the decision node describes the pathway of first administering Empiric 
Antibiotics to a patient with a suspected infection. This branch ended with a chance node 
with the possible outcomes of sending a Specimen For MCS or not sending a Specimen For 
MCS to investigate the source of infection. If a specimen was not sent for MCS, the branch 
ended with a terminal node and was allocated a payoff. If a specimen was sent for MCS, the 
branch ended with a chance node with the possible outcomes of MRSA isolated or MRSA 
not isolated. If MRSA was not isolated the branch ended with a terminal node and a payoff. If 
MRSA was isolated, the branch ended with a chance node with the possible outcomes of 
discontinuing Empiric Antibiotics or continuing Empiric Antibiotics. The discontinuing Empiric 
Antibiotics branch ended with a chance node with the possible outcomes of No Antibiotics, 
Other Antibiotics, or MRSA-Specific Antibiotics administered. These three branches all 
ended with a terminal node and a payoff. The branch continuing with Empiric Antibiotics also 
ended with a terminal node and a payoff.  
 
The second branch from the decision node describes the pathway of first sending a 
Specimen For MCS when a patient had a suspected infection. This branch ended with a 
chance node with the possible outcomes of starting Empiric Antibiotics while waiting for the 
MCS results or to wait for the MCS results without starting Empiric Antibiotics. If Empiric 
Antibiotics were started while waiting for the MCS results, a second chance node was added 
to the branch with the outcomes of MRSA isolated or MRSA not isolated. If MRSA was not 
isolated, a terminal node and a payoff were assigned to that branch. If MRSA was isolated, a 
third chance node was assigned with the possible outcomes of discontinuing Empiric 
Antibiotics or continuing Empiric Antibiotics. The discontinuing Empiric Antibiotics branch 
ended with a fourth chance node with the possible outcomes of No Antibiotics, Other 
Antibiotics, or MRSA-Specific Antibiotics administered. These three branches all ended with 
a terminal node and a payoff. The branch continuing Empiric Antibiotics also ended with a 
terminal node and a payoff. However, if after a specimen was sent for MCS, the outcome 
was to wait for the results without receiving Empiric Antibiotics, a chance node was added to 
this branch with the possible outcomes of MRSA isolated or MRSA not isolated. If MRSA 
was not isolated, a terminal node and a payoff were assigned to that branch. If MRSA was 
isolated, another chance node was assigned with the possible outcomes of discontinuing 
Empiric Antibiotics or continuing Empiric Antibiotics. The discontinuing Empiric Antibiotics 
branch ended with a chance node with the possible outcomes of No Antibiotics, Other 
Antibiotics or MRSA-Specific Antibiotics administered. These three branches all ended with a 
terminal node and a payoff. The branch continuing Empiric Antibiotics also ended with a 
terminal node and a payoff.  
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The third branch from the decision node describes the pathway for when a Specimen For 
MCS was taken and at the same time Empiric Antibiotics were administered when an 
infection was suspected. The first chance node had the possible outcome of either MRSA 
isolated or MRSA not isolated. If MRSA was not isolated a terminal node and a payoff were 
assigned to that branch. If MRSA was isolated a second chance node was allocated to that 
branch with the possible outcomes of discontinuing Empiric Antibiotics or continuing Empiric 
Antibiotics. The discontinuing Empiric Antibiotics branch ended with a third chance node with 
the possible outcomes of No Antibiotics, Other Antibiotics or MRSA-Specific Antibiotics 
administered. These three branches all ended with a terminal node and a payoff. The branch 
continuing Empiric Antibiotics also ended with a terminal node and a payoff.  
 
The fourth branch was to send a Specimen For Xpert MRSA testing when an infection was 
suspected. This branch ended with a chance node with the possible outcomes of MRSA 
isolated or MRSA not isolated. The branch of MRSA not isolated ended with a terminal node 
and a payoff. The branch of MRSA isolated ended with a chance node with two possible 
outcomes of either to immediately start MRSA-Specific Antibiotics or to first confirm the 
MRSA result by a culture and sensitivity test and administer Empiric Antibiotics while waiting 
for the culture and sensitivity test results. The branch of starting with MRSA-Specific 
Antibiotics ended with a chance node with the outcome of either confirming by culture and 
sensitivity tests or not confirming by culture and sensitivity tests. These two branches ended 
with a terminal node and a payoff. The alternative branch of first confirming by culture and 
sensitivity tests and administering Empiric Antibiotics while waiting also ended with a chance 
node with the possible outcomes of continuing Empiric Antibiotics or stopping Empiric 
Antibiotics and starting MRSA-Specific Antibiotics once the culture and sensitivity test results 
were available. These two branches ended with a terminal node and a payoff.  
 
3.7.4.3 Decision-Tree-Analytic Model Parameters 
Once the structure Decision-Tree-Analytic Models were complete, the respective parameters 
were calculated and entered into the models. The variable costs for these models were 
derived from the cost-utilization calculations conducted per ward. The probabilities entered 
for the actual models were based on the data collected from the retrospective records of the 
patients in the study population   
  
3.7.4.3.1 Variables  
Variables are parameters that are allocated to the branches of the tree. They contain the 
numeric value for the parameter as well as the high and low values for the parameter, which 
are used for sensitivity analysis. The numeric values for the parameters were obtained from 
the cost calculations conducted. The costs entered for the Antibiotic variables 
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(cDailyEmpiricAntibiotic, cDailyMrsaSpecificAntibiotic and cDailyOtherAntibiotic) were the 
average of the daily antibiotic cost per ward. The costs entered for the NHLS laboratory test 
variables (cSpecimenM and cSpecimenCS) were the average of the NHLS laboratory test 
cost per ward. For each antibiotic variable the standard deviation of the daily antibiotic cost 
per ward was calculated and added to the average cost to calculate the high value and 
subtracted from the average to calculate the low value. For the NHLS laboratory test 
variables, the standard deviation of the NHLS laboratory test cost per ward was also 
calculated and used to obtain the high and low values. When a negative value was obtained, 
zero was entered for the low value.  
 
For the cXpertMRSA variable, the average cost of one Xpert MRSA test was used and 50% 
was added to the cost for the high value and 50% was subtracted from the cost for the low 
value.  
 
For the theoretical situation that was run using variables to represent equal probabilities for 
each branch in the model, the numeric value for the probability variables created was either 
0.5 or 0.33 depending on the number of branches present when allocating the probability. To 
obtain the high values and low values for the probability variables, 50% was added and 50% 
was subtracted from the numeric value of the variable (i.e. 0.5 or 0.33). 
 
3.7.4.3.2 Probabilities  
The probability of a patient following a certain pathway was then added to the models. 
Probabilities were assigned to every branch that came out from a chance node. On the 
models, the probability of an outcome was represented by the number below its respective 
branch. The sum of the branch probabilities from a chance node was equal to one.  
 
The probabilities for the actual models were derived from the information obtained from the 
patients’ retrospective records. For the theoretical arm introducing the Xpert MRSA, the sub-
trees that were the same as the clinical arms had the same probabilities as the clinical arms 
and the sub-trees that represented the theoretical situation were assigned equal probabilities 
of 0.5 when there were two branches and 0.33 when there were three branches emanating 
from a chance node.  
 
The actual decision-tree-analytic models were then run by creating and using variables to 
allocate equal probabilities to each branch of the model for each ward. These were then 
referred to as the equal decision-tree-analytic models. For these models, it was assumed 
that a patient had an equal chance of experiencing either outcome, thus equal probabilities 
were allocated to each branch (0.50 when there were two branches and 0.33 when there 
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were three branches). For these models, instead of using numeric values, variables were 
created and used as the probabilities for each branch. 
 
3.7.4.3.3 Payoffs 
At every terminal node, payoffs were allocated. Payoffs represent the total cost of each 
pathway from the decision node until that terminal node. The payoffs were calculated by 
adding the cost variables that were used within each pathway to determine the total cost per 
patient entering that pathway. 
 
3.8 Data Analysis  
3.8.1 Analysis of Ethnographic Observations  
A distinguishing feature between qualitative and quantitative research is that in qualitative 
research, data analysis is a continuous process as it is performed both during and after data 
collection. Inductive Analysis was used to analyse the ethnographic observations that were 
conducted. 
 
After each observation, the data collected was organised and divided into small sections 
based on different concepts and transcribed onto Excel so that it would be easy to analyse. 
Data coding then occurred, which involved first identifying segments in the data. Each 
segment represented one concept or an essential aspect of information and was then 
assigned to a minimum of one code that describes the segment. Once the codes were 
allocated to the segments, a list of all the codes used in each section was formulated and 
analysed to remove codes that were repeated and then sorted into the important codes, 
major codes and minor codes. Codes which were similar were grouped together into a 
category which was then named to describe the group of codes. The relationships between 
the categories were then studied in order to find patterns in the data. These patterns were 
then used as a basis for describing the results and informed the quantitative research that 
followed.  
 
3.8.2 Analysis of Retrospective Records and Antibiotic Utilization Review  
3.8.2.1 Retrospective Patient Data Analysis  
The retrospective records of the patients that were identified to have MRSA in the two wards 
in 2013 were accessed from the Hospitals Medical Records Room. Once the data collected 
from the patients’ retrospective records was entered onto Excel templates, they were sorted 
according to demographic, antibiotic and microbiology laboratory test data per ward.  
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3.8.2.1.1 Antibiotic Utilization Review   
Within the patients’ retrospective records, there were doctors’ prescription charts and nurses’ 
administration charts showing all the medication that was prescribed and administered to the 
patient. For each patient, the antibiotics on these charts were recorded on the patient's 
individual case report form, transferred to an Excel spread sheet and then summarised 
below. It was found that many of the prescriptions were incomplete and therefore 
assumptions had to be made and some antibiotics had to be excluded due to insufficient 
data. These assumptions are discussed in Section 5.9. 
 
The total number of antibiotic prescriptions per ward was calculated and then analysed by 
sorting them into three different types: Empiric, MRSA-Specific and Other Antibiotics. The 
range, median, average and total number of each type of antibiotic administered per ward 
was calculated. 
 
For each antibiotic administered the following analysis per ward was then conducted: 
- The range, median and average number of days of administration  
- The number of patients that received the antibiotic  
- The number of prescriptions for the antibiotic  
 
Lastly, for each antibiotic the Prescribed Daily Dose (PDD) of each antibiotic administered to 
each patient was calculated and compared to the WHO DDD. The DDD used in this study 
were last updated on 19 December 2013 (World Health Organization Collaborating Centre 
for Drug Statistics Methodology, 2013) .  
 
3.8.2.1.2 Microbiology Laboratory Test Data Review 
Within the patients’ retrospective records, there were printouts of NHLS laboratory test 
results or tables in which the HCPs recorded the laboratory test results. However, the print-
outs were not always present and the tables were not always complete. Therefore, to 
determine and analyse the NHLS laboratory tests that isolated MRSA in the study 
population, the data received from the NHLS Information System was used and not the 
NHLS laboratory tests in the patient records, although these were used to cross-reference in 
the case of missing data.   
 
For each ward the following analysis was conducted regarding the microbiology laboratory 
tests that isolated MRSA: 
- Total number of tests per ward 
- Range and average number of tests per patient  
- Percentage of the different types of specimens that isolated MRSA   
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3.8.3 Cost Analysis Cost Calculations  
Various cost calculations were conducted using the costing databases in conjunction with the 
antibiotic utilization data obtained from the patients' retrospective records and the information 
received from the NHLS Information Systems regarding the NHLS laboratory tests that 
isolated MRSA in the study population. Costing calculations were conducted separately for 
each ward. 
 
3.8.3.1 Antibiotic Cost Calculations 
The daily cost and the total utilization cost was calculated for each antibiotic administered to 
each patient in each ward. The daily cost was the cost of the antibiotic per day per patient 
and was calculated by multiplying each patient’s prescribed daily dose by the cost of that 
antibiotic. The total utilization cost was the total cost of the antibiotic administered to the 
patient and was calculated by multiplying the patient's daily cost by the number of days that 
the antibiotic was administered to the patient. The daily costs were then categorised as the 
daily cost of Empiric Antibiotics, the daily cost of MRSA-Specific Antibiotics and the daily cost 
of Other Antibiotics.  
 
The average daily utilization costs and the average total utilization cost for each of the 
different antibiotics administered were also calculated per ward. For each different antibiotic, 
the average daily utilization cost was calculated by adding each patient's daily utilization cost 
for that antibiotic and dividing it by the number of patients that received that antibiotic. The 
average total utilization cost was calculated for each different antibiotic by adding each 
patient's total utilization cost and dividing it by the number of patients that received that 
antibiotic.  
  
Thus the following antibiotic cost-utilization calculations were done for each patient in the 
study population:  
- Daily utilization cost per patient: 
o per antibiotic (cost of antibiotic x patient's daily dose) 
 per Empiric Antibiotic  
 per MRSA-Specific Antibiotic  
 per Other Antibiotic 
o of all antibiotics administered (sum of Daily utilization cost per antibiotic per patient) 
 of all Empiric Antibiotics administered  
 of all MRSA-Specific Antibiotics administered  
 of all Other Antibiotics administered  
- Total utilization cost per patient: 
o per antibiotic (cost of antibiotic x patient's daily dose x duration) 
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o all antibiotics administered (sum of Total utilization cost per antibiotic per patient) 
 
For each ward in the study population the following antibiotic cost-utilization calculations 
were done: 
- Total and average cost of:  
o the daily utilization cost (sum of each patient's daily utilization cost) 
o the Empiric Antibiotic daily utilization cost 
o the MRSA-Specific Antibiotic daily utilization cost 
o the Other Antibiotic daily utilization cost 
o the total utilization cost (sum of each patient's total utilization cost) 
 
For each antibiotic used in the study population the following calculations were done for each 
ward: 
- The average number of days for which that antibiotic was used   
- The average cost per day of the antibiotic  
- The average total cost of the antibiotic  
 
3.8.3.2 NHLS Laboratory Test Cost Calculations 
Using the information received from the NHLS Information System, the hospital numbers of 
the patients that isolated MRSA in the orthopaedic and vascular wards were selected. The 
laboratory test numbers that were allocated to each of these patient hospital numbers were 
identified. On the costing information sheet, the laboratory test number was used to identify 
all the steps and respective costs that were associated with that laboratory test. This was 
done for each laboratory test number. The calculated cost of each laboratory test was then 
allocated back to the patient hospital number that had that test. To maintain patient 
confidentiality and anonymity, the actual laboratory test numbers were changed to allocated 
laboratory test numbers (for example LT601, LT602) in this study.   
 
This had to be done as the cost of each laboratory test differed due to a variation in the steps 
that were conducted in each laboratory test. The sum of all the laboratory tests conducted for 
each patient was then calculated. The costs were also separated into Microscopy cost and 
Culture and Sensitivity costs. 
 
The following laboratory test cost-utilization calculations were done for each patient in the 
study population:  
- Cost per NHLS laboratory test per patient (based on the laboratory test number) 
- Cost of only microscopy per NHLS laboratory test per patient 
- Cost of only culture and sensitivity per NHLS laboratory test per patient 
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- Total cost of all NHLS laboratory tests used per patient  
- Total cost of only microscopy in all NHLS laboratory tests used per patient  
- Total cost of only culture and sensitivity in all NHLS laboratory tests used per patient  
 
For each ward in the study population the following laboratory test cost-utilization 
calculations were done: 
- Average cost of one NHLS laboratory test  
- Average cost of microscopy for one NHLS laboratory test 
- Average cost of culture and sensitivity for one NHLS laboratory test  
- Total and average cost of all NHLS laboratory tests used  
- Total and average cost of only microscopy in all NHLS laboratory tests used  
- Total and average cost of only culture and sensitivity in all NHLS laboratory tests used  
 
3.8.3.3 Antibiotic Utilization plus NHLS Laboratory Tests Cost Calculations  
For each patient the sum of the total cost of antibiotics administered and the total cost of 
NHLS laboratory tests conducted that isolated MRSA was calculated to obtain the total 
Antibiotic Utilization and NHLS Laboratory Test cost per patient.  
 
3.8.4 Analysis of the Decision-Tree-Analytic Models 
Once the structures of the decision-tree-analytic models were complete, the models were 
analysed by performing Rollback, Rankings, Tornado and Sensitivity Analysis. The analysis 
of each model was interpreted to assess the effects of the different variables, probabilities 
and pathways in the tree. The analysis of the models were then compared  to evaluate the 
differences in costs in order to ultimately assess whether using the current Conventional 
Culture Method or the Xpert MRSA tests for MRSA would be cost-saving in the current 
setting. The preference set for the models was simple single-attribute calculations, with the 
optimal path for decisions being low.  
 
3.8.4.1 Rollback and Rankings 
The decision-tree-analytic models were first analysed by performing the Rollback analysis 
which calculated the expected values of each node. It is important to note that decision-tree 
calculations are performed backwards, from right to left. Thus it is termed rollback, as the 
values of each pathway are rolled back from the terminal node back to the decision node in 
order to present an expected value for each pathway. The payoff values and path probability 
were calculated at each terminal node and the expected values were calculated at each 
chance node. The expected value of the ideal pathway was shown at the decision node and 
the ideal pathway was also indicated as a coloured branch, with the non-ideal pathways 
represented by two slash marks (TreeAge Software INC, 2013). 
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By selecting the decision node and performing a Ranking Analysis, a text report was 
generated which ranked the various alternative pathways from the decision node along with 
their expected values. The rankings analysis also showed the incremental value which was 
the difference between two pathways. The strategy with the highest ranking was essentially 
the optimal pathway with the lowest cost. 
 
The Ranking Analysis was performed for each model and then tabulated in order to compare 
the rankings of the different pathways depicted in the models.  
  
3.8.4.2 Sensitivity Analysis  
One-way Sensitivity Analyses were conducted for each variable in each of the decision-tree-
analytic models. This process was conducted for all four decision-tree-analytic models. Once 
all the One-way sensitivity analyses were completed, the graphs were interpreted and 
discussed.  
 
3.8.4.3 Tornado Analysis  
The one-way sensitivity analyses of all the variables from a particular decision-tree-analytic-
model could be represented in a single graph called a Tornado Diagram. Each variable in the 
decision-tree-analytic model was displayed in the Tornado Diagram as a different- coloured 
horizontal bar. The range of the expected values that were created when varying the variable 
was represented by the length of the bar, as the x-axis of the Tornado Diagram showed the 
expected value. Variables that were potentially the most uncertain and had a great effect on 
the expected value were represented as wide bars on the Tornado Diagram and were 
situated at the top of the diagram. The rest of the variables were also arranged and displayed 
in an order causing the narrowest bar to be situated at the bottom of the diagram closest to 
the x-axis.  
 
 49 
 
4. RESULTS   
 
4.1 Study Population  
The study population consisted of all patients in an orthopaedic ward and vascular ward at 
CMJAH in 2013 that were identified as having isolated MRSA according to the data received 
from the NHLS data information systems. 
 
4.1.1 Patient Characteristics and Demographic Data 
The demographic data of the patients in the study population was obtained from their 
retrospective records. The data from the two wards was not directly compared as they are 
two different types of clinical wards and the patients presented with different clinical 
conditions. 
 
4.1.1.1 Orthopaedic Ward  
From the 18 patients that were identified to have MRSA in the orthopaedic ward in 2013, two 
of these patients’ retrospective records were inaccessible from the Hospital's Medical 
Records Room. Thus, the demographic data and patient characteristics of the 16 patients 
relating to gender, age, length of stay in hospital, diagnosis and operations was summarised. 
The ages of the patients ranged from 17 years to 70 years, with an average age of 47 years 
and 68.75% were male. The length of stay in hospital per patient was calculated by counting 
the number of days between their date of admission and date of discharge. The average 
length of stay of a patient with MRSA in the orthopaedic ward was 48 days, but length of stay 
ranged from 17 days to 97 days as shown in Table 2. When looking at the main diagnosis of 
the patients, presented in Table 3, 62.50% had chronic osteomyelitis and 31.25% recorded a 
form of sepsis. For some of the patients more than one diagnosis and operation was 
recorded on their discharge sheet. Diagnoses and operations that occurred in one patient 
only were classified as Other. 56.25% of the patients had DRI (Debridement, Reaming and 
Irrigation) operations and 31.25% of the patients underwent an operation to remove a nail, 
plate or prosthesis.  
 
Table 2: Age and Length of Stay in Hospital of the Patients in the Study Population in 
the Orthopaedic Ward in 2013 
n=16 Range Median Average 
Age (Years) 17 - 70 45 47 
Length of Stay (Days) 17 - 97 41 48 
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Table 3: Number of Patients with Common Diagnoses, Operations and Procedures 
Performed in the Study Population in the Orthopaedic Ward in 2013 
 Number of Patients 
Diagnosis  
Chronic Osteomyelitis 10 
Arthritis 2 
Sepsis 5 
Other 6 
  
Operation / Procedure  
Remove Nail/plate/prosthesis 5 
DRI 9 
Debridement 4 
Revision  2 
Arthrotomy 2 
Amputation  2 
Other 6 
  
4.1.1.2 Vascular Ward   
Thirty-six patients in the vascular ward were identified as having MRSA in 2013. However, 
seven of these patients’ retrospective patient records were excluded due to missing data. 
The demographic data and patient characteristics of the 29 patients relating to gender, age, 
length of stay in hospital, diagnosis and operations was summarised and shown in Table 4 
and Table 5. The age of the patients ranged from 39 years to 89 years with an average age 
of 61 years and 75.86% of the patients were male. The length of stay in hospital per patient 
was calculated by counting the number of days between their date of admission and date of 
discharge. The average length of stay of a patient with MRSA in the vascular ward was 38 
days, but the length of stay ranged from four days to 125 days for a patient who had multiple 
conditions including severe sepsis and nosocomial pneumonia before passing away. 
Diabetes mellitus and hypertension were commonly diagnosed in these patients and were 
thus excluded when summarising their diagnoses. Some patients had more than one 
diagnosis and operation recorded on their discharge sheet. Diagnoses and operations that 
were only present in one patient were classified as Other. 37.93% of the patients had a form 
of sepsis, 34.48% had Peripheral Vascular Disease (PVD) and 37.93% had other diagnoses. 
72.41% had either a Below-Knee Amputation or an Above-Knee-Amputation, 58.62% had 
debridement and 41.38% had other operations.  
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Table 4: Age and Length of Stay in Hospital of the Patients in the Study Population in 
the Vascular Ward in 2013 
n=29 Range Median Average 
Age (Years) 39 - 89 59 61 
Length of Stay (Days)   4 - 125 35 38 
 
Table 5: Number of Patients with Common Diagnoses, Operations and Procedures 
Performed in the Study Population in the Vascular Ward in 2013  
 Number of Patients 
Diagnosis  
PVD 10 
Sepsis 11 
Infra/Fem-Pop Disease 6 
Ischemia 5 
Other 11 
  
Operation / Procedure  
Amputation 21 
Debridement 17 
Bypass 6 
Formalisation  3 
Superficial Skin Graft  3 
Other 12 
 
4.2 Ethnographic Observations  
4.2.1 Clinical Ward Observations  
Clinical observations were conducted in the orthopaedic ward and the vascular ward. From 
the data that was observed and collected, the clinical practices in the two wards were similar 
and therefore both clinical observations are described as one. Figure 5 outlines the various 
aspects that were observed and documented during the observations in the orthopaedic and 
vascular wards.      
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Figure 5: Various Clinical Aspects Observed in the Orthopaedic and Vascular Wards 
 
4.2.1.1 Ward Rounds 
A team of HCPs that conducted the morning ward rounds was observed. The team always 
consisted of the medical interns that were currently allocated to that ward and a nurse that 
was on duty in the ward. Doctors, specialists, consultants of the ward and other HCPs such 
as a radiologist and physiotherapist were also part of the team on some mornings.  
 
4.2.1.2 Patient Notes 
For each patient the medical intern greeted the patient and opened the patient’s record to 
read the previous doctor's written notes. Some patients were asked about pain, current 
symptoms, or other brief questions related to the patient’s condition. The intern also looked 
for any new laboratory test results, x-rays and current medication prescriptions in the 
patient's record and these were discussed with the team of HCPs on the current ward round. 
If a patient was recovering post-surgery, the patient’s wound was checked or movement of 
the limb assessed. The medical intern then wrote the date and the key points from the ward 
round below the previous notes in the patient’s record. The nurse present on the ward round 
wrote in her book the instructions discussed amongst the HCPs, for example, how often the 
patient’s irrigation drip should be measured.  
 
4.2.1.3 Infection Control 
The use of antiseptic/disinfectant hand-rub and hand washing practices of HCPs during the 
wards was observed and documented. D-Germ hand-rub was placed on some of the 
WARD 
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patient’s bedside tables in the orthopaedic ward. In the vascular ward, a medical intern 
carried around a bottle of D-Germ hand-rub from patient to patient during the ward round. 
HCPs did not consistently use D-Germ hand-rub after consultation with each patient. In most 
cases, HCPs only used D-Germ hand-rub after physical contact with the patient and HCPs 
washed their hands after exposing and touching a patient’s wound. It was common practice 
amongst the HCPs to use D-Germ at the end of the ward round. 
 
On the walls of the wards there were posters regarding infection control Standard 
Precautions, with the following information: 
- Applied to all patients at all times irrespective of diagnosis 
- All body fluids (except sweat) are regarded as potentially infectious: 
o If it is wet, wear gloves 
o If it can splash/spray or aerolise wear a mask/goggles 
o Wear a gown or plastic apron  
o Wash hands:  
 Before and after patient care 
 After touching body fluids 
 After removing gloves 
 Before caring for another patient   
 
During the routine morning ward rounds it was observed that PPE such as masks, gloves 
and gowns were infrequently used by HCPs. Gloves were worn if a wound was exposed or a 
drip was inserted or a specimen taken. The nurses wore disposable gowns and gloves when 
changing patients' bedding or wound dressings. There was no consistent protocol followed 
regarding the use of PPE in the wards.  
 
4.2.1.4 Septic Workup 
Routinely the nurse measured the patient’s temperature twice daily. If the patient’s 
temperature was above 37.5°C or the patient displayed symptoms of an infection, a septic 
workup was initiated. This included but was not limited to requesting a chest x-ray to 
determine the source of infection; taking a urine specimen and sending it to the microbiology 
laboratory for MCS; drawing blood for a full blood count; and testing for C Reactive Protein. 
The nurse usually administered a stat dose of paracetamol and depending on the severity of 
the patient’s symptoms; a broad-spectrum Empiric Antibiotic was administered while waiting 
for the MCS laboratory test results. During ward rounds, the HCPs tried to follow up on the 
results of the MCS laboratory tests and often, if the results were not available, could not be 
found, or if the patient's symptoms deteriorated, the HCPs requested that another specimen 
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be taken and sent to the microbiology laboratory for MCS, which in some case resulted in 
unnecessary laboratory tests being conducted.  
 
Once the patient’s MCS laboratory results were available, their antibiotic prescription was 
changed accordingly by the HCPs, although this was subject to a time delay as the 
antibiotics would only be changed during the HCPs next ward round and certain antibiotics 
such as linezolid required that a consultant or senior doctor sign a motivation form before the 
antibiotic could be dispensed and administered to the patient.   
 
4.2.1.5 Isolation  
If a patient displayed signs of a serious infection and isolation of the patient was required, the 
patient was moved to a smaller room with only two beds in the ward. This room served as 
the patient’s isolation. However, if a second patient also required isolation due to the same or 
different infection, and there were no other available small rooms, the second patient was 
placed in the same room as the first patient. If there were no smaller rooms available, the 
patient was placed in the corner of the main room in the ward.  
 
4.2.1.6 Antibiotic Administration  
Blood cultures were not done pre-operatively, but tissue specimens from operations and 
procedures were sent to the microbiology laboratory and the results sent back to the ward. In 
the orthopaedic ward, it was a common practice that post-operative patients received IV 
gentamicin until laboratory results reporting no infection were obtained. If the laboratory 
results reported an infection, the antibiotics were changed accordingly. Following the 
instructions from the HCPs during the ward rounds, the nurses also extracted fluid from the 
patient’s wound irrigation system and sent it to the microbiology laboratory to check for 
infection. 
 
In some cases there was a time delay, ranging from a few hours to a few days, between 
when the laboratory results were received indicating that a patient had MRSA and when the 
patient’s antibiotics were changed to MRSA-Specific Antibiotics. In other cases, some 
patients did not receive MRSA-Specific Antibiotics.     
 
The observations aided in gaining a clearer understanding of the daily clinical practices of 
HCPs regarding the current management of patients suspected of having an MRSA infection 
and the clinical pathways that follow, depending on whether the patient had MRSA or not. 
The knowledge gained from the observations greatly assisted in understanding and 
interpreting the patient records when looking at the retrospective patient records. 
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4.2.2 NHLS Microbiology Laboratory Observations  
Observation at the Bacteriology Bench of the NHLS Microbiology Laboratory at CMJAH 
provided an explanation of the current method used when a sample for a suspected infection 
was received. The laboratory procedure, from when a specimen for a suspected infection 
was received until a confirmed diagnosis was made, was documented with special attention 
to the steps involved when a Gram-positive, Staphylococcus aureus or MRSA infection was 
suspected and detected. 
 
4.2.2.1 Conventional Culture Process  
The observations demonstrated that when a sample for a suspected infection was received 
in the laboratory, the Conventional Culture Method was used to determine the type of 
infection. The Conventional Culture Method has three main steps: Microscopy, Culture and 
Sensitivity, commonly referred to as “MCS”. However, to clearly describe the observations, 
two additional preparation steps were included. Therefore, all five steps are listed in Figure 6 
and thereafter each step is explained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Steps Involved in the Conventional Culture Method   
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 56 
 
4.2.2.1.1 Planting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Process Involved in the Planting Step 
The first step of the Conventional Culture Method in the microbiology laboratory was referred 
to as “Planting” and is explained in Figure 7. The process of staining the microscopy slide 
was: firstly, crystal violet was applied for one minute and then rinsed with water; secondly, 
Gram's iodine was applied for one minute and rinsed with water; thirdly, Gram's decolourize 
was applied for ten seconds and rinsed with water; lastly, Gram's safranin was applied for 30 
seconds and rinsed with water. The complete process of Planting took approximately ten 
minutes per sample.  
 
4.2.2.1.2 Microscopy 
 
 
 
 
 
 
 
Figure 8: Process Involved in the Microscopy Step 
 
The second step observed was “Microscopy” which is outlined in Figure 8. The identified 
were cells and bacteria were recorded on the working card for each sample. Staphylococcus 
Receiving and identifying the type of sample.  
Depending on the type of sample, the type and number of agar plates were taken out.  
A part of the sample was swabbed on to each agar plate and on the microscopy slide.  
The microscopy slide was then placed on the hot-plate to dry.  
While waiting for the microscopy slide to dry, a metal rod was heated over a Bunsen-burner.  
The heated rod was used to streak each agar plate. 
The plates were then incubated. 
The dried microscopy slide was then stained several times. 
The microscopy slide was finally dried again on the hot-plate. 
One drop of immersion oil was applied onto the slide to view bacteria at 100 X magnification. 
The prepared slide was read under a microscope. 
The presence of neutrophils, lymphocytes, erythrocytes, cocci, bacilli etc. were identified. 
Staphylococcus aureus = Gram-positive cocci in clusters.    
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aureus presents as Gram-positive cocci in clusters under the microscope. The process of 
microscopy took approximately five minutes.  
 
4.2.2.1.3 Culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Process Involved in the Culture Step 
 
The third step observed was “Culture” and is unfolded in Figure 9. The following was 
observed for one plate focusing on the identification of Staphylococcus aureus. If small white 
colonies were present, there was a possibility of Gram-positive cocci, which required a 
catalase test to be conducted to identify if it was a staphylococcus or streptococcus infection. 
Working on the MacConkey agar plate, a pin was used to pick from the agar and the picked 
agar was placed on the lid of the plate. One drop of catalase reagent (hydrogen peroxide) 
was placed on the picked agar on the lid. If it bubbled, it was termed catalase-positive, which 
indicated that it was staphylococcus. If it did not bubble, it was termed catalase negative, 
which indicated that it was streptococcus. If it was catalase-positive, the staphaurex test was 
then performed. One drop of staph xtra latex was placed on the test card. The mixing stick 
was used to pick from the agar and then rubbed on the test card. If the blue agglomerated, it 
was termed staphaurex-positive, which indicated that it was Staphylococcus aureus. If there 
was no growth of fine growth on the agar plates, the plates were incubated for a further 24 
hours. If there was mixed growth, sub-culturing was performed. The results were entered on 
the corresponding working card. The culture step took place over approximately five to ten 
minutes per plate. 
Agar plates were retrieved from the incubator.  
One laboratory person had read the agar plates that were incubated for 24 hours. 
Another laboratory person had read the agar plates that were incubated for 48 or 72 hours. 
The agar plate was opened to read the growth on the plate.  
The plate was also passed across the nose to identify the smell of possible organisms.  
If small white colonies were present  possibility of Gram-positive cocci. 
Catalase test  If it bubbled (Catalase positive) = Staphylococcus. 
Staphaurex test  If the blue agglomerated (staphaurex-positive) = Staphylococcus aureus. 
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4.2.2.1.4 Picking 
 
 
 
 
 
 
 
 
 
Figure 10: Process Involved in the Picking Step 
 
If Staphylococcus aureus was identified, the next step observed was “Picking” as described 
in Figure 10. A heavy inoculum (adding too much organism) was avoided as it could lead to a 
false MRSA reading. Picking took approximately two minutes.  
 
4.2.2.1.5 Antibiotic Sensitivity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Process Involved in the Antibiotic Sensitivity Step 
The organism was emulsified in normal saline: 
An inoculation loop was burnt over a Bunsen-burner 
Some organism was picked from an agar plate 
The picked organism was placed into a test tube which contained normal saline.  
The aim was to obtain a 0.5 McFarland.   
A sterile swab was dipped into the solution made and swabbed onto two Mueller Hinton agar 
plates and labelled P1 + FOX and P2 + FOX.  
The antibiotic disc dispenser P1 was placed and stamped onto the P1 + FOX plate and the 
antibiotic disc dispenser P2 was placed and stamped onto the P2 + FOX plate. 
A FOX disc was then placed onto the middle of each of the plates.  
These plates were then incubated and read after 24 hours.  
If there was growth around an antibiotic disc  The organism was resistant to that antibiotic.  
If there was a clear zone around an antibiotic disc  The organism was sensitive to that 
antibiotic. 
To identify if it was MRSA  FOX zone was measured   If the zone was less than  22 mm it 
indicated that it was MRSA.  
If MRSA was identified  A Vanco Etest was performed.   
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The final step of the Conventional Culture Method was “Antibiotic Sensitivity” using the disc 
diffusion method as shown in Figure 11. The preparation of the antibiotic sensitivity plates for 
incubation took about five minutes. After incubation, to identify if it was MRSA, the FOX 
(Cefoxitine) zone was measured. If the zone was greater than 22 mm it indicated that it was 
Staphylococcus aureus. If the zone was less than 22 mm it indicated that it was MRSA. The 
results were then entered onto the corresponding working card; this process took 
approximately two minutes.  
 
If MRSA was identified, the zone size of the vancomycin disk was not measured. Rather, a 
Vanco Etest was performed. This was done by blood agar being picked from a plate that had 
the organism; an inoculum of 0.5 McFarland in normal saline was prepared; the solution was 
swabbed on an agar plate; the Etest strip was placed on the plate and then the plate was 
incubated. After 24 hours the plate was read, the results were entered on the corresponding 
working card; this process took approximately two minutes.   
 
Once the laboratory personnel had worked with the required samples and plates in each 
step, they transferred the daily results from the working cards onto a computer system which 
was accessible to the doctors as provisional results. Once all tests and readings had been 
performed for a sample, after 48 to 72 hours depending on the type of growth, the results 
were checked by the pathologist and the results were finalised.  
 
4.2.2.2 Timing Involved in the Conventional Culture Method 
Before and after each step, the laboratory personnel swabbed the working bench with 
alcohol and wore gloves and a laboratory coat at all times. The laboratory personnel did not 
perform the complete process of MCS for each individual plate; rather they performed each 
step for all the plates before moving onto the next step. It was difficult to allocate an exact 
time to each step as the reading and interpreting of some plates took longer than others due 
to the growth patterns.  
 
Table 6: Hands-on Time and Incubation Time Involved in the Conventional Culture 
Method at the NHLS Microbiology Laboratory at CMJAH 
 Planting Microscopy Culture Picking Sensitivity 
Hands-on Time 
(Minutes) 
 10 5 5 - 10 2 10  
Incubation Time 
(Hours) 
24  24  24  
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Therefore, as illustrated in Table 6, the hands-on time allocated to each time was not the 
exact time but rather the approximate and average time that the laboratory personnel spent 
performing that process for one specimen. The incubation time was also not always standard 
as additional incubation time was required depending on the growth of the organisms, or 
further process that needed to be performed. The culture process was performed after initial 
incubation of 24 hours and thereafter performed again once the plates were incubated for 48 
hours and 72 hours if required. For the Antibiotic Sensitivity process an additional 24 hour 
incubation period was added if a Vanco Etest was performed. 
 
The observations at the bacteriology bench of the NHLS Microbiology Laboratory at CMJAH 
assisted in understanding and interpreting the patient records when looking at the 
retrospective patient records. The observations also helped gain an understanding of why a 
definite time cannot be allocated to the process, as well as an awareness of the numerous 
amounts of resources involved in this process. Thus, these observations informed the type of 
enquires and research to be conducted using the qualitative research methods that follow in 
the rest of the study.  
 
4.2.3 Antibiotic Dispensary Observations  
Information regarding the current antibiotic dispensing policies for inpatients was obtained by 
observations and assistance from the pharmacist in charge of the antibiotics designated area 
at CMJAH’s main dispensary. The main dispensary at CMJAH has a designated room for the 
storage and dispensing of antibiotics. Access is restricted unless a pharmacist is present and 
there is a designated Antibiotics Stewardship pharmacist in charge. 
 
There were no written protocols available regarding the general policies used for dispensing 
antibiotics to inpatients at CMJAH. The pharmacist said that they mainly follow the decisions 
of the Pharmacy and Therapeutic Committee and this may differ between wards within 
CMJAH and between hospitals.  
 
4.2.3.1 Prescribing and Dispensing of Antibiotics  
The process of prescribing and dispensing antibiotics to inpatients was explained by a 
pharmacist. In the wards, the doctors prescribe antibiotics on the patient’s prescription chart. 
The nurse then copies the prescription onto a dispensary order form and attaches the 
relevant signed motivation forms. If the antibiotic for a patient was urgent, the nurse would 
bring the order form to the dispensary and take the medication back to the ward. If the 
antibiotic for a patient was not urgent, runners fetched the forms from the wards and later 
delivered the antibiotics to the wards. Depending on the availability of stock of the requested 
antibiotics, the dispensary normally dispensed three, five or seven days’ supply of the 
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antibiotic prescribed for the patient. It was then the duty of the nurse to manage the 
antibiotics in the ward. On Tuesdays and Wednesdays the dispensary dispensed antibiotics 
for seven days. On Mondays, Thursdays and Fridays the dispensary dispensed antibiotics 
for five days. If a new patient was admitted and needed antibiotics during the weekend, the 
antibiotics were administered if there were extra antibiotics available in the ward, or they 
were taken from the emergency cupboard or, if there were none, a pharmacist would be 
called in. If there were remaining antibiotics from one patient, they were often used for 
another patient requiring the same antibiotic but waiting for theirs to arrive. However, 
antibiotics were mainly dispensed on a per-patient basis. A small quantity of antibiotics such 
as metronidazole, cloxacillin and clindamycin were kept as ward stock. The dispensary did 
not receive many prescriptions for antibiotics from the orthopaedic ward, as the orthopaedic 
ward ordered most of their Empiric Antibiotics in bulk once a week.  
  
4.2.3.2 Restricted Use 
Due to the potential for misuse of antibiotics, certain antibiotics had restricted use and the 
dispensary required stipulated documents before dispensing them. Table 7 provides an 
example of the restricted dispensing of antibiotics at CMJAH based on the information 
obtained from the pharmacist.  
 
Table 7: Example of Restricted Dispensing of Certain Antibiotics at CMJAH   
Antibiotic 
Motivation 
Required 
Authorisation 
Laboratory 
Results Required 
Vancomycin Yes Prescribing Doctor and Consultant  No  
Linezolid  Yes Certain Consultants only Yes  
Carbapenems  Yes Prescribing Doctor and Consultant  Yes  
 
For vancomycin, the dispensary required a motivation form to authorise the prescription. The 
form had to have two signatures, one from the prescribing doctor and one from the 
consultant. If the consultant was unavailable, any senior doctor could sign and authorise the 
form. Laboratory results were not required for vancomycin to be dispensed. In contrast, the 
dispensary was strict with dispensing linezolid. Microbiology laboratory results were first 
required and linezolid was dispensed only if there were no Other Antibiotics that could be 
used, as it was more expensive compared to vancomycin. With regard to meropenem, 
imipenem and ertapenem, microbiology laboratory results were also required before these 
antibiotics were dispensed. However, the dispensary was flexible and it depended on each 
individual patient’s case.  
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4.2.3.3 Antibiotic Stewardship 
Observations as well as enquiry in the wards and dispensary revealed the following about 
the existing Antibiotic Stewardship programme at CMJAH:  
 The pharmacists were not actively involved in the programme.  
 The pharmacist felt that if they were actively involved and present during the ward 
rounds they would be able to improve the current Antibiotic Stewardship programme. 
They would be able to guide prescribing and immediately inform the doctors if certain 
antibiotics were out of stock and to prescribe an alternative to prevent a delay in 
treatment.  
 When a pharmacist does not dispense certain antibiotics or has certain requirements 
before dispensing, at times the doctors and nurses would disagree with the 
pharmacist and feel that the pharmacist was denying the use of antibiotics or did not 
trust the doctor’s judgment. However, if a pharmacist was actively present in the ward 
they would be able to explain their reasoning.  
 A pharmacist would also be able to oversee the manner in which the antibiotics were 
controlled and administered in the ward as the ward often returns expired antibiotics 
which is wasteful as the antibiotics could have been used for patients in other wards. 
 If pharmacists do become involved in the wards, it was felt that more pharmacists 
would be needed and clinical pharmacologists would need to be introduced.  
 
4.2.4 Qualitative Analysis of Ethnographic Observation  
Inductive analysis was used to analyse the information obtained from the observations Table 
8, Table 9 and Table 10 are the summarised tables of the codes and categories along with 
explanations and the patterns derived from the observations in the wards, NHLS 
Microbiology Laboratory and Antibiotic Dispensary. The detail tables that were used to list all 
the codes to classify them in their respective categories are shown in Appendix 6 (Table 34, 
Table 35 and Table 36).  
 
4.2.4.1 Clinical Ward Observations  
 
Table 8: Summarised Codes and Categories Identified from the Ethnographic 
Observations in the Clinical Wards at CMJAH 
Categories Codes 
Communication   HCP-HCP; HCP-Patient; HCPs; Ward Rounds; Nurses 
Routine  Ward Rounds; Nurses 
Patient Records Ward Rounds; Doctors' Notes; Prescriptions; X-rays; NHLS reports 
Infection HCP-Patient; Ward Rounds; Nurses; Antiseptic hand rub; Hand-
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Control   washing; PPE; Isolation 
Antibiotics   NHLS Report; Empiric; Changed; Authorisation; Pre/Post-op  
Inconsistent   
HCPs; Doctors Notes; Anti-septic hand rub; Hand-washing; PPE; 
Protocols 
Specimens for 
MCS    
NHLS Reports; Redone; Pre/Post-op; Wound Irrigation; Confirmed; 
Suspected 
Delay  
Prescriptions; NHLS Reports; Empiric; Change; Authorisation; 
Isolation 
Infection NHLS Reports; Empiric; Pre/Post-op; Suspected; Confirmed; Isolation 
 
Based on the codes and categories in Table 8, patterns regarding the observations at the 
wards were deduced. The main patterns identified were Underlying Themes and Daily 
Practices. The Pattern of Daily Practices included the observed daily practices of HCPs 
regarding Infection Control, Specimens for MCS, Antibiotics and Patient Records. The 
pattern of Underlying Themes consisted of Routine, Communication, Inconsistent, Delay and 
Unavailable. 
 
4.2.4.2 NHLS Microbiology Laboratory Observations  
 
Table 9: Summarised Codes and Categories Identified from the Ethnographic 
Observations in NHLS Microbiology Laboratory at CMJAH  
Categories Codes 
Suspected MRSA 
Infection   
Specimen; Gram-positive cocci in clusters; Catalase-positive; 
Staphylococcus; Staphaurex-positive; Staphylococcus aureus; FOX 
Zone; Vanco Etest 
Conventional 
Culture Method 
Planting; Microscopy; Culture; Picking; Sensitivity; Vanco Etest   
Hands-on Time    
Ten minutes; Five minutes; Five to ten minutes; Two minutes; Ten 
minutes 
Incubation Times   24 Hours/48 Hours/72 Hours; 24 Hours; 24 Hours 
Results   
Recorded; Working card; Computer system; Provisional; Checked; 
Finalised  
Disposable 
Resources    
 Agar plates; Swab; Microscopy slide; Stains; Water; Immersion oil; 
Catalase test kit; Staphaurex test kit; Saline; Antibiotic discs; Etest 
strip 
Fixed Resources  
Microscope; Hot-plate; Metal rods; Inoculation loops; Test tubes; 
Bunsen-burner; Incubator; Antibiotic disc dispensers 
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From the codes and categories in Table 9, two important patterns relating to the observations 
at the NHLS Microbiology Laboratory were identified. The first pattern was time, which 
included hands-on time, which was the time spent by the laboratory personnel physically 
performing the processes and the incubation time which was the time that the agar plates 
had to be kept in the incubator. This pattern highlighted that not only is the Conventional 
Culture Method a lengthy process, it is a laborious process as well. The second pattern was 
the resources involved in performing the Conventional Culture Method, which was 
categorised as Disposable resources, those that were needed per specimen tested and 
fixed, or Capital resources. This pattern emphasised the amount of resources required to 
perform one test.  
 
4.2.4.3 Antibiotic Dispensary Observations  
 
Table 10: Summarised Codes and Categories Identified from the Ethnographic 
Observations in Antibiotic Dispensary at CMJAH  
Categories Codes 
Protocols   Not written; Differ; Per-patient; Ward; Dispensary  
Prescribing    
Per-patient; Ward; Doctors; Patient’s prescription chart; Dispensary 
order form; Motivation 
Dispensing   
Per-patient; Ward; Motivation; Runners; Dispensary; Waiting; 
Three/five/seven days  
Nurses  
Dispensary order form; Manage ward stock; Administer; Emergency 
cupboard; Roll-over  
Urgent     Emergency cupboard; On-call; Roll-over 
Authorisation   
Per-patient; Doctors; Motivation; Restricted; Waiting; Vancomycin; 
Linezolid; Carbapenems; MCS results 
Antibiotic 
Stewardship  
Ward; Doctors; Dispensary; Pharmacist inactive; Advantages; Out of 
stock; Expired; Communication  
Problems   Waiting; Out of stock; Expired; Communication 
  
Patterns of Current Procedure and Improvement were derived from the codes and categories 
in Table 10, from the observations at the antibiotics designated area of the main dispensary. 
The patterns were a basic emphasis of the Current Procedures involved in Prescribing, 
Dispensing and Authorisation as compared to the need for Improvement in the areas of 
Antibiotic Stewardship, Protocols and the current Problems Identified. The patterns revealed 
the manner in which the observed practices were carried out and suggested areas that 
needed further investigation using qualitative research methods. 
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4.3 Retrospective Records and Antibiotic Utilization Review 
4.3.1 Antibiotic Utilization Review  
4.3.1.1 Orthopaedic Ward  
A total of 103 antibiotic prescriptions were recorded for the 16 patients that had MRSA in the 
orthopaedic ward in 2013. However, 23 (24.27%) of these antibiotic prescriptions were 
excluded due to missing information. Therefore, a total of 78 antibiotic prescriptions were 
administered to the 16 patients. These 78 prescriptions were analysed and summarised in 
Table 11.  
 
Table 11: Number of Antibiotics Administered per Patient and in Total in the 
Orthopaedic Ward in 2013 
Number of Antibiotics 
Administered 
Per Patient Orthopaedic Ward 
Range Median Average Total 
Empiric Antibiotics 1 - 7 2.50 2.75 44.00 
MRSA-Specific Antibiotics  0 - 5  2.00 1.69 27.00 
Other Antibiotics  0 - 2 0.00 0.44 7.00 
All Antibiotics 2 - 9 4.00 4.88 78.00 
 
Each patient was administered a range of two to nine antibiotics, an average of five 
antibiotics per patient. The antibiotics administered were divided into Empiric Antibiotics, 
MRSA-Specific Antibiotics and Other Antibiotics. Of the antibiotics administered, 56.41% 
were Empiric Antibiotics which consisted of co-amoxiclav, gentamicin, cloxacillin and 
cefazolin. A range of one to seven Empiric Antibiotics were administered to each patient with 
an average of three Empiric Antibiotics per patient. The only MRSA-Specific Antibiotics 
administered in this ward were vancomycin, linezolid and rifampicin, which made up only 
34.62% of the total number of antibiotics. A patient received a range of between zero to five 
and an average of two MRSA-Specific Antibiotics. The remaining 8.97% were Other 
Antibiotics that were administered including cefotaxime, ertapenem, ciprofloxacin, 
ceftazidime and metronidazole.  
 
From the 78 antibiotics that were prescribed and administered to the 16 MRSA-positive 
patients, there were 18 antibiotics that were administered at different strengths and routes of 
administration, of which 12 were different antibiotics. Cefazolin IVI was commonly used in the 
orthopaedic ward, as 62.50% of the patients received cefazolin IVI; 20.51% of the 
prescriptions were for cefazolin either intra-operatively or post-operatively. Gentamicin was 
commonly administered as an irrigation system in the orthopaedic ward (to 68.75% of 
patients). Although all 16 patients had MRSA diagnosed, only nine of these patients received 
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MRSA-Specific Antibiotics during their time in the ward. It was also common that rifampicin 
was administered to eight out of the nine patients that received vancomycin.  
 
The number of days that an antibiotic was administered varied between the different 
antibiotics and patients, as shown in Table 12. Some patients received more than one 
prescription of the same antibiotics at different times during their time in hospital and this is 
also demonstrated in Table 12.  
 
Table 12: Number of Days of Administration, Number of Patients and Number of 
Prescriptions per Antibiotic in the Orthopaedic Ward in 2013 
Antibiotic 
Number of Days Number of 
Patients 
Number of 
Prescriptions Range Average 
Cefazolin IVI 1 - 12 2 10 16 
Gentamicin Irrigation System  3 - 32 14 11 11 
Vancomycin IVI 1 - 19 9 9 11 
Rifampicin  4 - 19 12 8 8 
Vancomycin Irrigation System  2 - 8 4 6 6 
Cloxacillin Capsules  10 - 20 15 4 5 
Cloxacillin IVI 1 - 10 5 3 4 
Co-amoxiclav 625 mg Tablets 14 - 29 21 3 3 
Co-amoxiclav 1 g Tablets  1 - 13 7 2 2 
Co-amoxiclav 1.2 g IVI  4 - 6 5 1 2 
Linezolid 1 - 6 4 2 2 
Ertapenem IVI 1 - 6 4 2 2 
Co-amoxiclav 0.6 g IVI  3 3 1 1 
Cefotaxime 9 9 1 1 
Metronidazole 7 7 1 1 
Ciprofloxacin  32 32 1 1 
Ceftazidime IVI 19 19 1 1 
Ceftazidime Irrigation System 1 1 1 1 
 
The doses of the antibiotics prescribed and administered to patients in the orthopaedic ward 
varied. Therefore, for each antibiotic prescribed and administered, the PDD was calculated 
and compared to the WHO DDD and is presented in Table 13. PDDs were not calculated for 
18 antibiotic prescriptions that were administered via an irrigation system, as the 
corresponding WHO DDD for irrigation systems were not available. Out of the 60 
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prescriptions, 40% of the PDD were equal to the DDD and 40% of the PDD were higher than 
the DDD. The remaining 20% of the DDD were lower than the PDD.  
 
Table 13: World Health Organization Defined Daily Dose (DDD) versus Prescribed 
Daily Dose (PDD) for Antibiotics in the Orthopaedic Ward in 2013 
Antibiotic 
WHO Per Prescription 
DDD (g) PDD (g) 
Number of 
Prescriptions 
Vancomycin IVI 2.00 2.00 8 
    1.00 2 
    9.00 1 
Linezolid oral 1.20 1.20 2 
Amoxicillin 500 mg oral  1.00 1.75 2 
 
  1.50 3 
Amoxicillin 1 g IVI  3.00 1.50 1 
 
  3.00 2 
Rifampicin oral 0.60 1.20 7 
    0.60 1 
Cloxacillin oral 2.00 4.00 5 
Cloxacillin IVI 2.00 2.00 1 
    3.00 1 
    4.00 2 
Cefazolin IVI  3.00 2.00 4 
    6.00 2 
    1.00 4 
    3.00 6 
Ertapenem IVI 1.00 1.00 1 
    1.00 1 
Cefotaxime IVI 4.00 9.00 1 
Metronidazole  1.50 1.20 1 
Ciprofloxacin oral 1.00 1.00 1 
Ceftazidime IVI 4.00 4.00 1 
 
4.3.1.2 Vascular Ward  
A total of 151 antibiotic prescriptions were recorded for the 29 patients that had MRSA in the 
vascular ward in 2013. However, 42 (27.81%) of these antibiotic prescriptions were excluded 
due to missing information. Therefore, a total of 109 antibiotic prescriptions were 
 68 
 
administered to the 29 patients. These 109 prescriptions were then analysed and 
summarised in Table 14.   
 
Table 14: Number of Antibiotics Administered per Patient and in Total in the Vascular 
Ward in 2013 
Number of Antibiotics 
Administered 
Per Patient Vascular Ward 
Range Median Average Total 
Empiric Antibiotics  0 - 8 1.00 1.62 47.00 
MRSA-Specific Antibiotics  0 - 4 0.00 0.72 21.00 
Other Antibiotics  0 - 5 1.00 1.41 41.00 
All Antibiotics 1 - 13 3.00 3.76 109.00 
 
Each patient was administered a range of one to thirteen antibiotics with an average of four 
antibiotics per patient. The antibiotics administered were categorised into Empiric Antibiotics, 
MRSA-Specific Antibiotics and Other Antibiotics. Of the antibiotics administered, 43.12% 
were Empiric Antibiotics which consisted of piperacillin/tazobactam, co-amoxiclav, cloxacillin, 
gentamicin, amoxycillin and cefazolin. A range of zero to eight Empiric Antibiotics was 
administered to each patient with an average of two Empiric Antibiotics per patient. The only 
MRSA-Specific Antibiotics administered in this ward were vancomycin and rifampicin, which 
made up only 19.27% of the total number of antibiotics. A patient received a range of 
between zero to four and an average of one MRSA-Specific Antibiotics. The remaining 
37.61% were Other Antibiotics that were administered including ertapenem, meropenem, 
imipenem, clindamycin, ciprofloxacin, metronidazole, ceftazidime, cefepime, clarithromycin, 
ciprofloxacin, cefuroxime, amikacin and co-trimoxazole. 
 
From the 109 antibiotics that were prescribed and administered to the 29 MRSA-positive 
patients, there were 27 antibiotics that were administered at different strengths and routes of 
administration, of which 20 were different antibiotics. Piperacillin/Tazobactam was a 
commonly used Empiric Antibiotic in the vascular ward (37.93% of patients). Co-amoxiclav 
was also commonly administered to the patients in the vascular ward. Although all 29 
patients were diagnosed with MRSA, only 11 of these patients received MRSA-Specific 
Antibiotics, of which all 11 patients received vancomycin and one patient received 
vancomycin and rifampicin during their time in the ward.  
 
The number of days that an antibiotic was administered varied between the different 
antibiotics and patients and is shown in Table 15. Some patients received more than one 
prescription of the same antibiotics at different times during their time in hospital and this is 
also demonstrated in Table 15.  
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Table 15: Number of Days of Administration, Number of Patients and Number of 
Prescriptions per Antibiotic in the Vascular Ward in 2013 
Antibiotic 
Number of Days Number of 
Patients 
Number of 
Prescriptions Range Average 
Vancomycin IVI 1 g 1 - 11 3 11 20 
Piperacillin/Tazobactam 1 - 14 6 11 19 
Co-amoxiclav IVI 1.2 g 1 - 20 6 13 14 
Meropenem IVI 1 g  1 - 11 6 5 6 
Cefepime IVI 1 g 2 - 9 5 5 5 
Ertapenem IVI 1 g 1 - 4 3 4 4 
Metronidazole IVI 5 - 11 7 4 4 
Co-amoxiclav 625 mg Tablets 10 - 13 12 3 3 
Meropenem IVI 500 mg  5 - 6 6 3 3 
Imipenem IVI 1 g  1 - 5 3 1 3 
Ciprofloxacin IVI  4 - 12 7 3 3 
Gentamicin IVI 3 - 7 4 2 3 
Co-amoxiclav 1 g Tablets  4 - 19 12 2 2 
Cloxacillin IVI 1 g  4 - 13 9 2 2 
Ceftazidime IVI 1 g  6 - 9 8 2 2 
Metronidazole Tablets  2 - 4 3 2 2 
Amoxycillin Capsules  1 - 13 7 1 2 
Clarithromycin  Tablets 1 - 6 4 1 2 
Co-Trimoxazole 1 - 7 4 1 2 
Clindamycin IVI 600 mg 17 17 1 1 
Cloxacillin Capsules  3 3 1 1 
Ciprofloxacin Tablets 9 9 1 1 
Cefepime IVI 2 g 5 5 1 1 
Rifampicin IVI  3 3 1 1 
Amikacin  1 1 1 1 
Cefuroxime IVI 3 3 1 1 
Cefazolin IVI 1 1 1 1 
 
For each antibiotic prescribed and administered in the vascular ward, the PDD was also 
calculated and compared to the DDD and is presented in Table 16. From the 109 
prescriptions, 39% of the PDD were equal to the DDD and 39% of the PDD were higher than 
the DDD. The remaining 22% of the DDD were lower than the PDD.  
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Table 16: World Health Organization Defined Daily Dose (DDD) versus Prescribed 
Daily Dose (PDD) for Antibiotics in the Vascular Ward in 2013 
Name 
WHO Per Prescription 
DDD (g) PDD (g) 
Number of 
Prescriptions 
Vancomycin IVI 1 g 2.00 0.50 2 
    1.00 1 
    1.00 6 
    2.00 8 
    3.00 1 
    2.00 1 
    4.00 1 
Piperacillin 4 g   14.00 16.00 15 
    12.00 1 
    4.00 1 
    8.00 2 
Amoxicillin 1 g IVI  3.00 3.00 13 
    4.00 1 
Meropenem IVI 1 g  2.00 3.00 4 
    2.00 1 
    1.00 1 
Cefepime IVI 1 g 2.00 3.00 1 
    2.00 4 
Ertapenem IVI 1 g 1.00 1.00 3 
    2.00 1 
Metronidazole IVI 1.50 1.50 4 
Amoxicillin 500 mg oral  1.00 1.50 3 
Meropenem IVI 500 mg  2.00 1.50 3 
Imipenem IVI 1 g  2.00 2.00 1 
    3.00 2 
Ciprofloxacin IVI  0.50 1.20 1 
    0.80 1 
    4.00 1 
Gentamicin IVI 0.24 0.24 3 
Amoxicillin 875 mg oral  1.00 2.00 1 
    3.00 1 
Cloxacillin IVI 1 g  2.00 4.00 2 
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Ceftazidime IVI 1 g  4.00 2.00 2 
Metronidazole Tablets  1.50 1.20 2 
Amoxycillin Capsules  1.00 2.00 2 
Clarithromycin  Tablets 0.50 2.00 2 
Co-Trimoxazole 1.92 0.96 1 
    1.92 1 
Clindamycin IVI 600 mg 1.80 1.80 1 
Cloxacillin Capsules  2.00 8.00 1 
Ciprofloxacin Tablets 1.00 1.00 1 
Cefepime IVI 2 g 2.00 6.00 1 
Rifampicin IVI  0.60 0.60 1 
Amikacin  1.00 0.75 1 
Cefuroxime IVI 3.00 4.50 1 
Cefazolin IVI 3.00 2.00 1 
 
4.3.2 Microbiology Laboratory Test Data Review 
When an infection was suspected, different types of specimens could be taken and sent to 
the NHLS Microbiology Laboratory to identify the pathogen using the Conventional Culture 
Method. If the patient had an open wound or an infected area, the specimen was commonly 
taken from that area. In Figure 12 and Figure 13, the pie charts show the different types of 
specimens that were taken and that isolated MRSA in the two wards.  
 
4.3.2.1 Orthopaedic Ward  
Within the orthopaedic ward, a total of 46 NHLS laboratory tests were conducted that 
isolated MRSA. Each patient had a range of one to ten with an average of three NHLS 
laboratory tests (based on the laboratory test number) that were conducted and that isolated 
MRSA. 
 
Fluid, irrigation fluid and tissue specimens each isolated 12 out of the 46 MRSA results in the 
orthopaedic ward as shown in Figure 12.  
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Figure 12: Types of Specimens Taken that Isolated MRSA in the Orthopaedic Ward in 
2013 
 
4.3.2.2 Vascular Ward  
Within the vascular ward, a total of 45 NHLS laboratory tests were conducted that isolated 
MRSA. Each patient had a range of one to four with an average of two NHLS laboratory tests 
(based on the laboratory test number) that were conducted and that isolated MRSA. 
 
From the 45 specimens that isolated MRSA in the vascular ward, 18 were from tissue, 14 
were pus swabs and 7 were from pus as illustrated in Figure 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Types of Specimens Taken that Isolated MRSA in the Vascular Ward in 2013  
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4.4 Cost Analysis  
4.4.1 Antibiotic Cost Calculations  
The cost per antibiotic administered per patient in each ward is shown in Appendix 7 (Table 
37 and Table 38). The summarised Tables of the sum of costs of the antibiotics administered 
per patient and the costs of the antibiotics per ward are shown below for each ward.  
 
4.4.1.1 Orthopaedic Ward  
The sum of the total utilization cost of antibiotics administered to each patient ranged from 
R307.18 to R11 926.85 with an average of R2 925.31 per patient. The sum of the daily cost 
of antibiotics administered to each patient ranged from R42.56 to R1 695.04 with an average 
of R408.42 per day as shown in Table 17.  
 
Table 17: The Daily Cost and Total Utilization Cost of Antibiotics per Patient in the 
Orthopaedic Ward in 2013 
Patient 
Number 
Daily Cost (R) Total 
Utilization 
Cost (R) 
Empiric 
MRSA- 
Specific 
Other Total 
369P03 99.23 282.66 0.00 381.88 2418.56 
369P09 116.74 0.00 0.00 116.74 978.58 
369P12 145.71 1364.64 184.68 1695.04 11926.85 
369P15 55.29 93.94 0.00 149.23 1246.66 
369P06 107.23 48.66 368.33 524.22 3851.81 
369P08 110.47 377.44 0.00 487.91 4338.20 
369P13 97.42 0.00 0.00 97.42 307.18 
369P14 173.59 0.00 0.00 173.59 1431.67 
369P02 16.01 0.00 368.74 384.74 2228.84 
369P04  18.74 95.63 0.00 114.38 1201.56 
369P16 42.56 0.00 0.00 42.56 470.36 
369P05 119.77 0.00 0.92 120.69 1011.25 
369P10 132.52 375.74 0.00 508.26 2512.50 
369P07 107.76 377.44 0.00 485.20 2684.58 
369P01 95.76 95.63 0.00 191.39 4209.32 
369P11 107.76 801.03 152.74 1061.53 5987.08 
Total 1546.57 3912.81 1075.40 6535.78 46804.99 
Average 96.66 244.55 67.21 408.42 2925.31 
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60% of the daily cost of antibiotics administered was for the MRSA-Specific Antibiotics 
administered and 24% of the daily cost of antibiotics administered was for Empiric 
Antibiotics. 
 
Table 18: The Average Daily Cost, Number of Days and Total Utilization Cost per 
Antibiotic in the Orthopaedic Ward in 2013 
Antibiotics 
Average 
Daily 
Cost (R) 
Number 
of days 
Total Utilization 
Cost (R) 
Co-amoxiclav 625 mg Tablets 3.47 21 71.63 
Co-amoxiclav 1 g Tablets  2.71 7 18.96 
Co-amoxiclav 1.2 g IVI  37.56 5 187.80 
Co-amoxiclav 0.6 g IVI  21.48 3 64.44 
Gentamicin Irrigation System  95.76 14 1358.05 
Rifampicin  1.59 12 20.35 
Vancomycin Irrigation System  250.50 4 1033.30 
Vancomycin IVI 115.29 9 1093.07 
Cloxacillin Capsules  15.28 15 226.12 
Cloxacillin IVI 34.09 5 180.92 
Cefotaxime 184.68 9 1662.12 
Cefazolin IVI 10.50 2 24.76 
Linezolid 564.49 4 1975.72 
Ertapenem IVI 368.33 4 1289.16 
Metronidazole 0.41 7 2.85 
Ciprofloxacin  0.92 32 29.37 
Ceftazidime IVI 120.00 19 2279.93 
Ceftazidime Irrigation System 32.74 1 32.74 
 
As per Table 18, the average daily cost of the antibiotics administered ranged from R0.41 for 
metronidazole to R564.49 for linezolid. The average total utilization cost ranged from R2.85 
for metronidazole for an average of seven days, to R2 279.93 for ceftazidime IVI for an 
average of 19 days. 
 
4.4.1.2 Vascular Ward  
The sum of the total utilization cost of antibiotics administered to each patient ranged from 
R8.00 to R15 092.31 with an average of R2 398.42 per patient. The sum of the daily cost of 
antibiotics administered to each patient ranged from R2.71 to R2 435.65 with an average of 
R462.51 per day as shown in Table 19. 
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Table 19: The Daily Cost and Total Utilization Cost of Antibiotics per Patient in the 
Vascular Ward in 2013 
Patient 
Number 
Daily Cost (R) Total 
Utilization 
Cost (R) 
Empiric 
MRSA- 
Specific 
Other Total 
395P02 480.00 187.87 1767.77 2435.65 15092.31 
395P03 37.56 46.97 81.60 166.124 933.66 
395P04 0.00 0.00 377.85 377.85 1511.40 
395P05 37.56 0.00 504.86 542.42 4156.8 
395P06 454.46 0.00 768.15 1222.62 5921.98 
395P07 0.00 399.23 132.846 532.07 1439.20 
395P08 240.00 0.00 0.00 240.00 1200.00 
395P09 243.47 140.90 870.54 1254.91 8669.95 
395P11 517.56 0.00 0.00 517.56 1830.24 
395P12 2.71 0.00 0.00 2.71 51.45 
395P13 37.56 0.00 0.92 38.48 233.62 
395P14 0.00 0.00 232.50 232.50 1231.32 
395P16 240.00 0.00 368.63 608.63 1809.55 
395P17 37.56 0.00 0.00 37.56 225.36 
395P18 82.98 93.94 0.00 176.91 1657.75 
395P19 30.56 23.48 65.48 119.52 704.47 
395P20 8.00 0.00 0.00 8.00 8.00 
395P21 817.56 93.94 520.22 1431.72 6270.04 
395P22 287.88 0.00 0.00 287.88 1055.16 
395P23 480.00 0.00 61.53 541.53 3544.29 
395P24 37.56 93.94 0.00 131.496 394.416 
395P25 277.56 408.36 554.87 1240.786 3916.214 
395P28 37.56 93.94 0.00 131.50 375.67 
395P29 0.00 0.00 104.10 104.10 508.20 
395P30 420.00 0.00 192.34 612.34 4381.70 
395P31 4.06 0.00 0.00 4.06 16.25 
395P32 50.08 0.00 0.00 50.08 1001.6 
395P33 3.47 0.00 0.00 3.47 45.06 
395P36 37.56 281.81 40.92 360.29 1368.58 
Total 4903.26 1864.36 6645.13 13412.76 69554.23 
Average 169.08 64.29 229.14 462.51 2398.42 
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Of the daily cost of antibiotics administered 14% was due to the MRSA-Specific Antibiotics 
administered and 37% of the daily cost of antibiotics administered was due to the Empiric 
Antibiotics.  
 
Table 20: The Average Daily Cost, Number of Days and Total Utilization Cost per 
Antibiotic in the Vascular Ward in 2013 
Antibiotics 
Average 
Daily 
Cost (R) 
Number 
of days 
Total Utilization 
Cost (R) 
Piperacillin/tazobactam  214.74 6 1357.89 
Co-amoxiclav IVI 1.2 g 38.45 6 259.34 
Co-amoxiclav 625 mg Tablets 3.47 12 40.44 
Co-amoxiclav 1 g Tablets 3.39 12 33.85 
Vancomycin IVI 1 g 77.50 3 272.41 
Ertapenem IVI 1 g 460.41 3 1289.16 
Meropenem IVI 1 g  314.88 6 2099.17 
Meropenem IVI 500 mg  191.58 6 1085.62 
Imipenem IVI 1 g  250.93 3 815.53 
Clindamycin IVI 600 mg 31.46 17 534.89 
Cloxacillin IVI 1 g  41.95 9 356.59 
Cloxacillin Capsules 30.56 3 91.67 
Ciprofloxacin  IVI  310.90 7 1575.23 
Ciprofloxacin Tablets 0.92 9 8.26 
Ceftazidime IVI 1 g  65.48 8 491.10 
Cefepime IVI 1 g 45.01 5 233.24 
Cefepime IVI 2 g 116.73 5 583.65 
Metronidazole Tablets  0.30 3 0.91 
Metronidazole  IVI 16.12 7 104.75 
Gentamicin IVI 47.88 4 207.48 
Amoxicillin Capsules  0.82 7 5.71 
Clarithromycin Tablets 7.68 4 26.87 
Rifampicin IVI  314.42 3 943.26 
Amikacin  20.61 1 20.61 
Cefuroxime IVI 47.06 3 141.18 
Cefazolin  IVI 8.00 1 8.00 
Co-trimoxazole  0.38 4 1.90 
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As per Table 20, the average daily cost of the antibiotics administered ranged from R0.30 for 
metronidazole tablets to R460.41 for ertapenem IVI. The average total utilization cost ranged 
from R0.91 for metronidazole tablets for an average of three days, to R2 099.17 for 
meropenem IVI 1g for an average of six days. 
 
4.4.2 NHLS Laboratory Test Cost Calculations  
The sum of all the laboratory tests conducted per patient was calculated and is shown in the 
tables below. Appendix 7 (Table 39 and Table 40) provides details of the cost per laboratory 
test per patient. 
 
4.4.2.1 Orthopaedic Ward  
In the orthopaedic ward, the cost per NHLS laboratory test that isolated MRSA ranged from 
R118.38 to R592.80 with an average of R335.09 per test. Each laboratory test had only one 
microscopy step and the cost of the microscopy step was a standard cost of R36.93 with the 
exception of one code which was R38.41. The Culture and Sensitivity Cost varied between 
R81.45 and R555.87 per laboratory test, as a combination of different Culture and Sensitivity 
steps were conducted per laboratory test. The detailed laboratory steps and costing 
information was not available for one patient (369P14). 
 
As some patients had more than one laboratory test conducted that isolated MRSA, the sum 
of the laboratory tests was calculated for each patient to obtain the total cost of laboratory 
tests per patient, as displayed in Table 21. The total cost of laboratory tests that isolated 
MRSA per patient ranged from R260.13 to R3184.23 with an average of R921.51 per patient.  
 
Table 21: The Microscopy, Culture and Sensitivity and Total Costs of the NHLS 
Laboratory Tests conducted that isolated MRSA per patient in the Orthopaedic Ward 
in 2013 
Patient Number 
Cost (R) 
Total Price 
(R) Microscopy 
Culture and  
Sensitivity 
369P03 221.58 1443.46 1665.04 
369P09 73.86 538.25 612.11 
369P12 73.86 582.44 656.30 
369P15 36.93 223.20 260.13 
369P06 73.86 574.60 648.46 
369P08 258.51 2707.40 2965.91 
369P13 36.93 223.20 260.13 
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369P14 0.00 0.00 0.00 
369P02 36.93 223.20 260.13 
369P04 36.93 223.20 260.13 
369P16 38.41 232.13 270.54 
369P05 73.86 731.50 805.36 
369P10 73.86 504.24 578.10 
369P07 73.86 618.78 692.64 
369P01 369.30 2814.93 3184.23 
369P11 147.72 1477.19 1624.91 
Total  1626.40 13117.72 14744.12 
Average per Patient 101.65 819.86 921.51 
Average per Test 36.96 298.13 335.09 
  
4.4.2.2 Vascular Ward  
In the vascular ward, the cost per NHLS laboratory test that isolated MRSA ranged from 
R168.37 to R660.40 with an average of R373.03 per test. Each laboratory test had only one 
microscopy step and the cost of the microscopy step was either R36.93 or R38.41. The 
Culture and Sensitivity Cost varied between R131.44 and R623.47 per laboratory test, as a 
combination of different Culture and Sensitivity steps were conducted per laboratory test. 
The detailed laboratory steps and costing information was not available for one patient 
(395P33). 
 
As some patients had more than one laboratory test conducted that isolated MRSA, the sum 
of the laboratory tests was calculated for each patient to obtain the total cost of laboratory 
test per patient and is displayed in the Table 22. The total cost of laboratory test per patient 
ranged from R168.37 to R1 492.05 with an average of R565.97 per patient.  
 
Table 22: The Microscopy, Culture and Sensitivity and Total Costs of the NHLS 
Laboratory Tests that isolated MRSA per patient in the Vascular Ward in 2013 
Patient Number 
Cost (R) 
Total Price 
(R) Microscopy 
Culture and 
Sensitivity 
395P02 73.86 1033.01 1106.87 
395P03 73.86 632.44 706.30 
395P04 36.93 223.2 260.13 
395P05 36.93 532.04 568.97 
395P06 110.79 787.19 897.98 
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395P07 76.82 545.59 622.41 
395P08 36.93 592.08 629.01 
395P09 36.93 223.2 260.13 
395P11 36.93 131.44 168.37 
395P12 36.93 223.2 260.13 
395P13 73.86 446.4 520.26 
395P14 152.16 1339.89 1492.05 
395P16 73.86 903.84 977.70 
395P17 38.41 341.84 380.25 
395P18 73.86 663.48 737.34 
395P19 36.93 247.03 283.96 
395P20 73.86 606.27 680.13 
395P21 73.86 658.61 732.47 
395P22 36.93 479.38 516.31 
395P23 36.93 223.2 260.13 
395P24 36.93 510.64 547.57 
395P25 73.86 639.66 713.52 
395P28 36.93 223.2 260.13 
395P29 38.41 232.13 270.54 
395P30 73.86 589.65 663.51 
395P31 36.93 579.7 616.63 
395P32 38.41 354.96 393.37 
395P33 0.00 0.00 0.00 
395P36 73.86 813.08 886.94 
Total  1636.76 14776.35 16413.11 
Average per Patient 56.44 509.53 565.97 
Average per Test 37.20 335.83 373.03 
  
4.4.3 Antibiotic Utilization plus NHLS Laboratory Tests Cost Calculation    
For each patient the total cost of Antibiotics administered plus NHLS laboratory tests 
conducted was calculated and is presented in Appendix 7 (Table 41 and Table 42). 
 
4.4.3.1 Orthopaedic Ward  
Cost Calculations of Antibiotic Utilization plus NHLS Laboratory Tests per Patient in the 
Orthopaedic Ward in 2013 were performed. The total sum of the Antibiotic Utilization Cost 
and total NHLS cost per patient in the orthopaedic ward ranged from R567.31 to R12 583.15 
as illustrated in Figure 14.  
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4.4.3.2 Vascular Ward 
Cost Calculations of Antibiotic Utilization plus NHLS Laboratory Tests per Patient in the 
Vascular Ward in 2013 were performed. The total sum of the Antibiotic Utilization Cost and 
total NHLS cost per patient in the vascular ward ranged from R45.06 to R16 199.18 as 
illustrated in Figure 15. 
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Figure 14: Total Cost of Antibiotics Administered plus NHLS Laboratory Tests Conducted per Patient in the Orthopaedic Ward in 2013 
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Figure 15: Total Cost of Antibiotics Administered plus NHLS Laboratory Tests Conducted per Patient in the Vascular Ward in 2013 
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4.5 Decision-Tree-Analytic Models 
Two decision-tree-analytic models were developed depicting the various management 
pathways of patients with a suspected infection, one for the orthopaedic ward and one for the 
vascular ward. Once the structures of these decision-tree-analytic models were complete, 
numeric values were entered into the tree as variables, probabilities and payoffs. The two 
decision-tree-analytic models were first run using the actual probabilities that occurred in the 
clinical setting in each ward and are referred to as the “actual decision-tree-analytic models”. 
The two decision-tree-analytic models were then run by using variables to allocate equal 
probabilities to each branch for each ward and are referred to the “equal decision-tree-
analytic models”. 
 
4.5.1 Decision-Tree-Analytic Model Structure and Parameters  
4.5.1.1 Variables   
Separate variables were created for each ward as the costs and probabilities differed. 
Variables starting with the prefix “c” were variables denoting the cost of antibiotics or testing 
methods and variables starting with the prefix “p” were variables denoting the probability of 
an event occurring. These variables are described in Table 23 and Table 24.   
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Table 23: Variables used in the Decision-Tree-Analytic Models for the Orthopaedic Ward 
Name Description 
Root 
Definition 
Low Value High Value 
     
cSpecimenM Cost of Specimen Sent for Microscopy R101.65 2.16 201.14 
cSpecimenCS Cost of Specimen Sent for Culture and Sensitivity R819.86 0.00 1682.00 
cDailyMrsaSpecificAntibiotic Average cost of MRSA-Specific Antibiotic per patient per day R244.55 0.00 617.15 
cDailyEmpiricAntibiotic Average cost of Empiric Antibiotic per patient per day R96.66 53.21 140.11 
cDailyOtherAntibiotic Average cost of Other Antibiotics per patient per day R67.21 0.00 198.05 
cXpertMRSA Cost of 1 Xpert MRSA Kit R307.52 153.76 461.28 
          
pEmpiricAntibiotics Probability of Receiving Empiric Antibiotics 0.50 0.00 1.00 
pMrsaSpecificAntibiotics Probability of Receiving MRSA-Specific Antibiotics 0.50 0.00 1.00 
pMrsaIsolated Probability of MRSA Isolated 0.50 0.00 1.00 
pSpecimenSentMCS Probability of a Specimen being Sent for MCS 0.50 0.00 1.00 
pConfirmationByCS Probability of Confirmation of MRSA by Culture and Sensitivity 0.50 0.00 1.00 
pXpertMRSA Probability of Xpert MRSA test 0.50 0.00 1.00 
pOtherAntibiotics Probability of Receiving Other Antibiotics 0.50 0.00 1.00 
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Table 24: Variables used in the Decision-Tree-Analytic Models for the Vascular Ward 
Name Description 
Root 
Definition 
Low Value High Value 
    
 
    
CSpecimenM Cost of Specimen Sent for Microscopy R56.44 26.98 85.90 
cSpecimenCS Cost of Specimen Sent for Culture and Sensitivity R509.53 216.10 802.96 
cDailyMrsaSpecificAntibiotic Average cost of MRSA-Specific Antibiotic per patient per day R64.29 0.00 180.62 
cDailyEmpiricAntibiotic Average cost of Empiric Antibiotic per patient per day R169.08 0.00 385.02 
cDailyOtherAntibiotic Average cost of Other Antibiotics per patient per day R229.14 0.00 616.36 
cXpertMRSA Cost of 1 Xpert MRSA Kit R307.52 153.76 461.28 
    
 
    
pEmpiricAntibiotics Probability of Receiving Empiric Antibiotics 0.50 0.00 1.00 
pMrsaSpecificAntibiotics Probability of Receiving MRSA-Specific Antibiotics 0.33 0.17 0.50 
pMrsaIsolated Probability of MRSA Isolated 0.50 0.00 1.00 
pSpecimenSentMCS Probability of a Specimen being Sent for MCS 0.50 0.00 1.00 
pConfirmationByCS Probability of Confirmation of MRSA by Culture and Sensitivity 0.50 0.00 1.00 
pXpertMRSA Probability of Xpert MRSA test 0.50 0.00 1.00 
pOtherAntibiotics Probability of Receiving Other Antibiotics 0.33 0.17 0.50 
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4.5.1.2 Complete Decision-Tree-Analytic Models  
For each ward the completed decision-tree-analytic models with the variables, probabilities 
and payoffs are shown, first with their actual probabilities and then with the variables for 
equal probabilities. Figure 16 and Figure 17 represent the decision-tree-analytic models for 
the orthopaedic ward followed by Figure 18 and Figure 19 which represent the decision-tree-
analytic models for the vascular ward   
 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Actual Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in the 
Orthopaedic Ward  
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Figure 17: Equal Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in the 
Orthopaedic Ward  
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Figure 18: Actual Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in the 
Vascular Ward  
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Figure 19: Equal Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in the Vascular 
Ward 
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4.5.2 Analysis of the Decision-Tree-Analytic Models 
The decision-tree-analytic models generated when Rollback was run showing the Rankings, 
Path Probabilities and Payoff are illustrated in Appendix 8 (Figure 37, Figure 38, Figure 39 
and Figure 40).  
 
4.5.2.1 Rankings  
Table 25 compares the rankings of the strategies for the two decision-tree-analytic models 
when Rollback was run with the actual and equal probabilities in the orthopaedic and 
vascular ward.  
 
Table 25: Rankings for the Decision-Tree-Analytic Models run with Actual and then 
Equal Probabilities in the Orthopaedic and Vascular Ward 
Strategy 
Orthopaedic (R) Vascular (R) 
Actual Equal Actual Equal 
Empiric Antibiotic 1 213.92 395.10 833.35 357.92 
Specimen For MCS 1 262.72 675.78 805.88 453.19 
Empiric Antibiotic & Specimen For MCS 1 203.56 693.54 790.85 546.76 
Specimen For Xpert MRSA 1 178.32 742.92 864.69 626.59 
 
In the current clinical setting in the orthopaedic ward, the optimal strategy was when Empiric 
Antibiotics were administered and Specimen For MCS was taken at the same time. However, 
if the Xpert MRSA tests were to be implemented in this current setting in the orthopaedic 
ward, the optimal strategy would be to first take a Specimen For Xpert MRSA testing. When 
equal probabilities were assigned to the orthopaedic ward, the optimal strategy was to first 
administer Empiric Antibiotics.  
 
As in the current clinical setting in the orthopaedic ward, the optimal strategy in the current 
clinical setting in the vascular ward was also when Empiric Antibiotics were administered and 
a Specimen For MCS was taken at the same time. If the Xpert MRSA tests were to be 
implemented in this current setting in the vascular ward, the strategy of sending a Specimen 
For Xpert MRSA testing was the most expensive strategy. When equal probabilities were 
assigned to the vascular ward, the optimal strategy was also to first administer Empiric 
Antibiotics.  
 
4.5.2.2 Payoffs and Path Probabilities     
The payoff’s expected value and the path probability for each individual branch in each tree 
were calculated and are displayed in Table 26 and Table 27. The expected value represents 
the total cost of a single management pathway for a patient with a suspected infection and 
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the path probability represents the chance of that pathway occurring. For each branch, the 
payoff’s expected value was the same for the actual decision-tree-analytic models and for 
the equal decision-tree-analytic models, however, the path probabilities differed. The terminal 
nodes for each branch were numbered as scenario numbers, with scenario number one 
being the pathway to the end of the first top branch, scenario number two being the branch 
below that, until scenario 18, being the last bottom branch in the orthopaedic tree and 
scenario 25 being the last bottom branch in the vascular tree.  
 
Table 26: The Expected Value of the Payoffs and the Path Probabilities for the 
Decision-Tree-Analytic Models in the Orthopaedic Ward 
Scenario 
Number 
Expected 
Value (R) 
Path Probability 
Actual Equal 
1 96.66 0.00 0.50 
2 1 114.83 0.33 0.12 
3 1 262.72 0.67 0.12 
4 198.31 0.00 0.25 
5 1 114.83 0.00 0.12 
6 1 262.72 0.50 0.12 
7 198.31 0.00 0.25 
8 1 262.72 0.50 0.12 
9 1 166.06 0.00 0.12 
10 101.65 0.00 0.25 
11 1 114.83 0.40 0.25 
12 1 262.72 0.60 0.25 
13 198.31 0.00 0.50 
14 552.07 0.25 0.12 
15 1 371.93 0.25 0.12 
16 1 320.70 0.25 0.12 
17 1 468.59 0.25 0.12 
18 307.52 0.00 0.50 
 
The total value (expected value of a payoff) for a management pathway for a patient with a 
suspected infection in the orthopaedic ward ranged from R96.66 to R1 468.59. However, the 
pathway costing R96.66 had an actual probability of zero thus indicating that it did not occur 
in clinical practice. The pathway with the highest probability in the actual decision-tree-
analytic model had an expected value of R1 262.72. 
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Table 27: The Expected Value of the Payoffs and the Path Probabilities for the 
Decision-Tree-Analytic Models in the Vascular Ward 
Scenario 
Number 
Expected 
Value (R) 
Path Probability 
Actual Equal 
1  169.08 0.00 0.50 
2  735.05 0.23 0.04 
3  964.19 0.23 0.04 
4  799.34 0.43 0.04 
5  904.13 0.10 0.12 
6  225.52 0.00 0.25 
7  735.05 0.01 0.04 
8  964.19 0.20 0.04 
9  799.34 0.40 0.04 
10  904.13 0.20 0.12 
11  225.52 0.00 0.25 
12  565.97 0.20 0.08 
13  795.11 0.00 0.08 
14  630.26 0.00 0.08 
15  56.44 0.00 0.25 
16  735.05 0.67 0.08 
17  964.19 0.00 0.08 
18  799.34 0.00 0.08 
19  904.13 0.33 0.25 
20  225.52 0.00 0.50 
21  371.81 0.25 0.08 
22  881.34 0.25 0.08 
23 1 155.21 0.25 0.17 
24 1 050.42 0.25 0.17 
25  307.52 0.00 0.50 
 
In the vascular ward, the total value (expected value of a payoff) for a management pathway 
for a patient with a suspected infection ranged from R56.44 to R1 155.21. The pathway 
which had the expected value of R56.44 had an actual path probability of zero, thus 
indicating that this did not occur in clinical practice. The pathway with the highest probability 
in the actual decision-tree-analytic model had an expected value of R735.05. 
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4.5.2.3 Sensitivity and Threshold Analysis  
One-way sensitivity analyses were performed for each variable in each decision-tree-analytic 
models. The Sensitivity Analysis Graphs along with threshold reports were interpreted. Only 
those Sensitivity Analysis Graphs which showed a change in the optimal strategy are 
discussed and shown in Figure 20 to Figure 32 below. 
 
As all of the sensitivity analyses were performed from the decision node, each line on the 
one-way sensitivity analysis graph represented one of the strategies that emitted from the 
decision node. However, when two of the strategies had the same expected value, then 
these two lines were superimposed and appeared as one line on the graph. For each 
variable selected, the one-way sensitivity analysis graph showed the Expected Values of the 
strategies on the y-axis and the range (low to high value) of the selected variable on the x-
axis. The x-axis was labelled according to the description of the selected variable. The points 
plotted on the graph were a function of each strategy’s expected value when increasing the 
cost of the selected variable.  
 
A threshold occurs when two lines in the sensitivity analysis graph cross over and causes the 
optimal strategy to change. Thresholds are indicated on the Sensitivity Analysis graphs 
shown below by a grey vertical dotted line and further details of the thresholds are reported 
in the Threshold Tables in Appendix 9 (Table 43, Table 44, Table 45, Table 46). The Variable 
Value is the value of the variable at the point at which the Threshold is reached. The 
Expected Value represents the equal Expected Value of Strategy 1 and Strategy 2 at the 
Threshold.  
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4.5.2.3.1 One-Way Sensitivity Analyses Performed for the Variables in the Decision-
Tree-Analytic Models in the Orthopaedic Ward  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: One-Way Sensitivity Analysis Graph for the Variable 
cDailyEmpiricAntibiotic in the Actual Decision-Tree-Analytic Model in the Orthopaedic 
Ward 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: One-Way Sensitivity Analysis Graph for the Variable 
cDailyMrsaSpecificAntibiotic in the Actual Decision-Tree-Analytic model in the 
Orthopaedic Ward 
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Figure 22: One-Way Sensitivity Analysis Graph for the Variable cSpecimenCS in the 
Actual Decision-Tree-Analytic Model in the Orthopaedic Ward 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: One-Way Sensitivity Analysis Graph for the Variable cSpecimenM in the 
Actual Decision-Tree-Analytic Model in the Orthopaedic Ward 
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Figure 24: One-Way Sensitivity Analysis Graph for the Variable cXpertMRSA in the 
Actual Decision-Tree-Analytic Model in the Orthopaedic Ward 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: One-Way Sensitivity Analysis Graph for the Variable pSpecimenSentMCS in 
the Equal Decision-Tree-Analytic Model in the Orthopaedic Ward 
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For the variable cSpecimenM, the expected values of three strategies of Empiric Antibiotic, 
Empiric Antibiotic & Specimen For MCS and Specimen For MCS, increased as the cost of 
the variable increased and thus indicated that all three strategies were sensitive to this 
variable in both the actual and equal decision-tree-analytic models. However, all four 
strategies were sensitive to variables cSpecimenCS, cDailyMrsaSpecificAntibiotic and 
cDailyEmpiricAntibiotic, as all of the lines in these sensitivity analysis graphs deviated from 
the horizontal in both the actual and equal decision-tree-analytic models.  
 
The expected values of the strategy of Specimen For Xpert MRSA testing were represented 
as an increasing function of the variable cXpertMRSA and were thus sensitive to the Cost of 
One Xpert MRSA Kit. The remaining three strategies of Empiric Antibiotic, Specimen For 
MCS and Empiric Antibiotic & Specimen For MCS, appeared as horizontal lines with no 
increase and were thus not sensitive to the variable cXpertMRSA. This was true for both 
situations using the actual and the equal probabilities in the orthopaedic ward.  
 
Regarding the sensitivity analysis conducted for variables representing the equal 
probabilities in the orthopaedic ward, the following could be deduced. The decision-tree-
analytic model was sensitive to the probability of MRSA isolated, as the expected values of 
all four strategies increased as the probability of isolating MRSA increased. The expected 
value of all four strategies also changed as the variable pEmpiricAntibiotics increased, thus 
showing that the decision-tree-analytic model was sensitive to the probability of receiving 
antibiotics. For the variable pConfirmationByCS, only the expected values of the Specimen 
For Xpert MRSA strategy increased as the probability of confirmation by culture and 
sensitivity increased and for the variable pSpecimenSentMCS, only the expected value of the 
Empiric Antibiotic Strategy increased as the probability of a specimen being sent for MCS 
increased. The strategies Specimen For MCS and Specimen For Xpert MRSA were sensitive 
to the variable pMrsaSpecificAntibiotics as their expected values increased as the probability 
of receiving MRSA-Specific Antibiotics increased.  
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4.5.2.3.2 One-Way Sensitivity Analyses Performed for the Variables in the Decision-
Tree-Analytic Models in the Vascular Ward  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: One-Way Sensitivity Analysis Graph for the Variable cDailyOtherAntibiotic 
in the Actual Decision-Tree-Analytic Model in the Vascular Ward 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 27: One-Way Sensitivity Analysis Graph for the Variable 
cDailyMrsaSpecificAntibiotic in the Actual Decision-Tree-Analytic Model in the 
Vascular Ward 
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Figure 28: One-Way Sensitivity Analysis Graph for the Variable cXpertMRSA in the 
Actual Decision-Tree-Analytic Model in the Vascular Ward 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: One-Way Sensitivity Analysis Graph for the Variable 
cDailyEmpiricAntibiotic in the Actual Decision-Tree-Analytic Model in the Vascular 
Ward 
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Figure 30: One-Way Sensitivity Analysis Graph for the Variable 
cDailyEmpiricAntibiotic in the Equal Decision-Tree-Analytic Model in the Vascular 
Ward 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: One-Way Sensitivity Analysis Graph for the Variable pMrsaIsolated in the 
Equal Decision-Tree-Analytic Model in the Vascular Ward 
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Figure 32: One-Way Sensitivity Analysis Graph for the Variable pSpecimenSentMCS in 
the Equal Decision-Tree-Analytic Model in the Vascular Ward 
  
For the decision-tree-analytic models with the actual and equal probabilities in the vascular 
ward, the sensitivity analysis for the variables cSpecimenM, cSpecimenCS, 
cDailyEmpiricAntibiotic, cXpertMRSA, pConfirmationByCS, pEmpiricAntibiotics, 
pMrsaIsolated and pSpecimenSentMCS were the same as the sensitivity analysis in the 
orthopaedic ward, as the same strategies were sensitive and changed as the respective 
variable changed.  
 
For the variable cDailyOtherAntibiotic, in the actual decision-tree-analytic model, the 
expected values of the two strategies of Empiric Antibiotics and Specimen For MCS 
increased as the cost of receiving daily Other Antibiotics increased and in the equal decision-
tree-analytic model, the expected value of the three strategies of Empiric Antibiotics, Empiric 
Antibiotic & Specimen For MCS and Specimen For Xpert MRSA increased as the cost of 
receiving daily Other Antibiotics increased, thus showing that both models were sensitive to 
this variable. In the actual decision-tree-analytic model, the expected value of the three 
strategies of Empiric Antibiotics, Specimen For MCS and Specimen For Xpert increased as 
the cost of receiving daily MRSA-Specific Antibiotics increased. However, in the equal 
decision-tree-analytic model, the expected value of the strategy Empiric Antibiotic & 
Specimen For MCS also increased, in addition to the other three strategies, as the cost of 
receiving daily MRSA-Specific Antibiotics increased and hence was sensitive to the 
cDailyMrsaSpecificAntibiotic variable.  
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Regarding the sensitivity analysis conducted for variables representing the equal 
probabilities in the vascular ward, the results that were different to the orthopaedic ward are 
discussed below. For the variable pMrsaSpecificAntibiotics, the expected value of all four 
strategies increased as the probability of receiving MRSA-Specific Antibiotics increased. The 
expected value of the three strategies of Empiric Antibiotics, Empiric Antibiotic & Specimen 
For MCS and Specimen For MCS increased as the variable pOtherAntibiotics increased. A 
change in expected value indicated that the strategy was sensitive to the variable.  
 
4.5.2.4 Tornado Analysis   
Within a Tornado Diagram, each horizontal bar symbolised a one-way sensitivity analysis 
performed at the decision node for a variable. A thick vertical line in any of the variables ’ 
horizontal bar represented a threshold that occurred at the corresponding expected value on 
the x-axis. Threshold lines that were drawn at the end of a horizontal bar could imply that 
within a part of the stipulated range, the optimal strategy had an expected value that did not 
change. The expected value of the optimal strategy was shown on the Tornado Diagram as a 
dotted vertical line. The thresholds and the expected values represented in these Tornado 
Diagrams have already been discussed in the previous sections on decision-tree-analytic 
models. The Tornado Diagrams for the decision-tree-analytic models are shown in Figure 33,  
Figure 34, Figure 35 and Figure 36 as well as described below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Tornado Diagram for the Actual Decision-Tree-Analytic Model in the 
Orthopaedic Ward  
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Figure 34: Tornado Diagram for the Actual Decision-Tree-Analytic Model in the 
Vascular Ward 
 
In the Tornado Diagrams for the actual decision-tree-analytic models in the orthopaedic and 
vascular wards, the variable cSpecimenCS was displayed as the top widest bar (variable 
index 0) and thus had the greatest influence on the overall expected value and was the most 
uncertain variable in the decision-tree-analytic models. In the Tornado Diagram of the actual 
decision-tree-analytic model in the orthopaedic ward, the variable 
cDailyMrsaSpecificAntibiotic had a variable index of 1. However, in the Tornado Diagram of 
the actual decision-tree-analytic model in the vascular ward the variable 
cDailyMrsaSpecificAntibiotic had the narrowest bar at the bottom (variable index 5) and could 
be said to have had the least effect on the model's expected value. The variable 
cXpertMRSA was placed third (variable index 2) in both the tornado diagrams and thus had a 
moderate effect on the model's expected values.  
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Figure 35: Tornado Diagram for the Equal Decision-Tree-Analytic Model in the 
Orthopaedic Ward 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 36: Tornado Diagram for the Equal Decision-Tree-Analytic Model in the 
Vascular Ward 
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In the Tornado diagram for the equal decision-tree-analytic model in the orthopaedic ward, 
the variable pSpecimenSentMCS was displayed as the top widest bar and in the Tornado 
diagram for the equal decision-tree-analytic model in the vascular ward, the variable 
cDailyEmpiricAntibiotc was displayed as the top widest bar, thus these variables had the 
greatest influence on the overall expected value and were the most uncertain variables. The 
variable cXpertMRSA was the tenth variable (variable index of 10), the third variable from the 
bottom of the equal decision-tree-analytic models in the orthopaedic and vascular wards, 
thus suggesting that if equal probabilities were applied to the current clinical settings, the 
cost of the Xpert MRSA tests would not have a weighty effect on the model's expected 
values. 
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5. DISCUSSION  
 
5.1 Overview of Research  
PCR test rapidly tests for MRSA within a few hours. Despite the benefits that may be 
associated with these PCR tests, research needed to be conducted to assess whether it 
would be cost-effective to implement these tests within the current setting of a South African 
public hospital. However, once the research began, it was found that there was no baseline 
data regarding the daily practices, costs and management pathways associated with using 
the current Conventional Culture Method that is used to test for MRSA in public hospitals in 
South Africa.  
 
Therefore, the objectives of this study were set. Firstly, to conduct observations in the 
hospital wards, NHLS Microbiology Laboratory and the main dispensary at CMJAH in order 
to document the current daily practices relating to MRSA testing and management. 
Secondly, to carry out a retrospective utilization review of the treatment pathways and 
laboratory tests conducted, associated with MRSA in the study population. Thirdly, to 
perform a cost analysis using the utilization and costing data obtained to determine the costs 
associated with the antibiotics used and the laboratory tests that isolated MRSA in the study 
population. Lastly, to develop decision-tree-analytic models to compare the current costs and 
management pathways associated with the Conventional Culture Method versus theoretical 
situations arising if using the Xpert MRSA tests were to be implemented in the current setting 
to determine the method that would be most cost-saving in the South African public 
healthcare setting. 
  
As there are only a limited number of studies in the South African healthcare context which 
report on the various aspects of this research, international studies were also used as a 
reference source for discussing and comparing the results obtained in this study. However, a 
direct comparison could not be made as many factors need to be taken into account when 
comparing the healthcare setting in South Africa and other countries. The key results from 
each section of this study are discussed in relation to the current setting as well as the 
published literature and guidelines.  
 
5.2 Burden of MRSA  
In 2014, the WHO published a document entitled Antimicrobial Resistance: Global Report on 
Surveillance, which reflects the global picture of antibiotic resistance in 2013 based on the 
information that was available. This report acknowledges that although antibiotic resistance 
is a growing concern globally, there are several gaps of missing information regarding 
antibiotic resistance due to reasons such as no surveillance or lack of standardised 
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surveillance methodologies and their implementation in certain areas. As a result, the exact 
economic extent of antibiotic resistance cannot be measured. The WHO report also 
highlights that antibiotic resistance is a liability to the economy. However, another alarming 
gap of missing information is that the true cost of antibiotic resistance is unknown and is 
largely represented by estimates, thus indicating another area in which information is missing 
and the need for research to be conducted. In order to efficiently deal with the problem of 
increasing antibiotic resistance, these gaps need to be filled. These gaps were identified and 
addressed in the context of this study regarding the current cost and management pathways 
for a patient with a suspected MRSA infection (World Health Organization, 2014). 
 
Within certain settings, especially amongst high-income countries, surveillance for 
antimicrobial resistance has already been implemented and is now part of HCPs daily 
practice. However, within settings such as those in which resources are limited, antimicrobial 
microbial surveillance has not been implemented and thus there is no consistent surveillance 
data available for these areas. Thus the WHO collected data from various sources regarding 
the resistance of antibiotics used in the treatment of infections due to certain bacteria, 
Staphylococcus aureus being one of them. Based on the regions that contributed data 
relating to MRSA, the percentage of MRSA amongst Staphylococcus aureus ranged from 
0.3% to 90%. It can be seen in Table 28 that within parts of the region there is a large 
difference between the smallest and largest value of the overall reported range of resistant 
proportion. Focusing on the national data obtained from nine countries in the African Region, 
the overall reported range of MRSA amongst Staphylococcus aureus was 12% to 80% 
(World Health Organization, 2014). 
  
Table 28: The Overall Reported Range of Staphylococcus aureus Resistance to Beta-
lactam Antibacterial Drugs (MRSA) Obtained from Data Sources in Various Regions 
(Adapted from: World Health Organization, 2014, Table 7) 
Data Sources (minimum of 30 tested isolates)             
(n = Number of Countries) 
Overall Reported Range of 
Resistant Proportion (%) 
African Region: National data (n=9) 12 – 80 
Region of the Americas: National data or report (n=15) 21 – 90 
Eastern Mediterranean Region: National data (n=4) 10 – 53 
European Region: National data or report (n=36) 0.3 – 60 
South-East Asia Region: National reports (n=3) 10 – 26 
Western Pacific Region: National data (n=16) 4.0 – 84 
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5.2.1 Burden of MRSA in South Africa 
The WHO report mentioned above also provided details of the percentage of resistance 
within individual countries. In South Africa, the prevalence of MRSA amongst 
Staphylococcus aureus infections was 52%. This data was obtained from national data that 
tested 1 177 invasive isolates samples in 2012 (World Health Organization, 2014).  
 
A systematic review conducted by Nyasulu and co-authors (2012), entitled Antimicrobial 
Resistance Surveillance among Nosocomial Pathogens investigated the prevalence of 
resistance of antimicrobial drugs in organisms, one of them being Staphylococcus aureus. 
This review included studies from both public and private hospitals in South Africa between 
2000 and 2009. Due to different methodologies used in the studies included, resistance to 
both cloxacillin and methicillin was reported. Therefore, the prevalence of cloxacillin 
resistance amongst Staphylococcus aureus isolates was 29% and the prevalence of 
methicillin resistance amongst Staphylococcus aureus isolates was 33% (Nyasulu et al., 
2012).  
 
Studies focusing specifically on the percentage of MRSA in either private or public hospitals 
in South Africa have been conducted. Within the South African private hospitals included in a 
study, the percentage of MRSA ranged from 29% to 46% during the period January 2006 to 
June 2006 (Brink et al., 2007). Comparatively, within the South African public hospitals 
included in a study, the percentage of MRSA ranged from 24% to 59% during 2010 (Bamford 
et al., 2011). Although these results are taken from different settings and times and a direct 
comparison cannot be made, it may be suggested that South African public hospitals had a 
higher rate of MRSA than South African private hospitals.  
 
A further report, Antimicrobial Resistance Surveillance from Sentinel Public Hospitals, South 
Africa, 2013, obtained data on antimicrobial susceptibility testing regarding common 
organisms isolated from blood cultures at various public hospitals in South Africa during a 
12-month period. 2 424 Staphylococcus aureus isolates from blood cultures were recorded at 
the selected public hospitals in 2013. The number of cases of Staphylococcus aureus 
isolates from blood cultures ranged from 186 to 227 per month. Of the Staphylococcus 
aureus isolates that were tested with cefoxitin, 41% were reported to be resistant to cefoxitin 
and thus considered to be MRSA. However, only 37% of the Staphylococcus aureus isolates 
that were tested with oxacillin and other beta-lactam antibiotics were recorded as resistant. 
Focusing specifically on CMJAH, 41% of the Staphylococcus aureus isolates that were 
tested with Cefoxitin were resistant, as compared to 47%, 40% and 18% recorded 
respectively at Chris Hani Baragwaneth Hospital, King Edward VIII Hospital and Nelson 
Mandela Academic Hospital respectively (Perovic et al., 2014).  
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Another study focusing on cases of Staphylococcus aureus bacteraemia in three academic 
hospitals in South Africa, between September 2012 and September 2013, reported that 
overall MRSA was present in 36% of these cases. The individual percentages of MRSA 
isolates amongst the cases of Staphylococcus aureus bacteraemia per hospital were 
reported as 24% in Helen Joseph Hospital, 26% in Steve Biko Academic Hospital and 
Tshwane District Hospitals and 58% in CMJAH which had the highest percentage (Fortuin-de 
Smidt et al., 2015).    
 
As a variance in the percentage of MRSA resistance amongst Staphylococcus aureus 
isolates in South Africa can be seen from the studies above, it is important to consider the 
factors that could account for this variance such as the hospitals that were included in the 
report and the types of samples that were used to obtain data regarding the isolates  
 
5.3 Study Population  
The data received from the NHLS Corporate Data Warehouse Information Systems was 
used to derive the study population. After sorting and filtering the data as well as setting the 
inclusion and exclusion criteria, the orthopaedic ward and vascular ward were included in the 
study population. The literature below also demonstrates that patients in the orthopaedic and 
vascular wards are amongst the patients that are more susceptible to infection with MRSA.  
 
There are various factors that predispose patients in the orthopaedic ward and undergoing 
orthopaedic surgery to infections due to MRSA. These factors include but are not limited to 
undergoing surgery, insertion of invasive medical devices, having prostheses or supporting 
structures and immobilisation after operations (Lee et al., 2010). These factors can also be 
identified in the patients in this study population that had MRSA in the orthopaedic ward, as 
they underwent surgery and post-surgical procedures as well as having supporting structures 
such as prosthesis, nails or plates. 
 
As noted by Lee and co-authors (2010), there are several similarities between patients in an 
orthopaedic ward and patients in a vascular ward, such as having co-morbidities, being 
elderly and in most cases undergoing planned elective procedures more often than 
unplanned emergency procedures. However, there are also noticeable differences between 
these two groups of patients (Lee et al., 2010). These differences can be recognised in the 
patients in this study population as although the patients in both wards had underlying 
conditions and underwent surgical procedures, the types of conditions and procedures 
differed between the two wards.  
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The nature of both orthopaedic surgery and vascular surgery is invasive. However, in 
orthopaedic surgery the bacterial contamination remains more localised due to the 
procedures involving articular spaces and soft tissue as compared to vascular surgery, in 
which bacterial contamination can easily move and spread as the procedures involve 
creating a direct opening into the bloodstream, as well as the possible occurrence of vascular 
insufficiency (Lee et al., 2010).   
 
Patients in the vascular ward diagnosed with vascular disease often also have conditions 
such as poor circulation, diabetes, chronic sepsis, ulcers and gangrene, which make them 
vulnerable to acquiring infections due to MRSA. It has been shown that in certain countries 
MRSA is a main cause of infection in patients that had vascular surgery as well as infections 
in vascular wounds and grafts (Earnshaw, 2002). These conditions were also identified in the 
patients in this study population that had MRSA in the vascular ward, as many of them had 
diabetes, hypertension, PVD and a form of sepsis. Not only has infection due to MRSA 
become common amongst patients undergoing vascular surgery, it has additional critical 
consequences such as increased need for amputation and removal of grafts (Lee et al., 
2009).  
 
In both of the wards, there was a wide range regarding length of stay in hospital. The 
orthopaedic ward had an average of 48 days in hospital and the vascular ward had an 
average of 38 days in hospital. Studies have found that a patient with an infection due to 
MRSA would have a longer stay in the orthopaedic and vascular wards compared to those 
patients without an MRSA infection; however, the number of additional days varies between 
the studies.  A study conducted on vascular surgery patients reported the median number of 
days that a patient with MRSA stayed in hospital was 24 days (Cowie et al., 2005) and a 
study conducted on orthopaedic surgery patients reported the average number of days that a 
patient with MRSA stayed in hospital was 88 days (Tai et al., 2004). The variation in the 
number of days spent in hospital for patients with HAIs may also be due to factors such as 
their age, initial diagnosis, co-morbidities, surgical procedures and overall well-being. An 
additional factor is that while patients with HAIs experience a prolonged stay in hospital, they 
are at a high risk of acquiring HAIs (Schulgen et al., 2000). 
 
5.3.1 Patient Characteristics and Demographic Data 
Although the objective was to perform a utilization review of the antibiotics administered and 
laboratory tests conducted with the results of MRSA in order to formulate management 
pathways for patients in the study population, basic demographic data was first collected to 
gain an understanding of the study population. The factors that could predispose patients in 
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an orthopaedic or vascular ward to acquire an MRSA infection have been discussed. 
However, in light of the study’s results, the following can be emphasised.  
 
The median age of the patients in the orthopaedic ward (45 years) and vascular ward (59 
years) was much younger than the median ages that are common in patients undergoing 
orthopaedic surgery (65 years) (Lee et al., 2010) and vascular surgery (73 years) (Lee et al., 
2009). In both wards, more than half of the patients were male, which correlates to a study 
which found that males are at a higher risk for MRSA than females, despite previous 
research which demonstrated no noticeable difference of the risk of MRSA in males and 
females (Kupfer et al., 2010) 
 
5.4 Ethnographic Observations  
Qualitative research methods of ethnography and inductive analysis were used to collect, 
record and analyse the data obtained from the observations (McMillan et al., 2014). The 
observations conducted in the CMJAH orthopaedic and vascular wards as well as the NHLS 
Microbiology Laboratory and Main Dispensary, aided in gaining an understanding of the 
current clinical practices of HCPs when managing a patient with a suspected MRSA 
infection, the current method used to test for MRSA in the laboratory and the current process 
of dispensing antibiotics to inpatients. Having this understanding also assisted this study 
when interpreting the retrospective patient records, formulating the patient management 
pathways, performing the cost analysis and developing the decision-tree-analytic models.  
 
5.4.1 Clinical Ward Observations  
The clinical ward observations were conducted only during the morning ward rounds over a 
period of one week per ward, therefore the information discussed below is based only on the 
practices observed and cannot be taken as a general comment on the wards. Another point 
is that only the general practices were observed qualitatively and a quantitative assessment 
was not conducted thus, it is not possible to make direct comparison to many studies that 
quantitatively report on the various aspects in the ward, infection control and treatment of 
patients with MRSA.  
 
Although similar practices were noticed in the orthopaedic ward and the vascular ward 
regarding HCPs practices during the morning ward rounds, the similarity in the practices was 
not always due to similar protocols being followed in these two wards, nor could it imply that 
they were the ideal practices. A pattern identified was that within the wards, certain practices 
of the HCPs were done routinely, while others were inconsistent.  
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5.4.1.1 Ward Rounds 
Routinely, every morning, an HCP and a nurse would start the ward round in order to follow 
the progress of each patient, and during the course of the ward rounds, other HCPs would 
join or leave the team. As observed in the ward rounds in this study, ward rounds have been 
described by other studies as a time during which various HCPs meet to discuss patients’ 
management pathways (Liu et al., 2013). It is also common practice in other hospitals to 
have a multi-disciplinary team present during ward rounds, as observed in CMJAH, although 
the actual members present may differ between hospitals (Busby et al., 1992)    
 
It was observed that during a patient’s stay in the ward, different HCPs with the same 
qualifications would attend to the patient. Being treated by numerous HCPs may impose 
possible disadvantages to the patient such as:   
 It is time-intensive to establish which tests were requested by the previous HCPs and 
then to follow up if these tests were actually conducted and if the results were 
received and interpreted.  
 If the laboratory test information is not easily accessible, the same tests may be 
reordered and conducted, resulting in unnecessary costs and use of resources. 
 Repeat medication prescriptions were made even though they were already 
prescribed on the current prescription chart. 
 Medicines were not signed off to discontinue the medication before prescribing an 
alternative. 
 Differing styles of the HCPs patient notes in the patient’s record, thus making it 
difficult to look back and understand the patient's complete history without suspecting 
that information was missing. For example: detailed notes compared to basic points. 
Observing these patterns helped in understanding certain aspects when extracting data from 
patients’ retrospective records.  
  
During the ethnographic observations, the different forms of communication were observed 
and included in the pattern of Underlying Themes. Despite there being numerous HCPs on 
the team and in the wards, the communication observed between the HCPs present was 
good, as there was a level of understanding and respect. However, the communication 
observed between some of the HCPs and the patients seemed to be lacking and brief . 
Absence of communication between HCPs and patients is neither a unique nor new issue 
during ward rounds, as studies dating back to the 1960s discuss the implications and the 
importance of improving this issue (Busby et al., 1992; Ha et al., 2010).  
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5.4.1.2 Infection Control Practices 
When applying for ethics, hospital and ward approval to conduct this study, it was stated that 
the infection control practices of the HCPs would be observed and thus permission was 
granted to do so. However, in order to obtain a clear reflection of what happens in daily 
practice in the wards, only once the observations in the wards were complete was an enquiry 
made as to whether there are formal documented protocols in place regarding infection 
control in the wards. The Infection and Prevention Control Protocols (27/08/2013) that were 
made available in the ward were very general and thus a comparison to the observations 
could not be made. After much further enquiry, it could not be established whether or not 
there were other documented protocols that had not been made available, or if the HCPs 
currently in the ward were themselves unaware of additional protocols, or if those were 
actually the only documented protocols regarding infection control in the wards.  
 
A pattern of inconsistency was identified when analysing the infection control practices that 
were observed in the wards. During the observed ward rounds, antiseptic/disinfectant hand-
rub and hand washing basins was easily accessible and available in the wards; however, 
they were not always used as required. These practices varied between the different HCPs 
that were present on the ward rounds. Inconsistent hand washing practices are not 
uncommon. Globally there are numerous guidelines and studies relating to hand washing 
practices in the healthcare environment. In 2009, the WHO published the WHO Guidelines 
on Hand Hygiene in Health Care, which was formulated by a panel of specialists and 
implemented in healthcare settings of various economic rankings worldwide, thus 
emphasising the global nature and importance of correct hand washing practices (World 
Health Organization, 2009).  
 
This guideline consists of consensus recommendations for hand hygiene such as: 
Indications for hand hygiene; Hand hygiene techniques with Alcohol-Based Formulation or 
Soap and Water; Recommendations for surgical hand preparation; donning and removing 
non-sterile and sterile gloves. It also includes the model “The five moments for hand hygiene 
in health care” which are: 
1. Before touching a patient 
2. Before a clean/aseptic procedure 
3. After body fluid exposure risk 
4. After touching a patient 
5. After touching patient surroundings 
This model is incorporated in the WHO Multimodal Hand Hygiene Improvement Strategy and 
has already been implemented in numerous hospitals (World Health Organization, 2009).  
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It is well established that correct hand washing practices can prevent the further spread of 
infections. A recent review was conducted by looking at other studies to determine the extent 
to which hand hygiene practices affect the transmission of MRSA. The review concluded that 
the spread of MRSA is reduced by correct hand hygiene practice, however, studies need to 
be conducted to determine the exact extent and also the effects of other factors such as 
contact precautions (Marimuthu et al., 2014). 
 
Regarding the isolation practices for patients identified with MRSA, the pattern of lack of 
resources in terms of hospital space was recognised. The HCPs identified the need to isolate 
patients displaying signs of serious infection, but due to the lack of resources at times there 
were no specialised isolation areas within the two wards in order to implement the correct 
isolation procedures. The HCPs therefore had to take alternative courses of action, which 
even included moving the patient with an infection to the far corner of the current ward. As 
with most infection control practices, different hospitals implement different strategies 
depending on their available resources. As MRSA easily spreads, isolation may play an 
important role in the prevention of further MRSA infections. However, there is much 
controversy regarding the effectiveness of isolation practices, as there are certain 
disadvantages to isolating patients. In addition to the extra resources and costs associated 
with isolating a patient (Gould, 2006), the psychological effects of isolation on the patient and 
the HCPs work attitude towards isolated patients also have to be taken into account 
(Halcomb et al., 2008; Fätkenheuer et al., 2014; Seibert et al., 2014).  
 
5.4.1.3 Treatment of Patients 
The HCPs actions taken for a patient presenting with a suspected or confirmed infection 
were observed during the morning ward rounds. The nurses were consistent in routinely 
measuring the patients’ temperatures, as an increased temperature may indicate the 
presence of a suspected bacterial infection (Gopalan, 2005; Boyles et al., 2015). A pattern of 
routine was identified when analysing the steps taken for a patient with a suspected infection 
as the HCPs would always instruct that a septic work-up be performed and would stipulate 
which tests were to be done and if there was a need for empiric antibiotics to be 
administered while waiting for the test results. Although it is common practice for HCPs to 
initiate a septic work-up for a patient with suspected infection, a study conducted by O’Grady 
and co-authors (2008), concluded that when a patient presents with an increase in 
temperature, HCPs should not routinely order laboratory and other tests to be conducted, but 
should rather first perform a thorough clinical examination on the patient due to the fact that 
presence of fever does not necessarily mean the presence of infection. In this way 
unnecessary laboratory tests costs can be avoided.  
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A South African article acknowledges that in certain cases it can be challenging to diagnose 
HAIs. Despite there being various guidelines available to aid the diagnosis of infection and 
sepsis, presentation varies and some of the features mentioned to assist in the diagnosis of 
infection or sepsis are common features that most hospitalised patients present with, 
irrespective of whether they have an infection or not. Therefore, it is important that the 
patient’s medical records are used along with a clinical assessment to guide the diagnosis of 
an infection. In order for HCPs not to miss the presence of infection in a patient the HCPs 
should also be aware that certain groups of patients may not present with the common 
features of infection. HCPs also need to be aware that systemic features of infection may not 
be present in a patient with a localised infection (Gopalan, 2005). 
 
However, once the initial identification of a suspected infection and the ordering of a septic 
work-up were performed, patterns of disorganization, lack of communication, waiting and 
unavailable resources were identified.  These included:  
 Looking for information by paging through the patient’s records or piles of paper at 
the front of the ward.     
 Re-ordering of laboratory tests if the patient's MCS test results were not easily 
located. 
 Continuing with Empiric Antibiotics following confirmation of MRSA whilst waiting for 
motivation for MRSA-Specific Antibiotics from senior HCPs. 
 Continuing with Empiric Antibiotics following confirmation of MRSA if the patient’s 
clinical signs were not deteriorating. 
 
5.4.2 NHLS Microbiology Laboratory Observations  
To gain an understanding of the current process of identifying MRSA, ethnographic 
observations were conducted at the Bacteriology bench of the NHLS Microbiology 
Laboratory at CMJAH. When a specimen for a suspected infection was received at the 
laboratory, the Conventional Culture Method was used to identify the type of infection. The 
Conventional Culture Method consists of three main steps: Microscopy, Culture and 
Sensitivity, as well as two preparation steps of Planting and Picking.     
  
The Conventional Culture Method has been considered as the traditional method for the 
detection of MRSA (Havill, 2010). However, due to the limitations of this method such as its 
resource-intensive and time-intensive nature, researchers have continually been trying to 
develop an optimal method of detection for MRSA, hence the wide variety of MRSA testing 
techniques currently available. The Conventional Culture Method for the detection of MRSA 
consists of different phenotypic tests such as agar screening, disc diffusion, minimum 
inhibitory concentration and E-tests. The newer methods for the detection of MRSA use 
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genotypic techniques using PCR. Studies have been conducted to try and detect which 
method or combinations of methods are best at detecting MRSA (Adaleti et al., 2008; Datta 
et al., 2011).   
 
Upon analysing the data collected for the process of conducting the Conventional Culture 
Method, various patterns were deduced. The overall patterns that were identified when 
following the steps taken from when a specimen was received until a diagnosis was made 
were ones of routine, organization and systems. There were established routines and 
documented protocols in place that were followed systematically by the laboratory personnel 
during each step of conducting the Conventional Culture Method. The equipment and 
resources that were required to perform each step were well organised and easily accessible 
within the laboratory. However, in a healthcare setting in which resources are scarce, it was 
found that the Convention Culture Method is resource-intensive.   
 
Although there were a number of laboratory personnel that worked at the bacteriology bench, 
they worked well together as a team and would often ask each other for opinions when 
reading the plates. The Conventional Culture Method as such, largely relies on the laboratory 
personnel’s skill and expertise in preparing the plates, as well as their knowledge and 
judgement when reading the plates to identify possible organisms. This method also requires 
various techniques and tests to be conducted in order to obtain the diagnosis and the details 
of the organism identified. Therefore, different laboratory personnel perform different steps of 
the Conventional Culture Method and in this manner it serves as a double checking process 
to ensure that the previous step was prepared and had been read appropriately to ensure the 
accuracy of the results. At the end of the Conventional Culture process, before a patient’s 
results are finalised, they are first checked by a pathologist. Thus as observed, as well as 
documented, the Conventional Culture Method is not only a time and resource-intensive 
process, but also a labour-intensive process (Huletsky et al., 2005). 
 
Another pattern observed was the time involved in the Conventional Culture Method. Firstly, 
the nature of this method requires plates to be incubated for certain periods of time before 
they can be read, thus accounting for a three to five day wait before the confirmed test 
results are available. Secondly, the actual preparing and reading of the plates by the 
laboratory personnel is a time-intensive, tedious and hands-on task. The new PCR methods 
for the detection of MRSA are less time-intensive and provide the test results within a shorter 
period as compared to the traditional culture methods for the detection of MRSA; however, 
these new PCR tests are more costly (Havill, 2010).   
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Thirdly, it was observed that once the laboratory personnel had read each plate, they would 
write down the results on the corresponding patient's working card. On completion of reading 
all the plates, these results would then be entered onto the computer system and would be 
accessible to the HCPs as provisional results. However, this current system entails a time-
intensive double entering of results. If the results were entered straight onto the computer 
system, not only would this time be saved, but the HCPs would have the results sooner.   
 
The observations provided the knowledge in order to understand the costing system used for 
patients that had MCS tests done, as well as gave perspective on the timing and waiting 
periods that occur in the wards.    
  
5.4.3 Antibiotic Dispensary Observations  
To obtain a complete understanding of the management of patients with a suspected or 
confirmed infection, ethnographic observations were conducted in the antibiotics designated 
area of the dispensary at CMJAH. When interpreting the results regarding the procedure for 
dispensing antibiotics to inpatients, the patterns that were revealed alternated between 
routine and flexibility.    
 
Although there were no formal printed protocols available, the current antibiotic dispensing 
procedure that was executed was explained. As there was an established dispensing 
process that took place between the wards and dispensary, a pattern of routine was 
identified. Simultaneously, a pattern of flexibility was also present, as the dispensing process 
could differ slightly per patient depending on the severity of each patient’s condition. It was 
also said that although each ward had a dispensing system with the dispensary, the system 
kept on changing and could differ between wards as well as between different hospitals. 
Thus the pattern of flexibility appeared again.   
 
Along with the advancement in information and communication technology, there have been 
numerous developments in the area of hospital dispensing systems such as Automated 
Dispensing Cabinets (Rodriguez-Gonzalez et al., 2012), and Electronic Medical Records. 
However, in both developed and developing countries, research is being conducted 
regarding the implementation and benefits of these new systems (Fraser et al., 2005; Blaya 
et al., 2010). The dispensing system currently used between the wards and the dispensary is 
a manual one that involved the doctor writing prescriptions on the patients’ prescription 
charts; the nurse copying the prescriptions onto dispensary order forms; runners taking the 
forms to the dispensary; the pharmacist selecting and preparing the required antibiotics to be 
dispensed; and runners later returning to the ward with the antibiotics.  
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Once the antibiotics were in the ward it was then the responsibility of the nurses to 
administer and manage the ward stock. Although not always according to protocol, the 
nurses had their own system by which they managed the ward stock. As most antibiotics 
were dispensed on a per patient basis, if a patient no longer required an antibiotic that had 
been dispensed to the ward for that patient, then the nurse would often use that antibiotic for 
another patient requiring that same antibiotic, who was in the process of waiting for their 
prescription to be dispensed. When obtaining data from the patients’ retrospective records, 
this information helped in understanding the differences in waiting periods for antibiotics. 
Thus, patterns of responsibility, routine and flexibility were evident regarding the 
management of ward stock by the nurses. An article by Schellack and Meyer (2010), 
acknowledges that nurses perform most of the duties pertaining to the management of 
pharmaceutical ward stock, thus providing guidelines for the nurses pertaining to ward stock 
management. Certain aspects of these guidelines were similar to the observations in this 
study and the authors also emphasise the importance of continuous communication between 
the nurses in the wards and the pharmacist (Schellack et al., 2010). 
 
Patterns of restriction and requirements also emerged in the dispensing of certain antibiotics 
as an attempt to prevent further antibiotic resistance. Within the main dispensary of CMJAH, 
there was a small designated room for the storage and dispensing of antibiotics which had 
strict access rules in order to control the flow of antibiotics within the hospital. Stipulated 
documents such as motivations signed by senior HCPs and microbiology laboratory results 
were required per patient per antibiotic, in order to authorise the dispensing of specific 
antibiotics. Although these measures were designed to ensure the use of only essential 
antibiotics, the waiting for HCPs to sign motivations, or for the laboratory to release the 
patient's results, could cause delays for patients urgently requiring treatment. The dispensary 
is therefore flexible in urgent cases.   
 
In 2014 The Centers for Disease Control and Prevention documented the Core Elements of 
Hospital Antibiotic Stewardship Programs, and recommended that Antibiotic Stewardship 
Programmes should be implemented in all acute care hospitals. It also acknowledges that 
one universal Antibiotic Stewardship Programme is not possible as it would depend on 
individual hospitals, but that there are core elements that should be included in these 
programmes. One of the core elements is to “Implement Policies and Interventions to 
Improve Antibiotic Use”, which consists of broad interventions such as prior authorisation, 
which was seen in this study. Another broad intervention which, if implemented in this current 
study could prove to be beneficial is Antibiotic ‘Time-outs’, which requires that antibiotics 
prescribed to patients are reassessed after 48 hours by HCPs answering key questions 
(Centers for Disease Control and Prevention, 2014). 
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The presence of antibiotic stewardship was observed within the wards and in the antibiotics 
designated area of the dispensary. Patterns of establishment, improvement, strengthening 
and necessity were identified. It was deduced that currently, pharmacists are not actively 
involved in the antibiotic stewardship programme and that it was vital that the current 
antibiotic stewardship programme be strengthened by actively including pharmacists. 
Another Core Element of the Core Elements of Hospital Antibiotic Stewardship Programs is 
“Accountability and Drug Expertise”, which includes having one leader in charge of the 
overall antibiotic stewardship programme and one pharmacy leader as well as key support 
from other HCPs such as clinicians, nurses and laboratory personnel (Centers for Disease 
Control and Prevention, 2014). A review article by Mendelson (2015), suggests ways in 
which antibiotic stewardship could be implemented at a patient and programme level in order 
to assist in preventing the increasing problem of antibiotic resistance.   
 
The pharmacist in this study felt there would be numerous benefits if a strong antibiotic 
stewardship programme were to be established in the hospital. Amongst other things, an 
antibiotic stewardship programme would improve the relationship between the prescribers, 
nurses and the pharmacist; decrease the waiting period between prescribing and 
administration; facilitate implementation of standardised protocols; ensure optimal utilization 
of available resources including antibiotics; and ultimately prevent the emergence of 
antibiotic resistance. In South Africa, key antibiotic stewardship organizations included the 
Global Antibiotic Resistance Partnership–South Africa and the SAASP. The Department of 
Health has now developed and implemented the Antimicrobial Resistance National Strategy 
framework 2014-2024 with the purpose of improving patient outcomes, preventing antibiotic 
resistance and providing a framework for managing antibiotic resistance (Department of 
Health, 2014).  
 
5.5 Retrospective Records Review 
As established from observations in the wards, patient records are kept manually by HCPs 
writing in the patient's record. Once a patient is discharged, and after a period of time, the 
patient records are sent to the Hospital Medical Records Room to be stored. Within the 
Records Room the patient's record is transferred onto microfiche cards and then stored in 
drawers according to the patient's hospital number. Due to the limitations of manual paper 
patient records and with technological advances, hospitals globally are now implementing the 
use of electronic patient records. However, in the study areas at CMJAH this has not yet 
been introduced. The limitations arising from using the manual paper patient records system 
as seen in this study and documented from other studies, include patient records that were 
missing; duplication of information; disorganization of records; inconsistency between the 
quality and quantity of notes written by different HCPs (De Wet et al., 2001). The electronic 
 121 
 
patient records system seems to address these limitations, as well as has the further 
advantages of being able to identify, prevent and reduce medication errors (Radley et al., 
2013), and assist in antibiotic stewardship (Dalton et al., 2015). However, there are also 
possible disadvantages in using electronic patient records such additional costs and training 
required (De Wet et al., 2001). Therefore the feasibility of implementing the electronic patient 
records system in the context of each hospital should first be assessed.  
 
The retrospective records of the patients in this study population were accessed and viewed 
under a microfiche reader. Although ethics and hospital permission were granted for this 
study as well as approval from the head of the records room to collect the required data was 
obtained, printing of the records, taking pictures or the use of any electronics was not 
allowed. Thus the information required was written onto case report forms. Even in the case 
of newer records that are being scanned as PDF documents and viewed on a computer, the 
information gained could only be written down. This was a tedious and time-intensive 
process and extra care had to be taken to ensure that all the required information was 
correctly written down. An advantage of electronic patient records can be highlighted here, 
as they can provide researchers with easy access to clinical data (Fraser et al., 2005). 
 
Another advantage of electronic patient records over manual paper medical records is that 
the paper records are not always filled in completely; at times they are not easily understood 
by other HCPs; and they can also be misplaced, thus resulting in missing information (De 
Wet et al., 2001). From the derived study population of patients with MRSA in the 
orthopaedic and vascular wards, 16.67% of the patient records could not be found in the 
hospital’s records room, or could not be included due to various other reasons such as 
patient records that were unable to be obtained or missing data within the patient records.    
 
5.5.1 Antibiotic Utilization Review 
Information regarding a patient’s antibiotic history could be found on the doctors’ prescription 
charts and the nurses’ administration charts. The nurses’ administration charts were found to 
be a more reliable source of information, as their administration tables were more completely 
filled in as compared to the doctors’ prescription tables. Where possible, reasonable 
assumptions could be made, however, due to missing and incomplete prescription and 
administration charts, 24.27% of the antibiotic prescriptions from the orthopaedic ward and 
27.81% of the antibiotic prescriptions from the vascular ward had to be excluded from the 
analysis. Once again, the consequences of the current manual paper records system being 
used could be eliminated if an electronic patient record system were to be implemented (De 
Wet et al., 2001). 
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The antibiotics prescribed and administered to the patients in this study population were 
divided into Empiric, MRSA-Specific and Other Antibiotics. The average number of antibiotics 
that a patient received was five in the orthopaedic ward and four in the vascular ward 
however, the number ranged from one to 13 in the vascular ward.  Interestingly, a majority of 
the antibiotics administered in both the wards (56.41% in the orthopaedic ward and 43.12% 
in the vascular ward) were Empiric Antibiotics. A study conducted in ICUs at public and 
private hospitals in South Africa documented the antibiotic prescriptions of 248 patients.  
From the patients that were prescribed antibiotics, 73.5% of the patients received Empiric 
Antibiotics, the average number of antibiotics administered was three and the range of 
antibiotics prescribed at the same time was from one to ten per patient. Paruk and co-
authors (2012) state that the main reason for the high number of concurrent antibiotics was 
due to new antibiotics being started without the previous ones being stopped, this was also 
apparent when reviewing the patients’ retrospective records in this study.  
 
The percentage of empiric antibiotics could be decreased by decreasing the waiting period 
for laboratory test results by using rapid tests and improving the current system of 
communication and organization between the laboratory, the wards and HCPs (Geiger et al., 
2013). The use of empiric antibiotics is controversial as it may be considered as unnecessary 
administration of antibiotics and thus lead to further antibiotic resistance, however, their 
correct use may be beneficial (Solomkin et al., 2004; Paul et al., 2010). 
 
As all the patients in this study population had a confirmed laboratory diagnosis of MRSA, 
surprisingly, only 19.27% and 34.62% of the antibiotics administered were MRSA-Specific 
Antibiotics in the vascular and orthopaedic wards respectively. In both wards, not all of the 
patients in this study population received MRSA-Specific Antibiotics, as only nine out of the 
16 patients in the orthopaedic ward and 11 out of the 29 patients in the vascular ward 
received MRSA-Specific Antibiotics. Fortuin-de Smidt and co-authors (2015) conducted a 
study at three public hospitals in Gauteng, one of them being CMJAH, looking at the factors 
that are related to infections due to MRSA. They revealed that from the 36% of the cases 
that were identified as MRSA, directed treatment including MRSA-Specific Antibiotics were 
administered to only 59% of these cases. It is also important to note that death occurred in 
62% of the MRSA cases that did not receive vancomycin treatment (Fortuin-de Smidt et al., 
2015). However, in this study, upon enquiring in the orthopaedic and vascular wards as to 
why these patients with a confirmed laboratory diagnosis of MRSA did not receive MRSA-
Specific Antibiotics, it was suggested that in certain cases it was based on a patient’s clinical 
symptoms and if the patient was recovering then their current empiric antibiotics would not 
be changed to MRSA-Specific Antibiotics, or if the patient was not receiving any antibiotics 
then MRSA-Specific Antibiotics would not be initiated.  
 123 
 
In the orthopaedic ward, rifampicin was administered to eight out of the nine patients that 
received vancomycin for the treatment of MRSA. For MRSA bone or prosthetic joint 
infections, rifampicin can be used as an adjunctive therapy in combination with vancomycin 
(Kluytmans et al., 2009) and at times rifampicin is also used an adjunctive therapy for 
Staphylococcus aureus infections in South Africa (Jansen van Rensburg et al., 2012). 
Linezolid was used for only two patients in the orthopaedic ward. Although vancomycin has 
been seen as the “gold standard” for the treatment of MRSA, due to the development of 
resistance as well as pharmacokinetic and pharmacodynamics parameters, the use of 
vancomycin is being reviewed and replaced with alternative agents such as linezolid or 
daptomycin (Micek, 2007; Edwards et al., 2014). Studies have thus been conducted to 
investigate the costs and clinical benefits of using these alternative agents as compared to 
vancomycin. Despite the higher cost of linezolid, studies have shown that linezolid may be 
more cost-effective than vancomycin for MRSA skin and soft tissue infections (Bounthavong 
et al., 2009; Stephens et al., 2013), and MRSA pneumonia (Machado et al., 2005; Patel et 
al., 2014).  
  
As the WHO DDD can be used to monitor antibiotic usage in hospitals, the PDD of each 
antibiotic administered to each patient was calculated and compared to the WHO DDD. Only 
39% of the PDD in vascular and 40% of the PDD in orthopaedic ward were equal and 
matched the WHO DDD. These results are similar to the results of other studies which 
compared antibiotic PDD and WHO DDD. A study performed by de With and co-authors at a 
university hospital, found that only 36% of the PDD were equal to the DDD (de With et al., 
2009). Similarly, another study compared the DDD with the PDD of antibiotics used at a 
university hospital reported that for many of the antibiotic classes, the DDD was not equal to 
the average PDD. However, the study suggests that in conjunction with using the WHO DDD 
every hospital should formulate a standard measure to monitor antibiotic usage (Muller et al., 
2006). The WHO acknowledges that the DDD is a unit of measurement for comparing drug 
utilization and DDD may differ from the PDD due to individual patient characteristics (World 
Health Organization Collaborating Centre for Drug Statistics Methodology, 2012).  
 
5.5.2 NHLS Microbiology Data Review 
The retrospective records review showed differing methods of capturing patients’ laboratory 
test results, thereby reflecting a lack of standard data capturing processes. The printouts of 
the NHLS laboratory test results were a reliable source of data; however, they were not 
always present in the patient records. The other sources of data in which patients' laboratory 
test results were recorded, such as written on tables or as notes, could not be classified as 
reliable sources as it was seen that often the results were incompletely recorded and 
important information was missing.  
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As the information present in the retrospective patient records regarding their laboratory test 
results was not always reliable, information obtained from the NHLS Corporate Data 
Warehouse Information Systems was used to obtain the detailed information. Several well-
conducted and published studies relating to MRSA in South Africa have also obtained their 
data from the NHLS Corporate Data Warehouse Information Systems (Bamford et al., 2011; 
Jansen van Rensburg et al., 2012) and thus it can be seen as a reliable public sector 
database.  
 
It was found that when a patient had a suspected infection, numerous specimens were taken 
and sent to the microbiology laboratory to be tested. The number of laboratory tests reported 
in this study represents only those laboratory tests that isolated MRSA. In the orthopaedic 
ward, the patients had a range of between one to ten with an average of three microbiology 
laboratory tests conducted that isolated MRSA. In the vascular ward, however, the patients 
had fewer repeat tests, with a range of one to four, with an average of two microbiology 
laboratory tests conducted that isolated MRSA. 
 
To ensure the optimal management of patients, two-way communication has to occur 
between HCPs in the ward and the laboratory, in which the HCPs provide the laboratory with 
complete clinical information regarding the tests ordered per patient. This aids the laboratory 
in performing the correct tests, interpreting the results, and reducing the performance of 
unnecessary tests, thus decreasing costs, time and resource utilization (Georgiou et al., 
2011). These problems could be prevented and communication could be further improved if 
point of care testing were to be implemented in the wards in which PCR tests are conducted 
in the wards. Brenwald and co-authors (2010) conducted a study in which patients’ nasal 
swabs were tested using the Xpert MRSA tests that were implemented in the wards using 
the Xpert MRSA tests that were implemented in the microbiology laboratory. It was found 
that on average the test results from the ward were available more than ten hours earlier that 
the test results from the laboratory (Brenwald et al., 2010). A study by Parcell and Phillips 
(2014) showed another advantage of using the Xpert MRSA as point of care testing, in that it 
reduces the number of negative specimens that would be sent to the microbiology laboratory, 
thus enabling the negative test results to be available faster as well as reducing the work-
load of the laboratory personnel.  
 
Depending on the type of suspected infection, different types of specimens from different 
sites were taken and sent to the NHLS Microbiology Laboratory to be tested. From the tests 
that isolated MRSA in the orthopaedic ward, an equal number of fluid, irrigation fluid and 
tissue specimens were taken. This was not the case for the laboratory tests that isolated 
MRSA in the vascular ward as tissue specimens were most common, followed by pus swabs. 
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A study that investigated the antimicrobial susceptibility patterns of staphylococcus aureus 
isolates in KwaZulu-Natal found that from the MRSA isolates, 78.7% were from wound 
samples, 9.8% were from sputum and 3.3% were from otitis media (Shittu et al., 2006). 
 
5.6 Cost Analysis   
When a patient is discharged from CMJAH, they do not receive an itemised bill with details 
regarding the costs of the antibiotics administered and laboratory tests conducted and no 
records of this costing information were available. CMJAH, along with many public hospitals 
in South Africa, uses the UPFS as a guide for billing patients. The UPFS implements a group 
fee approach rather than an itemised billing approach, as well as patients are billed and 
grouped according to their income. Thus, two patients receiving the same medical treatment 
may be billed at different rates (Department of Health, 2009). Hence the requirement for 
obtaining separate antibiotic and NHLS laboratory test costing databases to manually 
calculate each individual antibiotic and laboratory utilization cost per patient in this study.   
 
Another reason as to why cost utilization calculations were performed for each antibiotic 
administered to each patient was because the dose, frequency and duration of antibiotics 
administered was not always standard. Although the NHLS data has standard costs per 
procedure, the cost of each laboratory test per patient has to be individually calculated as 
different procedures are conducted for each test.  
 
5.6.1 Antibiotic Cost Calculations 
Each patient received a different combination of antibiotics while in hospital and these 
antibiotics would change throughout their treatment. Thus, numerous calculations were 
conducted per patient. The sum of the cost of antibiotics administered per patient per day 
ranged from R42.56 to R1 695.04 with an average of R408.42 in the orthopaedic ward and 
R2.71 to R2 435.65 with an average of R462.51 in the vascular ward.    
 
In the orthopaedic ward it was interesting to note that although 56.41% of the antibiotics 
administered were Empiric Antibiotics, only 24% of the daily cost of antibiotics administered 
was due to Empiric Antibiotics and 60% of the daily cost of antibiotics administered was due 
to MRSA-Specific Antibiotics administered, which accounted for only 34.62% of all the 
antibiotics administered. However, in the vascular ward, 19.27% of the antibiotics 
administered were MRSA-Specific Antibiotics and 14% of the daily cost of antibiotics 
administered was due to MRSA-Specific Antibiotics administered. The lower cost of MRSA-
Specific Antibiotics in the vascular ward could due to the fact that linezolid, which has an 
average weighted price (contract) of R282.25 per 600 mg tablet, was not administered to any 
of the patients in the vascular ward.  
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When analysing the cost and utilization of individual antibiotics to the patients, the average 
daily cost of an antibiotic administered in the orthopaedic ward ranged from R0.41 for 
metronidazole to R564.49 for linezolid, while the average daily cost of an antibiotic 
administered in the vascular ward ranged from R0.30 for metronidazole tablets to R460.41 
for ertapenem IVI.  
 
Although the same antibiotic costing database was used when performing calculations for 
the orthopaedic and vascular wards, the average daily cost of an antibiotic differed between 
the two wards, as different doses and durations of treatment were used. For example, the 
average weighted price (contract) of vancomycin 1g vial is R46.97. The average daily cost of 
vancomycin was R115.29 in the orthopaedic ward and R77.50 in the vascular ward. The 
average number of days that antibiotics were administered also differed, as the average 
number of days that a patient received vancomycin was nine days in the orthopaedic ward 
and three days in the vascular ward.  
 
Due to the restricted use and high cost of linezolid, only two patients in the orthopaedic ward 
received linezolid and none of the patients in the vascular ward received linezolid. Despite 
the cost of linezolid being higher than the cost of vancomycin, studies have shown that 
linezolid may be more cost-effective than vancomycin for patients with MRSA (Machado et 
al., 2005; Stephens et al., 2013).   
 
5.6.2 NHLS Laboratory Tests Cost Calculations  
Depending on the steps taken for each laboratory test, the cost per test was calculated. The 
costs per step also differed slightly depending on the type of specimen being tested. Each 
laboratory test commences with one microscopy step which has a standard cost of either 
R36.93 or R38.41. Each culture and sensitivity step conducted thereafter had a separate 
cost.  
 
Therefore, once calculated, the cost per NHLS laboratory test that isolated MRSA ranged 
from R118.38 to R592.80 with an average of R335.09 per test in the orthopaedic ward and 
from R168.37 to R660.40 with an average of R373.03 per test in the vascular ward. Studies 
have shown that the Xpert MRSA tests are more expensive than the Conventional Culture 
Method (French, 2009; Havill, 2010; Marlowe et al., 2011), however, in both the wards in this 
study, the average cost of a Conventional Culture test that isolated MRSA was more 
expensive than the cost of one Xpert MRSA test (R307.52). Although the difference in cost 
may seem slight, it should be highlighted that if the Xpert MRSA test produces MRSA- 
positive results, further antibiotic  sensitivity tests would still need to be conducted and would 
thus further increase the cost of using the Xpert MRSA tests. 
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As established from the retrospective records, patients had multiple duplicated microbiology 
laboratory tests conducted. However, one could assume that the HCPs were unaware of the 
cost implications of numerous tests. The total cost of laboratory tests that isolated MRSA per 
patient ranged from R260.13 to R3 184.23 with an average of R921.51 per patient in the 
orthopaedic ward and from R168.37 to R1 492.05 with an average of R565.97 per patient in 
the vascular ward.    
 
5.6.3 Cost Calculations of Antibiotic Utilization plus NHLS Laboratory Tests per 
Patient   
A complete account of the antibiotics administered and the NHLS laboratory tests conducted 
that isolated MRSA per patient in the study population was calculated. The total sum of the 
Antibiotic Utilization Cost and the total of NHLS cost per patient ranged from R567.31 to 
R12 583.15 in the orthopaedic ward and from R45.06 to R16 199.18 in the vascular ward. 
Each patient’s total antibiotic utilization cost and total NHLS cost was then added to obtain a 
combined total cost per ward. The antibiotic utilization costs were responsible for the majority 
of the costs in the vascular ward (80.91%) and in the orthopaedic ward (76.04%).  
  
Many studies examining the additional patient management costs for a patient with an MRSA 
infection included other costs such as hospital stay costs, isolation costs, labour costs, 
screening costs and PPE costs. Studies also looked at the cost-effectiveness of using PCR 
tests instead of Conventional Culture tests and the sensitivity and specificity of the PCR tests 
as compared to the Conventional Culture tests (Gould, 2006; Wassenberg et al., 2010; Li et 
al., 2012; Tübbicke et al., 2012a). However, when calculating the management costs of a 
patient with an MRSA infection in this study, only the costs of antibiotics and microbiology 
laboratory tests that isolated MRSA were included, as it was assumed that all other costs 
would remain constant, irrespective of the testing methods. Due to the fact that the Xpert 
MRSA tests were not yet implemented in the study area, the cost-effectiveness (the cost of 
the additional clinical benefit), sensitivity and specificity could not be measured.   
 
5.7 Decision-Tree-Analytic Models  
International studies have developed decision-tree-analytic models to compare the costs of 
the Conventional Culture Method and the new PCR tests for MRSA. However, due to the 
South African public healthcare setting being different as compared to other healthcare 
settings, in areas such as access to healthcare and limited availability of resources (Ataguba 
et al., 2011) as well as differences in the implementation of surveillance and record keeping 
systems (Nyasulu et al., 2012), the results obtained from these international studies are not 
necessarily true to the South African context and cannot be directly applied to the public 
healthcare settings in South Africa.  
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Therefore, to depict the current management pathways of patients with a suspected 
infection, decision-tree-analytic models were developed for each ward in the study. Although 
the patient management pathways presented may not appear to follow standard clinical 
practice, they were derived from the observations conducted and data obtained from the 
patients’ retrospective records. A theoretical arm was added to each tree to evaluate the 
effect of implementing the Xpert MRSA tests in the current clinical settings. In addition, these 
models were then run depicting a theoretical situation of patients having an equal chance of 
receiving either management pathway, by using variables to assign equal probabilities to 
each pathway.   
  
The input parameters for the decision-tree-analytic models formulated in this study were 
delivered from the data obtained in this study from the patients’ retrospective records, 
observations and the cost analysis. In comparison to other studies that developed similar 
decision-tree-analytic models, some of these studies obtained their input parameters from 
conducting peer-reviewed literature searches (Brown et al., 2010; Hübner et al., 2012; 
Tübbicke et al., 2012a; Tübbicke et al., 2012b), while other studies obtained their input 
parameters from conducting actual research and trials on both the culture and Xpert MRSA 
tests (Li et al., 2012).  
 
The total cost of each possible management pathway for a patient with a suspected infection 
was calculated. It is interesting to note the wide range and high cost of these management 
pathways in both wards. If the Xpert MRSA tests were to be implemented in the current 
clinical settings, it is uncertain as to what the exact testing procedure would be, as the Xpert 
MRSA test results only reveal whether the patient is MRSA-positive or not. Hence, if a 
patient is MRSA-positive, further antibiotic sensitivity tests would need to be conducted. 
Therefore a variation in costs occurred as the potential situations were depicted. Several 
studies have been conducted introducing the implementation of the Xpert MRSA tests. 
However, a consistent clinical testing methodology could not be derived from these studies. 
Some studies involved comparing the sensitivity and specificity of the Xpert MRSA tests to 
the Conventional Culture Method thus using both of these testing methods concurrently 
(Andersen et al., 2010; Li et al., 2012). While another study suggested that the PCR test 
could be conducted first and thereafter the Conventional Culture test would only be 
conducted if the PCR test reflected a positive MRSA result (Tübbicke et al., 2012a). 
Furthermore, studies report that when using PCR tests, the Conventional Culture Method 
should be used as the final confirmation method (Wassenberg et al., 2010; Li et al., 2012). 
This is also in accordance with the Xpert MRSA package insert which stipulates that 
simultaneous tests using the culture method are required to obtain information regarding 
antibiotic susceptibility (Cepheid, 2012). 
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Ranking analysis was then performed, which evaluated the optimal strategy with the lowest 
cost. Despite the numerous differences found between the orthopaedic and vascular wards, 
the optimal strategy in the current clinical strategy in both of these wards was when Empiric 
Antibiotics were administered and a Specimen For MRSA was simultaneously taken. 
However, if the Xpert MRSA tests were to be implemented in the current settings, the Xpert 
MRSA strategy was the optimal strategy in the orthopaedic ward, but was the most 
expensive strategy in the vascular ward. Li and co-authors also developed a decision-tree-
analytic model using TreeAge to compare new strategies of implementing the Xpert MRSA 
tests with the current Conventional Culture strategy for screening hospital patients and found 
that the Xpert MRSA was the optimal strategy. These findings from Li and co-authors are in 
line with the results obtained for the orthopaedic ward in this study (Li et al., 2012).  
 
Furthermore, Brown and Paladino developed a decision-tree-analytic model on TreeAge, 
which included the effects of implementing the Xpert MRSA test on mortality and antibiotic 
usage and concluded that the current usage of empiric antibiotics is more costly than the 
costs of using the Xpert MRSA tests overall (Brown et al., 2010). Another study also 
formulated decision-tree-analytic models to evaluate the costs and effects that PCR tests 
would have on antibiotic usage for MRSA. This study reported that compared to empiric 
antibiotics that are administered without first having PCR test results, antibiotics administered 
which are guided by a PCR test result are more cost-efficient and lead to targeted antibiotic 
use for MRSA (Hübner et al., 2012). Although these studies evaluated the influence of MRSA 
tests on antibiotic usage for MRSA, they did not include a comparison arm reflecting the 
costs and consequence of the culture method on antibiotic usage. Therefore, this study 
investigated the costs and consequences of both the culture method and Xpert MRSA tests 
on antibiotic usage for a patient with suspected or confirmed MRSA.  
 
5.8 Limitations of the Study  
During this study, numerous challenges were faced and those that could not be overcome or 
changed may be seen as limitations of this study. The main limitations that affected this 
study are discussed below.  
 
5.8.1 Data Capturing  
The study was conducted at CMJAH, which is one of the main public sector hospitals in 
Johannesburg, South Africa. Within the wards included in the study, there was no electronic 
system for capturing data.  
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5.8.1.1 Patient Records 
The HCPs hand-wrote notes into the patient records and these notes were the only form of 
patient data recorded and available. Therefore, the patient records are based purely on the 
manner in which they were written into the patient records. Within these records were written 
notes from specialists, doctors, interns, nurses and other HCPs. Many limitations of this 
current manual system of record-keeping were identified while viewing the retrospective 
patient records.  
 
The quality and quantity of the notes written in the patient records were a major limitation and 
greatly impacted this study. When viewing the retrospective patient records, all the required 
information was recorded from the many different types of records in the patient records such 
as the doctors’ notes, discharge sheets, prescription charts, administration charts and 
laboratory test printouts. However, when analysing and comparing the data, the type of 
record that seemed the most valid was used as the standard record for that set of 
information. For example, the discharge sheet was used to obtain the diagnosis of each 
patient. 
 
When obtaining information regarding medications prescribed and administered to a patient, 
the doctors’ prescription charts and the nurses’ administration charts were used. However, a 
limitation of both these types of charts was that they were not always completely filled in and 
therefore a lot of data was missing. On the doctors’ prescription charts, some prescriptions 
were not complete as to strength of medication and route of administration, or other 
information was missing. Another challenge was that in many instances there was no date 
and signature in the column which indicates when the medication was discontinued. Other 
problems were that in some records there was more than one prescription chart running at 
the same time and the same or similar antibiotics had been prescribed. Overall, the nurses’ 
administration charts were more thoroughly completed than the doctors’ prescription charts. 
However, the spaces on the nurses’ prescription charts were small and thus difficult at times 
to read clearly. For both types of charts, it was difficult to read some of the handwriting and 
thus assumptions had to be made. When looking at the doctors’ prescription charts in 
conjunction with the nurses’ administration charts, at times there were antibiotics written on 
the doctor's prescription chart but not present on the nurse's administration chart. This could 
be due to many reasons such as doctors prescribing an out of stock antibiotic. For each 
patient, information regarding antibiotics was recorded from both the doctors’ prescription 
charts and the nurses’ administration charts. Information regarding antibiotics prescribed and 
administered was also recorded from the doctors’ notes, but in certain cases the information 
in the doctors' notes did not match up with the prescription and administration chart 
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information. Therefore, in the event of any discrepancy the information on nurses’ 
prescription charts was used, as it was chosen as the more reliable sore of information.   
 
There was also inconsistency in the information written in patient records. For example, in 
the doctor's notes the age of a patient would vary. Therefore, to standardise the patient 
information, the patient's discharge sheet was used to obtain the diagnosis, operations 
performed, admission date and discharge date. The age and gender of a patient was 
obtained from data received from the NHLS Information System.  
 
Within the patient records, the NHLS printouts of laboratory tests performed were not always 
present. In some records the results of the NHLS laboratory tests were written down in the 
doctors’ notes or at the bottom of the flow chart and they contained the written values of 
other tests conducted (Hb, Na, K, Cl, etc.). In some of the records for the vascular ward 
patients, A4 printed Tables could be found with headings for date, laboratory test number, 
Specimen, Identification and Sensitivity, on which the different laboratory test details were 
written down; or there were printed pages headed Lab Tests from MY PATIENT RESULTS, 
on which were noted details of the laboratory tests. The limitation that was identified when 
the laboratory test details and results were hand-written was that not all the information was 
written down and it was unclear whether the results were provisional or final and whether the 
date indicated the date that the specimen was taken or the date of the final report. The 
printed out pages from Lab Tests from MY PATIENT RESULTS had all the required 
information but they were present only in a few of the records. When viewing the records, 
laboratory test information was recorded from all of these sources present in a patient 's 
record. However, due to the various methods by which the laboratory tests were recorded in 
the records and that no consistent method was used to record them in all the records, the 
data received from the NHLS Information System regarding the laboratory tests conducted 
which isolated MRSA was the only data that was used for the laboratory tests for the study.  
 
When viewing the retrospective patient records, it seemed as if pages were missing. For 
example, when looking at the doctors' notes, there would be a blank period of dates for which 
there were no notes. This could be due to the actual page containing the doctors’ notes for 
that period going missing in the ward, or the page being lost when the records were scanned 
onto microfilm in the Records Room. 
 
5.8.1.2 Medical Records Room 
The Medical Records Room at CMJAH uses a tedious manual system with numerous 
limitations for storing, accessing and viewing patient records. When the scanning of patient 
records onto microfilm takes place, the pages are at times not scanned correctly and when 
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viewing the records, pages overlapped, were upside-down or blurred, thus making them 
difficult to read. Time had to be spent adjusting the viewer and trying to decipher the notes. 
Pages were often missing and had not always been scanned in the correct order. Only two 
working microfiche viewers were available and at times there was a delay if staff needed to 
view a record, or if another researcher was present, turns had to be taken. 
 
The manual system in the Medical Records room is slowly being replaced by an electronic 
computerised system. However, as there are a limited number of computers, access was 
allowed for only a few hours in the morning before the staff arrived at work. For both the 
manual and electronic system, taking pictures, printing or any other means of saving or 
copying the data was not permitted and thus all required information had to be handwritten 
on the case report forms. 
 
Once the required information had been retrieved from the patient records in the study 
population, the data was typed up and missing information was identified. Missing 
information was a limitation in this study and was dealt with in various ways. Doctors were 
consulted to explain certain concepts and trends that were noticed and where possible and 
acceptable, assumptions were made to try and reduce the amount of missing information.  
 
5.8.1.3 Main Dispensary  
The main dispensary at CMJAH also works on a manual system and there is currently no 
electronic system for dispensing data. This was a limitation as if this data were available it 
would have greatly assisted in analysing the dispensing of antibiotics to patients with MRSA. 
However, as this data was not available, the retrospective patient records had to be used. An 
electronic dispensing system would also greatly benefit the overall communication and 
dispensing process between the wards and the dispensary.  
 
5.8.2 Protocols 
Within the dispensary there were no written protocols that were strictly adhered to for the 
dispensing of antibiotics to inpatients. The protocols may have been formulated, but the 
pharmacists may not be aware of them and are thus not being followed. This is a limitation 
as there is no standardisation of the dispensing of antibiotics to inpatients and thus it was 
difficult to formulate clear management pathways as it was stated and observed in the 
retrospective patient notes that most dispensing is done on a per case basis. Within the 
wards that were observed in the study there were also no written protocols being followed 
with regard to antibiotic prescribing as it was stated that this was based on clinicians’ 
preferences and other factors. This poses a limitation as there was no standard against 
which to compare the current clinical practice. 
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5.8.3 Antibiotic Stewardship  
Currently there is also no active antibiotic stewardship programme implemented between the 
main dispensary and the wards included in the study at CMJAH. The absence of an antibiotic 
stewardship programme in this setting was a limitation, as in the records it could be seen that 
there was no effective communication between the doctors in the wards and pharmacist in 
the dispensary. This lack of communication could cause delayed antibiotic treatment, which 
should be avoided in order to ensure the optimal treatment of patients. If an antibiotic 
stewardship programme were to be initiated in this setting, it would have numerous benefits 
and would have a different effect on the implementation of the Xpert MRSA tests.  
 
As CMJAH is an academic hospital, there are various levels of HCPs that consult with the 
patients. The medical interns are sometimes unsupervised and at times they have to wait for 
a senior doctor to authorise certain procedures and prescriptions. The interns also rotate to 
different wards, making it difficult to follow up on a patient’s progress. 
 
5.8.4 Resources  
CMJAH as a public sector hospital often has to deal with basic and limited resources as well 
as medications being out of stock. This has a negative impact on patient care and was a 
limitation to this study as patient management pathways were affected when antibiotics were 
out of stock.  
 
5.8.5 Number of MRSA cases at CMJAH in 2013  
This study requested and received data regarding all the MRSA cases identified at CMJAH 
from 01 January 2013 to 31 December 2013. However, the limited number of patients 
identified with MRSA in the orthopaedic and vascular ward could be seen as a limitation as 
these numbers were used to populate the decision-tree-analytic models and thus could have 
impacted on the outcomes of the models. 
 
Although international studies have been conducted on a larger scale and have larger 
sample sizes, the unique outcomes obtained from the models in this study are not 
necessarily due to the small sample size, but rather due to the manner in which this hospital 
is managed as compared to other hospitals. If a larger number of MRSA cases were 
identified at CMJAH and met the inclusion criteria of this study, the outcomes obtained from 
these models would have had more certainty.  
 
Therefore, to address this limitation and the impact that it could have had on the outcomes of 
the models, equal decision-tree-analytic models were developed and analysed to evaluate 
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the outcome of using various theoretical probabilities for the number of patients identified 
with MRSA. 
 
5.9 Assumptions  
Certain assumptions were made during this study and they are discussed below.    
 
The two main costs associated with performing the Xpert MRSA test are the Xpert MRSA kit 
and the Gene Xpert System. Currently the NHLS Microbiology at CMJAH has the Gene 
Xpert System, as it is being used to perform other assays. Therefore, when calculating the 
cost of implementing the Xpert MRSA tests at CMJAH it was assumed that there is currently 
available capacity to perform the Xpert MRSA tests in the Gene Xpert Systems already 
present at the NHLS Microbiology Laboratory. Hence, no additional capital cost for 
purchasing the Gene Xpert System was included and only the cost of the Xpert MRSA kits 
was included. When calculating the costs of implementing the Xpert MRSA tests it was also 
assumed that each patient would have only one Xpert MRSA test.   
 
When analysing the antibiotics that were administered to the patients in the study population, 
assumptions were made in order to limit the amount of missing data and to perform the cost 
calculations. For IV administrations it was assumed that there was no vial-sharing and that a 
minimum of one of the smallest quantity of vials available was used if the dose administered 
was less than one vial. In cases where the same antibiotic was written several times, but with 
some of them written incompletely or lacking information, the cases that had missing 
information were ignored as it was assumed that it had been  incorrectly, or not completely, 
although ultimately the patient had received the antibiotic at least once. When an antibiotic 
was written down only once for a patient but there was insufficient information given, doses 
were not assumed as standard doses, thus patterns could not be derived from what had 
been administered. Information that was completely missing was dealt with by interpolation 
using the information that was available.       
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6. CONCLUSION  
 
The current management pathways for a patient with a suspected MRSA infection in the 
orthopaedic and vascular wards at CMJAH were formulated and costed by qualitative and 
quantitative research methods. Using the decision-tree-analytic models constructed, the 
costs of these management pathways were then compared to theoretical management 
pathways of implementing the Xpert MRSA tests in the current clinical setting.  
 
From the qualitative observations conducted in the two wards, the NHLS Microbiology 
Laboratory and antibiotic designated area of the main dispensary at CMJAH, it was found 
that the communication between these three areas of the hospital needs to be improved to 
enhance the management of patients with a suspected or confirmed MRSA infection.  
 
The findings from the qualitative observations were strengthened by the quantitative aspects 
of the study that followed. The retrospective utilization and records review highlighted the 
inconsistent utilization of antibiotics and the multiple NHLS laboratory tests conducted that 
isolated MRSA in the study population. The cost analysis emphasised that although 
unnecessary and repeated NHLS laboratory tests for MRSA were conducted and contributed 
to the costs, it was actually the cost of the numerous antibiotics administered that accounted 
for the majority of the costs of the patients in the study population.   
 
Based on the qualitative and quantitative findings, a single management pathway for a 
patient with a suspected MRSA infection could not be deduced and thus the various 
pathways that occurred were depicted in the decision-tree-analytic models per ward. The 
ideal pathway for a patient with a suspected MRSA infection in the current clinical setting in 
the orthopaedic and vascular wards is when a Specimen is Sent For MCS and Empiric 
Antibiotics are administered concurrently. It was found that if the Xpert MRSA tests were 
implemented in the orthopaedic ward, the optimal strategy for a patient with a suspected 
infection would be to first take a Specimen For Xpert MRSA testing. However, if the Xpert 
MRSA tests were implemented in the vascular ward, the most expensive strategy for a 
patient with a suspected infection would be to first take a Specimen For Xpert MRSA testing. 
 
Therefore, before new MRSA testing methods are introduced in the hospital, it is suggested 
that the current practices and pathways for MRSA should be further evaluated and improved.
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7. RECOMMENDATIONS AND FUTURE RESEARCH  
 
This study aimed to investigate the cost of the management pathways associated with using 
the current Conventional Culture Method versus the cost of management pathways that 
would follow if the new PCR testing for MRSA were to be implemented, in order to give a 
recommendation as to whether or not the of Xpert MRSA tests should be implemented at 
CMJAH. However, by conducting this study, various additional recommendations were 
identified.  
 
As the two wards that were involved in the study still use a manual paper-based system for 
recording patient notes and prescriptions, it is recommended that an electronic recording 
system be introduced, as it would provide numerous benefits to both HCPs and patients. The 
antibiotics designated area of the main dispensary of CMJAH also uses a manual paper-
based dispensing system, thus, if the current system were to be replaced by an electronic 
computer-based dispensing system, there would be improved control of antibiotic utilization. 
Electronic systems would also improve the communication between the HCPs in the wards, 
the dispensary and the microbiology laboratory, which would lead to a reduction in the 
number of MCS tests conducted, a decrease in the waiting period for the MCS results, 
prompt administration of antibiotics and enhanced patient management.  
  
Standard protocols and guidelines regarding managing patients with a suspected and 
confirmed infection and antibiotic prescribing and dispensing should be formulated and 
followed in the wards and dispensary. It is recommended that a strong Antibiotic Stewardship 
programme be developed and implemented at CMJAH which should include a 
multidisciplinary collaboration between the dispensary, the wards and the microbiology 
laboratory as well as follow the standards that are being set by the National Department of 
Health.  
 
To assist in the optimal use of scarce resources, it is recommended that HCPs should 
become cost conscious and be made aware of the financial implications of their daily 
practices when managing patients.  
 
It is recommended that the current system used in the Hospital’s Medical Record Room 
should be reviewed and updated to enable safe storage and easy access to retrospective 
patient records. If the various areas of the hospital were to start using electronic means of 
recording patient data it would be simple to update the current system in records room; if not, 
the patient data should be entered onto a computerised searchable database as it would aid 
gathering information for surveillance, utilization trends and future research.  
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As this study focused only on the direct antibiotic and laboratory test utilization costs of 
implementing the Xpert MRSA tests at CMJAH, it is recommended that once the current 
practices and management pathways for a patient with a suspected or confirmed MRSA 
infection are improved, future research should be conducted using TreeAge decision-tree-
analytic models to assess the cost-effectiveness and patient outcomes associated with 
implementing the Xpert MRSA tests at CMJAH.  
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8. APPENDICES  
 
APPENDIX 1 
8.1 Human Research Ethics Committee: Clearance Certificate  
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APPENDIX 2 
8.2 Letter of Research Permission 
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APPENDIX 3 
8.3 Data Collection Sheets  
8.3.1 Clinical Ward Observation Data Collection Sheet  
Clinical Ward Observations                       Ward :                                           Date:                                                                                                                           
 
Ward Rounds 
 
 
 
HCP-Patient interaction  
 
 
 
Antibiotics  
 
 
 
Infection Control 
 
 
 
Isolation 
 
 
 
Taking Specimens  
 
 
 
Suspected Infection 
 
 
 
Confirmed Infection 
 
 
 
Pre/Post-Operative Care 
 
 
 
Patient Notes 
 
 
 
Other  
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8.3.2 Microbiology Laboratory Observation Data Collection Sheet 
NHLS Microbiology Laboratory            Date: 
CONVENTIONAL CULTURE METHOD 
 Planting Microscopy Culture Picking Sensitivity 
Equipment Required 
     
Procedure 
 
 
 
 
 
 
 
 
    
Hands-On Time      
Incubation Time      
Recording of 
Results 
     
Other 
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8.3.3 Antibiotic Dispensary Observation Data Collection Sheet 
Antibiotics at the Main Dispensary                                                  Date: 
 
General policy for dispensing 
antibiotics  
 
 
 
 
 
Policy for antibiotics kept as 
ward stock   
 
 
 
Policy for  antibiotics dispensed 
on a per-patient basis 
 
 
 
 
Antibiotics which require 
Motivation 
 
Vancomycin: 
 
Linezolid: 
 
Carbapenems: 
 
 
 
Antibiotics which require 
Authorisation 
 
Vancomycin: 
 
Linezolid: 
 
Carbapenems: 
 
 
 
Antibiotics which require 
Laboratory Results 
 
Vancomycin: 
 
Linezolid: 
 
Carbapenems: 
 
 
Current Antibiotic Stewardship 
 
 
Other  
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APPENDIX 4 
8.4 Individual Patient Case Report Form 
PATIENT DETAILS 
ALLOCATED 
PATIENT # 
GENDER AGE 
ADMISSION 
DATE 
DISCHARGE 
DATE 
DIAGNOSIS / ICD10 CODE OPERATION TEMP 
        
 
ANTIBIOTICS 
DATE DRUG DOSAGE FORM STRENGTH DOSE FREQUENCY DURATION INSTRUCTIONS 
        
        
        
        
        
 
LABORATORY RECORDS FOR INFECTION 
Lab 
# 
Date 
Taken 
Date of 
Report 
Specimen Test G+C 
Culture Results 
Remark Entered 
Antibiotic 
[S] 
E-
Strip 
Remark Entered 
Aerobic Anaerobic 
              
              
              
              
              
 
DOCTOR'S NOTES ADDITIONAL INFORMATION 
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APPENDIX 5 
8.5 Costing Information  
8.5.1 Antibiotic Costing Information  
Table 29: Summary of the Database Medsas-contract-prices-INN-ATC 2013 Reflecting 
the Antibiotics used in the Orthopaedic Ward 
Item description (Medsas) 
Average 
weighted price 
(contract) 
Depot price 
(without 
mark-up) 
AMOXYCILLIN AND CLAVULANIC ACID TABLETS 500MG AND 
125MG;15'S 
R 17.33 R 20.90 
AMOXYCILLIN AND CLAVULANIC ACID TABLETS 875MG AND 
125MG;10'S 
R 13.54 R 14.93 
AMOXYCILLIN SODIUM AND POTASSIUM CLAVULANATE 
FOR INJECTION; 1000MG AND 200MG/VIAL 
R 12.52 R 13.50 
AMOXYCILLIN SODIUM AND POTASSIUM CLAVULANATE 
FOR INJECTION; 500MG AND 100MG/VIAL 
R 7.16 R 7.16 
GENTAMICIN INJECTION: 20MG PER 2ML; 2ML R 3.99 R 3.99 
RIFAMPICIN CAPSULES 600MG;100'S R 84.81 R 97.47 
VANCOMYCIN POWDER FOR INJECTION USP; 1000MG/VIAL R 46.97 R 52.17 
CLOXACILLIN SODIUM FOR INJECTION: 500MG/VIAL R 5.24 R 6.58 
CLOXACILLIN SODIUM CAPSULES 500MG; 100'S   R 190.98 
CEFOXITIN SODIUM FOR INJECTION: 1GM R 20.52 R 21.46 
CEFAZOLIN SODIUM INJECTION: 1G/VIAL R 4.00 R 4.65 
LINEZOLID TABLETS 600MG;10'S R 2,822.45 R 2,822.45 
ERTAPENEM SODIUM POWDER FOR INJECTION 1G;20ML R 368.33 R 368.33 
METRONIDAZOLE TABLETS PATIENT READY PACK; 
400MG;21'S 
R 2.85 R 2.85 
CIPROFLOXACIN TABLETS 500MG; 10'S R 4.59 R 4.86 
CEFTAZIDIME FOR INJECTION: 2G PER VIAL R 60.00 R 60.00 
CEFTAZIDIME FOR INJECTION: 1G PER VIAL R 32.74 R 32.74 
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Table 30: Summary of the Database Medsas-contract-prices-INN-ATC 2013 Reflecting 
the Antibiotics used in the Vascular Ward  
Item description (Medsas) 
Average 
weighted price 
(contract) 
Depot price 
(without 
mark-up) 
VANCOMYCIN POWDER FOR INJECTION USP; 1000MG/VIAL R 46.97 R 52.17 
AMOXYCILLIN SODIUM AND POTASSIUM CLAVULANATE 
FOR INJECTION; 1000MG AND 200MG/VIAL 
R 12.52 R 13.50 
CEFAZOLIN SODIUM INJECTION: 1G/VIAL R 4.00 R 4.65 
CLARITHROMYCIN TABLETS 500MG; 14'S R 26.87 R 30.80 
RIFAMPICIN INJECTION INTRAVENOUS; 300MG/VIAL   R 157.21 
PIPERACILLIN 4G AND TAZOBACTAM 500MG INJECTION; 
POWDER FOR RECONSTITUTION IN 50ML VIAL 
R 60.00 R 60.00 
CEFEPIME INJECTION; 1G/VIAL R 20.46 R 20.46 
CEFEPIME INJECTION; 2G/VIAL R 38.91 R 42.91 
MEROPENEM TRIHYDRATE ANHYDROUS INJECTION; 
500MG/VIAL 
R 63.86 R 63.86 
MEROPENEM TRIHYDRATE ANHYDROUS INJECTION; 
1G/VIAL 
R 125.95 R 125.95 
ERTAPENEM SODIUM POWDER FOR INJECTION 1G;20ML R 368.33 R 368.33 
AMOXYCILLIN AND CLAVULANIC ACID TABLETS 500MG AND 
125MG;15'S 
R 17.33 R 20.90 
AMOXYCILLIN AND CLAVULANIC ACID TABLETS 875MG AND 
125MG;10'S 
R 13.54 R 14.93 
GENTAMICIN INJECTION: 20MG PER 2ML; 2ML R 3.99 R 3.99 
CLOXACILLIN SODIUM FOR INJECTION: 500MG/VIAL R 5.24 R 6.58 
METRONIDAZOLE INTRAVENOUS INFUSION 500MG/ML; 
100ML 
R 5.37 R 5.36 
IMIPENEM AND CILASTATIN SODIUM FOR INJECTION 
:500MG AND 500MG;VIAL; 1'S 
R 47.05 R 56.75 
CEFTAZIDIME FOR INJECTION: 1G PER VIAL R 32.74 R 32.74 
AMIKACIN SULPHATE INJECTION: 250MG PER 2ML; 2ML R 6.87 R 6.87 
CEFUROXIME SODIUM FOR INJECTION: 750MG PER VIAL R 7.84 R 8.86 
CO-TRIMOXAZOLE TABLETS :TRIMETHOPRIM 80MG; 
SULPHAMETHOXAZOLE 400MG; 100'S 
R 12.68 R 12.68 
CLOXACILLIN SODIUM CAPSULES 500MG; 100'S   R 190.98 
AMOXYCILLIN TRIHYDRATE CAPSULES 500MG; 100'S R 20.41 R 27.00 
CLINDAMYCIN PHOSPHATE INJECTION: 600MG PER 4ML  R 10.49 R 10.93 
METRONIDAZOLE TABLETS 400MG; 100'S R 10.13 R 12.54 
CIPROFLOXACIN TABLETS 500MG; 10'S R 4.59 R 4.86 
CIPROFLOXACIN INJECTION 2MG/ML; 100ML R 31.09 R 31.09 
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8.5.2 NHLS Laboratory Test Costing Information  
Table 31: NHLS List of Prices of the Different Steps Used for the Laboratory Tests 
Conducted that Isolated MRSA in the Study Population in the Orthopaedic Ward 
TEST 
CODE 
TARIFF 
CODE 
TARIFF_DESC 
PRICE 
(R) 
CULTI 0120 ANAEROBE CONFIRMATORY SCREEN 34.01 
CULFL 0120 ANAEROBE CONFIRMATORY SCREEN 34.01 
  
 
  
 
CULTI 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULFL 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULPU 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULPU 0326 BIOCHEM ID BACTERIUM ABRIDGED 24.78 
  
 
  
 
CULFL 0327 BIOCHEM ID BACTERIUM EXTENDED 94.19 
  
 
  
 
CULTI 0240 CULTURE AEROBIC 47.44 
CULFL 0240 CULTURE AEROBIC 47.44 
CULPU 0240 CULTURE AEROBIC 47.44 
CULPU 0240 CULTURE AEROBIC 49.34 
  
 
  
 
CULTI 0245 CULTURE ANAEROBIC 34.01 
CULFL 0245 CULTURE ANAEROBIC 34.01 
  
 
  
 
CULTI 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULFL 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULPU 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULPU 0025 DISC SENSITIVITY (PER ORG) 62.58 
  
 
  
 
CULTI 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULFL 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULPU 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULPU 0080 MIC MBC KILL (MIC OR TUBE) 95.43 
  
 
  
 
CULTI 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULFL 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULPU 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULPU 0331 MICROSCOPY ONLY STAINED PREP 38.41 
  
 
  
 
CULTI 0162 RAPID AUTOMATED ANTIBIOTIC SUSCEPTIBILIT 127.99 
CULFL 0162 RAPID AUTOMATED ANTIBIOTIC SUSCEPTIBILIT 127.99 
  
 
  
 
CULFL 0161 RAPID AUTOMATED BACTERIAL IDENTIFICATION 112.83 
CULTI 0161 RAPID AUTOMATED BACTERIAL IDENTIFICATION 112.83 
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Table 32: NHLS List of Prices of the Different Steps Used for the Laboratory Tests 
Conducted that Isolated MRSA in the Study Population in the Vascular Ward 
TEST 
CODE 
TARIFF 
CODE 
TARIFF_DESC 
PRICE 
(R) 
CULFL 0120 ANAEROBE CONFIRMATORY SCREEN 35.37 
CULPU 0120 ANAEROBE CONFIRMATORY SCREEN 34.01 
CULTI 0120 ANAEROBE CONFIRMATORY SCREEN 34.01 
CULTI 0120 ANAEROBE CONFIRMATORY SCREEN 35.37 
        
CULBA 0160 AUTOMATED BLD CULT AEROBIC GROWTH 108.79 
CULBA 0170 AUTOMATED BLOOD CULT ANAEROBIC GROWTH 104.61 
        
CULBA 0326 BIOCHEM ID BACTERIUM ABRIDGED 24.78 
CULBA 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULFL 0326 BIOCHEM ID BACTERIUM ABRIDGED 24.78 
CULPU 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULPU 0326 BIOCHEM ID BACTERIUM ABRIDGED 24.78 
CULSP 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULST 0326 BIOCHEM ID BACTERIUM ABRIDGED 24.78 
CULST 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULTI 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULTI 0326 BIOCHEM ID BACTERIUM ABRIDGED 24.78 
CULUR 0326 BIOCHEM ID BACTERIUM ABRIDGED 23.83 
CULPU 0327 BIOCHEM ID BACTERIUM EXTENDED 94.19 
CULPU 0327 BIOCHEM ID BACTERIUM EXTENDED 97.96 
CULSP 0327 BIOCHEM ID BACTERIUM EXTENDED 94.19 
CULTI 0327 BIOCHEM ID BACTERIUM EXTENDED 94.19 
CULUR 0327 BIOCHEM ID BACTERIUM EXTENDED 94.19 
        
CULCT 0240 CULTURE AEROBIC 49.34 
CULFL 0240 CULTURE AEROBIC 49.34 
CULPU 0240 CULTURE AEROBIC 47.44 
CULPU 0240 CULTURE AEROBIC 49.34 
CULSP 0240 CULTURE AEROBIC 47.44 
CULTI 0240 CULTURE AEROBIC 47.44 
CULTI 0240 CULTURE AEROBIC 49.34 
        
CULFL 0245 CULTURE ANAEROBIC 35.37 
CULPU 0245 CULTURE ANAEROBIC 34.01 
CULPU 0245 CULTURE ANAEROBIC 35.37 
CULTI 0245 CULTURE ANAEROBIC 34.01 
CULTI 0245 CULTURE ANAEROBIC 35.37 
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CULST 0275 CULTURE FOR STAPH AUREUS 17.7 
CULST 0275 CULTURE FOR STAPH AUREUS 17.02 
        
CULBA 0025 DISC SENSITIVITY (PER ORG) 62.58 
CULBA 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULFL 0025 DISC SENSITIVITY (PER ORG) 62.58 
CULPU 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULPU 0025 DISC SENSITIVITY (PER ORG) 62.58 
CULSP 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULTI 0025 DISC SENSITIVITY (PER ORG) 60.17 
CULTI 0025 DISC SENSITIVITY (PER ORG) 62.58 
CULUR 0025 DISC SENSITIVITY (PER ORG) 60.17 
        
CULBA 0080 MIC MBC KILL (MIC OR TUBE) 95.43 
CULBA 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULFL 0080 MIC MBC KILL (MIC OR TUBE) 95.43 
CULPU 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULPU 0080 MIC MBC KILL (MIC OR TUBE) 95.43 
CULSP 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULTI 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
CULTI 0080 MIC MBC KILL (MIC OR TUBE) 95.43 
CULUR 0080 MIC MBC KILL (MIC OR TUBE) 91.76 
        
CULBA 0331 MICROSCOPY ONLY STAINED PREP 38.41 
CULBA 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULFL 0331 MICROSCOPY ONLY STAINED PREP 38.41 
CULPU 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULPU 0331 MICROSCOPY ONLY STAINED PREP 38.41 
CULSP 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULTI 0331 MICROSCOPY ONLY STAINED PREP 36.93 
CULTI 0331 MICROSCOPY ONLY STAINED PREP 38.41 
        
CULCT 0162 RAPID AUTOMATED ANTIBIOTIC SUSCEPTIBILIT 133.11 
CULPU 0162 RAPID AUTOMATED ANTIBIOTIC SUSCEPTIBILIT 127.99 
CULTI 0162 RAPID AUTOMATED ANTIBIOTIC SUSCEPTIBILIT 127.99 
        
CULCT 0161 RAPID AUTOMATED BACTERIAL IDENTIFICATION 117.34 
CULPU 0161 RAPID AUTOMATED BACTERIAL IDENTIFICATION 112.83 
CULTI 0161 RAPID AUTOMATED BACTERIAL IDENTIFICATION 112.83 
        
CULUR 0425 URINE BACTERIAL INHIBITION 28.58 
CULUR 0415 URINE CULTURE IDENTIFICATION 47.44 
CULUR 0405 URINE MICROSCOPY 36.93 
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8.5.3 Xpert MRSA Costing Information  
Table 33: Price of Cepheid Xpert MRSA Kits from the Quote Requested and Received 
(QT1005SP) 
Description 
Unit Price 
(R) 
VAT 14 % 
Total Price 
(R) 
Price per 
Test (R) 
Xpert MRSA/SA, SSTI 
Xpert MRSA/SA,BC 
Xpert SA Nasal Complete 10 Test Kits 
2697.50 
2697.50 
2697.50 
377.65 
377.65 
377.65 
3075.15 
3075.15 
3075.15 
307.52 
307.52 
307.52 
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APPENDIX 6 
8.6 Codes and Categories Identified from the Ethnographic Observations  
8.6.1 Codes and Categories Identified from the Ethnographic Observations in the Clinical Wards 
Table 34: Detailed Codes and Categories Identified from the Ethnographic Observations in the Clinical Wards  
            Categories  
Codes 
Communication Routine 
Patient 
Records 
Infection 
Control 
Antibiotics Inconsistent 
Specimen 
For MCS 
Delay Infection 
HCP-HCP X         
HCP-Patient X   X      
HCPs X     X    
Ward Rounds X X X X      
Nurses X X  X      
Doctors' notes   X   X    
Prescriptions   X     X  
X-rays   X       
NHLS reports   X  X  X X X 
Antiseptic hand rub    X  X    
Hand-washing    X  X    
PPE    X  X    
Protocols      X    
Empiric     X   X X 
Changed     X   X  
Authorisation     X   X  
Redone       X   
Wound Irrigation        X   
Pre/Post-op     X  X  X 
Isolation    X    X X 
Confirmed       X  X 
Suspected       X  X 
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8.6.2 Codes and Categories Identified from the Ethnographic Observations in the NHLS Microbiology Laboratory    
Table 35: Detailed Codes and Categories Identified from the Ethnographic Observations in the NHLS Microbiology Laboratory   
                      Categories 
Codes  
Suspected  
MRSA Infection 
Conventional 
Culture Method 
Hands-on 
Time 
Incubation 
Time 
Results 
Disposable 
Resources 
Fixed 
Resources 
Specimen X       
Gram-positive cocci in clusters X       
Catalase positive X       
Staphylococcus X       
Staphaurex-positive X       
Staphylococcus aureus X       
FOX Zone X       
Vanco Etest X       
Planting  X      
Microscopy  X      
Culture  X      
Picking  X      
Sensitivity  X      
Vanco Etest    X      
Ten minutes   X     
Five minutes   X     
Five to ten minutes   X     
24 Hours    X    
48 Hours    X    
72 Hours     X    
Recorded     X   
Working card     X   
Computer system     X   
Provisional     X   
Checked     X   
Finalised      X   
Agar plates      X  
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Swab      X  
Microscopy slide      X  
Stains      X  
Water      X  
Immersion oil      X  
Catalase test kit      X  
Staphaurex test kit      X  
Saline      X  
Antibiotic discs      X  
Etest strip      X  
Microscope       X 
Hot-plate       X 
Metal rods       X 
Inoculation loops       X 
Test tubes       X 
Bunsen-burner       X 
Incubator       X 
Antibiotic disc dispensers       X 
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8.6.3 Codes and Categories Identified from the Ethnographic Observations in the Antibiotic Dispensary 
Table 36: Detailed Codes and Categories Identified from the Ethnographic Observations in the Antibiotic Dispensary  
                          Categories 
Codes   
Protocols Prescribing Dispensing Nurses Urgent Authorisation 
Antibiotic 
Stewardship 
Problems 
Not written X        
Differ X        
Per-patient X X X   X   
Ward X X X    X  
Doctors  X    X X  
Patient’s prescription chart  X       
Dispensary order form  X  X     
Motivation  X    X   
Runners   X      
Dispensary  X  X    X  
Waiting   X   X  X 
Three/five/seven days   X      
Manage ward stock    X     
Administer    X     
Emergency cupboard    X X    
On-call     X    
Roll-over    X X    
Restricted      X   
Vancomycin      X   
Linezolid      X   
Carbapenems      X   
MCS results      X   
Pharmacist inactive       X  
Advantages       X  
Out of stock       X X 
Expired       X X 
Communication       X X 
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APPENDIX 7  
8.7 Cost Calculations  
8.7.1 Antibiotic Cost Calculations  
Table 37: The Daily Cost and Total Utilization Cost for Each Antibiotic Administered to 
Each Patient in the Orthopaedic Ward in 2013 
Patient 
Number 
Antibiotic and Dose 
Utilization Cost (R) 
Daily Total 
  
    
369P03 Augmentin PO 625 mg TDS for 14 days  3.47 48.52 
  Gentamicin Irrigation system 80 mg x 20 drops 4 hourly for 10 days  95.76 957.60 
  Rifampicin PO 600 mg daily for 4 days  0.85 3.39 
  Vancomycin Irrigation System 1 g X 20 drops 4 hourly for 5 days  281.81 1409.04 
        
369P09 Cloxacillin Irrigation System 1 g X 20 drops 4 hourly for 2 doses 20.98 20.98 
  Gentamicin Irrigation System 80 mg x 20 drops 4 hourly for 10 days 95.76 957.60 
        
369P12 Vancomycin 9 g stat for 9 days 422.71 3804.41 
  Cefotaxime 9 g stat for 9 days  184.68 1662.12 
  Cloxacillin IVI 1 g QID for 10 days  41.95 419.52 
  Kefzol IVI 2 g in op 8.00 8.00 
  Gentamicin Irrigation System  80 mg X 20 drops 4 hourly for 3 days  95.76 287.28 
  Vancomycin Irrigation System 1 g X 20 drops 4 hourly for 8 days 281.81 2254.46 
  Rifampicin PO 600 mg BD for 6 days 1.70 10.18 
  Linezolid PO 600 mg BD for 6 days 564.49 3386.94 
  Vancomycin IVI 1 g BD for 1 day  93.94 93.94 
        
369P15 Kefzol IVI 1 g TDS for 12 days  12.00 144.05 
  Kefzol 1 g In op  4.00 4.00 
  Kefzol 2 g In op  8.00 8.00 
  Kefzol 2 g In op  8.00 8.00 
  Kefzol 1 g In op  4.00 4.00 
  Kefzol 1 g stat in op 4.00 4.00 
  Cloxacillin PO 1 g QID for 15 days  15.28 229.18 
  Vancomycin IVI 1 g BD 9 days  93.94 845.42 
        
369P06 Augmentin PO 625 mg TDS for 29 days  3.47 100.51 
  Gentamicin Irrigation System 80 mg X 20 drops X 4 hourly for 32 days 95.76 3064.32 
  Ertapenem IVI 250 mg QID for 1 day  368.33 368.33 
  Rifampicin PO 600 mg BD for 17 days  1.70 28.84 
  Vancomycin IVI 1 g daily for 6 days  46.97 281.81 
  Kefzol 2 g In op 8.00 8.00 
        
369P08 Gentamicin Irrigation System 80 mg x 20 drops 4 hours for 22 days  95.76 2106.72 
  Kefzol IVI 1 g 3 doses TDS in op for 1 day  12.00 12.00 
  Augmentin PO 1 g BD for 13 days  2.71 35.20 
  Rifampicin PO 600 mg BD for 14 days  1.70 23.75 
  Vancomycin IVI 1 g BD for 14 days  93.94 1315.10 
  Vancomycin Irrigation System 1 g 20 drops 4 hourly  for 3 days 281.81 845.42 
        
369P13 Kefzol IVI 2 g TDS in op 24.01 24.01 
  Cloxacillin IVI 1 g QID for 6 days  41.95 251.71 
  Cloxacillin IVI 1 g TDS for 1 day 31.46 31.46 
        
369P14 Augmentin IVI 1.2 g TDS for 6 days  37.56 225.36 
  Gentamicin Irrigation System 80 mg 20 drops 4 hourly for 11 days  95.76 1053.36 
  Augmentin PO 1 g BD for 1 day  2.71 2.71 
  Augmentin IVI 1.2 g TDS for 4 days  37.56 150.24 
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369P02 Kefzol IVI 1 g in op 4.00 4.00 
  Ertapenem IVI 1 g daily for 6 days  368.33 2209.98 
  Kefzol IVI 1 g 3 doses TDS for 1 day  12.00 12.00 
  Flagyl PO 400 mg TDS for 7 days  0.41 2.85 
        
369P04  Augmentin PO 625 mg TDS for 19 days 3.47 65.85 
  Cloxacillin PO 1 g QID for 18 days 15.28 275.01 
  Vancomycin IVI 1 g BD for 9 days  93.94 845.42 
  Rifampicin PO 600 mg BD for 9 days  1.70 15.27 
        
369P16 Kefzol 1 g TDS in op for 1 day  12.00 12.00 
  Cloxacillin PO 1 g QID for 10 days 15.28 152.78 
  Cloxacillin PO 1 g QID for 20 days  15.28 305.57 
        
369P05 Ciprobay PO 500 mg BD for 32 days  0.92 29.37 
  Kefzol IVI 2 g TDS for 5 days  24.01 120.04 
  Gentamicin Irrigation System 80 mg 20 drops 4 hourly for 9 days 95.76 861.84 
        
369P10 Augmentin IVI 0.6 g TDS for 3 days now start Cloxacillin 21.48 64.44 
  Gentamicin Irrigation System 80 mg 20 drops 4 hourly for 14 days 95.76 1340.64 
  Cloxacillin PO 1 g QID for 11 days  15.28 168.06 
  Vancomycin IVI 1 g BD for 4 days  93.94 375.74 
  Vancomycin Irrigation System 1 g 20 drops 4 hourly for 2 days  281.81 563.62 
        
369P07 Gentamicin Irrigation System 80 mg 20 drops 4 hourly for 13 days  95.76 1244.88 
  Kefzol IVI 1 g 3 doses TDS for 1 day  12.00 12.00 
  Rifampicin PO 600 mg BD for 11 days  1.70 18.66 
  Vancomycin IVI 1 g BD for 9 days  93.94 845.42 
  Vancomycin Irrigation System 1 g 20 drops 4 hourly for 2 days  281.81 563.62 
        
369P01 Gentamicin Irrigation System 80 mg 20 drops 4 hourly for 25 days 95.76 2394.00 
  Vancomycin IVI 1 g BD for 19 days 93.94 1784.78 
  Rifampicin PO 600 mg BD for 18 days 1.70 30.53 
        
369P11 Kefzol IVI 1 g 3 Doses TDS for 1 day  12.00 12.00 
  Gentamicin Irrigation System 80 mg 20 drops 4 hourly for 7 days  95.76 670.32 
  Rifampicin PO 600 mg BD for 19 days  1.70 32.23 
  Vancomycin IVI 1 g BD for 19 days  93.94 1784.78 
  Ceftazidime IVI 2 g BD for 19 days  120.00 2279.93 
  Vancomycin Irrigation System 1 g BD for 6 days 93.94 563.62 
  Ceftazidime Irrigation System 1 g 20 drops for 1 day  32.74 32.74 
  Vancomycin IVI 1 g in op 46.97 46.97 
  Linezolid PO 600 mg BD for 1 day  564.49 564.49 
    
  
Total 
 
6534.78  46804.99 
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Table 38: The Daily Cost and Total Utilization Cost for Each Antibiotic Administered to 
Each Patient in the Vascular Ward in 2013 
Patient 
Number 
Antibiotic and Dose 
Utilization Costs (R) 
Daily Total 
  
    
395P02  Tazocin IVI 4.5 g QID for 2 days 240.00 480.00 
 
Ertapenem IVI 1 g BD for 4 days 736.66 2946.64 
 
Meropenem IVI 1 g TDS for 11 days  377.85 4156.35 
 
Tazocin IVI 4.5 g QID for 14 days  240.00 3360.00 
 
Clindamycin IVI 600 mg TDS for 17 days 31.46 534.89 
 
Vancomycin IVI 1 g Stat  46.97 46.968 
 
Vancomycin IVI 1 g BD for 11 days 93.94 1033.296 
 
Vancomycin IVI 1 g Stat  46.97 46.968 
 
Ciprofloxacin IVI 1 g QID for 4 days 621.80 2487.20 
 
      
395P03 Augmentin IVI 1.2 g TDS for 6 days  37.56 225.36 
 
Flagyl IVI 500 mg TDS for 5 days 16.12 80.58 
 
Vancomycin IVI 500 mg BD for 5 days  46.97 234.84 
 
Ceftazidime IVI 1 g BD for 6 days 65.48 392.88 
 
      
395P04 Meropenem IVI 1 g TDS for 4 days  377.85 1511.40 
 
    
 
395P05 Augmentin IVI 1.2 g TDS for 5 days  37.56 187.80 
 
Meropenem IVI 500 mg TDS for 6 days  191.58 1149.48 
 
Cefepime IVI 1 g TDS for 9 days  61.38 552.42 
 
Meropenem IVI 1g BD for 9 days 251.90 2267.10 
 
      
395P06 Augmentin IVI 1.2 g TDS for 1 day 37.56 37.56 
 
Cloxacillin IVI 1 g QID for 4 days  41.95 167.81 
 
Gentamicin 240 mg Daily for 3 days  47.88 143.64 
 
Augmentin IVI 1.2 g TDS for 1 day  37.56 37.56 
 
Tazocin IVI 4.5 g QID for 12 days  240.00 2880.00 
 
Imipenem IVI 1 g BD for 4 days  188.20 752.80 
 
Gentamicin IVI 240 mg daily for 3 days  47.88 143.64 
 
Imipenem IVI 1 g TDS for 5 days  282.30 1411.50 
 
Amoxil PO 1 g BD for 1 day 0.82 0.82 
 
Klacid PO 1 g BD for 1 day 7.68 7.68 
 
Imipenem IVI 1 g TDS for 1 day 282.30 282.30 
 
Amoxil PO 1 g BD for 13 days  0.82 10.61 
 
Klacid PO 1 g BD for 6 days  7.68 46.06 
 
      
395P07 Flagyl IVI 500 mg TDS for 5 days  16.12 80.58 
 
Cefepime IVI 2 g TDS for 5 days  116.73 583.65 
 
Vancomycin IVI 2 g daily for 3 days  93.94 281.81 
 
Vancomycin IVI 2 g BD for 1 day  187.87 187.87 
 
Vancomycin IVI 500 mg Stat 23.48 23.484 
 
Vancomycin IVI 1 g BD for 3 days  93.94 281.81 
 
      
395P08 Tazocin IVI 4.5 g QID for 5 days  240.00 1200.00 
 
      
395P09 Tazocin IVI 4.5 mg QID for 2 days  240.00 480.00 
 
Meropenem IVI 1 g TDS for 11 days  377.85 4156.35 
 
Ciprobay IVI 400 mg BD for 12 days  124.36 1492.32 
 
Augmentin PO 625 mg TDS for 10 days  3.47 34.66 
 
Vancomycin IVI 1 g daily for 6 days  46.97 281.808 
 
Vancomycin IVI 1 g BD for 8 days  93.94 751.488 
 
Ertapenem IVI 1 g daily for 4 days  368.33 1473.32 
 
      
395P11 Augmentin IVI 1.2 g TDS for 4 days  37.56 150.24 
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Tazocin IVI 4.5 g QID for 6 days  240.00 1440.00 
 
Tazocin IVI 4.5 g QID for 1 day  240.00 240.00 
 
      
395P12 Augmentin PO 1 g BD for 19 days  2.71 51.45 
 
      
395P13 Augmentin IVI 1.2 g TDS for 6 days  37.56 225.36 
 
Ciprobay PO 500 mg BD for 9 days 0.92 8.26 
 
      
395P14 Cefepime IVI 1 g BD for 2 days  40.92 81.84 
 
Meropenem IVI 500 mg TDS for 6 days  191.58 1149.48 
 
      
395P16 Tazocin IVI 2.25 g QID for 2 days  120.00 240.00 
 
Tazocin IVI 2.25 g QID for 10 days  120.00 1200.00 
 
Ertapenem IVI 1 g BD (1 dose) 368.33 368.33 
 
Flagyl PO 400 mg TDS for 4 days  0.30 1.22 
 
      
395P17 Augmentin IVI 1.2 g TDS for 6 days  37.56 225.36 
 
      
395P18 Cloxacillin IVI 1 g QID for 13 days  41.95 545.38 
 
Augmentin PO 625 mg TDS for 12 days  3.47 41.59 
 
Augmentin IVI 1.2 g TDS for 6 days  37.56 225.36 
 
Vancomycin IVI 1 g BD for 9 days 93.94 845.42 
 
      
395P19 Cloxacillin PO 2g QID for 3 days  30.56 91.67 
 
Vancomycin 500 mg TDS (1 dose) 23.48 23.48 
 
Ceftazidime IVI 1 g BD 9 days  65.48 589.32 
  
    
395P20 Kefzol IVI 2 g Stat  8.00 8.00 
 
      
395P21 Augmentin IVI 1.2 g TDS for 8 days  37.56 300.48 
 
Tazocin IVI 4.5 g QID for 13 days  240.00 3120.00 
 
Meropenem IVI 1 g stat 125.95 125.95 
 
Tazocin IVI 4.5 g QID for 1 day  240.00 240.00 
 
Flagyl IVI 500 mg TDS for 11 days  16.12 177.28 
 
Vancomycin IVI 1 g BD for 2 days  93.94 187.87 
 
Tazocin IVI 4.5 g QID for 7 days  240.00 1680.00 
 
Flagyl PO 400 mg TDS for 2 days  0.30 0.61 
 
Meropenem IVI 1 g TDS for 1 day  377.85 377.85 
 
Tazocin IVI 4.5 g Stat 60.00 60.00 
 
      
395P22 Tazocin IVI 4.5 g QID for 3 days  240.00 720.00 
 
Gentamicin IVI 240 mg daily for 7 days  47.88 335.16 
 
      
395P23 Tazocin IVI 4.5 g QID for 13 days  240.00 3120.00 
 
Tazocin IVI 4.5 g QID for 1 day  240.00 240.00 
 
Cefepime IVI 1  BD for 4 days  40.92 163.68 
 
Amikacin 750 mg Stat 20.61 20.61 
 
      
395P24 Augmentin IVI 1.2 g TDS for 8 days  37.56 300.48 
 
Vancomycin IVI 1 g BD for 1 day  93.94 93.936 
 
      
395P25 Augmentin IVI 1.2 g TDS for 1 day  37.56 37.56 
 
Tazocin IVI 4.5 g QID for 7 days 240.00 1680.00 
 
Ciprofloxacin IVI 400 mg TDS for 4 days 186.54 746.16 
 
Rifampicin IVI 600 mg daily for 3 days  314.42 943.26 
 
Vancomycin IVI 1 g daily for 2 days  46.97 93.94 
 
Ertapenem IVI 1 g BD for 1 day (1 dose) 368.33 368.33 
 
Vancomycin IVI 1 g BD for 1 day (1 dose) 46.97 46.968 
 
      
395P28 Augmentin IVI 1.2 g TDS for 5 days  37.56 187.80 
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Vancomycin IVI 1 g BD for 2 days  93.94 187.87 
 
      
395P29 Flagyl IVI 500 mg TDS for 5 days  16.12 80.58 
 
Zinacef IVI 1.5 g TDS for 3 days  47.06 141.18 
 
Cefepime IVI 1 g BD for 7 days  40.92 286.44 
 
      
395P30 Tazocin IVI 4.5 g QID 6 days 240.00 1440.00 
 
Tazocin IVI 4.5 g TDS for 11 days  180.00 1980.00 
 
Bactrim Oral 480 mg BD for 1 day  0.25 0.25 
 
Bactrim Oral 960 mg BD for 7 days 0.51 3.55 
 
Meropenem IVI 500 mg TDS for 5 days  191.58 957.90 
 
      
395P31 Augmentin Oral 1 g TDS for 4 days  4.06 16.25 
 
      
395P32 Augmentin IVI 1.2 g QID for 20 days  50.08 1001.60 
 
      
395P33 Augmentin PO 625 mg TDS for 13 days  3.47 45.06 
 
      
395P36 Augmentin IVI 1.2 g TDS for 13 days 37.56 488.28 
 
Vancomycin IVI 1 g TDS for 2 days  140.90 281.81 
 
Vancomycin IVI 1 g daily for 3 days  46.97 140.90 
 
Vancomycin IVI 1 g BD for 4 days  93.94 375.74 
 
Cefepime IVI 1 g BD for 2 days  40.92 81.84 
 
  
  
Total 
 
13412.76 69554.23 
  
 159 
 
8.7.2 NHLS Laboratory Test Cost Calculation  
Table 39: Cost of Each NHLS Laboratory Test that Isolated MRSA per Patient in the 
Orthopaedic Ward in 2013 
Patient 
Number 
Laboratory 
Test  
Number 
Cost (R) 
Total Price 
(R) Microscopy 
Culture and 
Sensitivity 
 
       
 369P03 LT601 36.93 291.22 328.15 
  LT602 36.93 139.29 176.22 
  LT603 36.93 139.29 176.22 
  LT604 36.93 291.22 328.15 
  LT605 36.93 291.22 328.15 
  LT606 36.93 291.22 328.15 
 
       
 369P09 LT607 36.93 315.05 351.98 
  LT608 36.93 223.2 260.13 
 
       
 369P12 LT609 36.93 291.22 328.15 
  LT610 36.93 291.22 328.15 
 
       
 369P15 LT611 36.93 223.2 260.13 
 
       
369P06 LT612 36.93 223.2 260.13 
  LT613 36.93 351.4 388.33 
 
       
 369P08 LT614 36.93 419.21 456.14 
  LT615 36.93 356.28 393.21 
  LT616 36.93 356.28 393.21 
  LT617 36.93 199.46 236.39 
  LT618 36.93 322.27 359.20 
  LT619 36.93 498.03 534.96 
  LT620 36.93 555.87 592.80 
 
       
 369P13 LT621 36.93 223.2 260.13 
 
       
 369P14 LT622       
  LT623       
         
 369P02 LT624 36.93 223.2 260.13 
 
       
 369P04 LT625 36.93 223.2 260.13 
 
       
369P16 LT626 38.41 232.13 270.54 
 
       
 369P05 LT627 36.93 199.46 236.39 
  LT628 36.93 532.04 568.97 
 
       
 369P10 LT629 36.93 223.2 260.13 
  LT630 36.93 281.04 317.97 
 
       
 369P07 LT631 36.93 267.39 304.32 
  LT632 36.93 351.39 388.32 
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 369P01 LT633 36.93 291.22 328.15 
  LT634 36.93 291.22 328.15 
  LT635 36.93 291.22 328.15 
  LT636 36.93 291.22 328.15 
  LT637 36.93 291.22 328.15 
  LT638 36.93 291.22 328.15 
  LT639 36.93 223.2 260.13 
  LT640 36.93 471.74 508.67 
  LT641 36.93 81.45 118.38 
  LT642 36.93 291.22 328.15 
 
       
 369P11 LT643 36.93 555.87 592.80 
  LT644 36.93 315.05 351.98 
  LT645 36.93 291.22 328.15 
  LT646 36.93 315.05 351.98 
 
       
Total   1626.40 13117.72 14744.12 
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Table 40: Cost of Each NHLS Laboratory Test that Isolated MRSA per Patient in the 
Vascular Ward in 2013 
Patient 
Number 
Laboratory 
Test 
Number 
Cost (R) 
Total Price 
(R) Microscopy 
Culture and  
Sensitivity 
 
       
395P02 LT501 36.93 599.94 636.87 
 
LT502 36.93 433.07 470.00 
 
       
395P03 LT503 36.93 409.24 446.17 
 
LT504 36.93 223.2 260.13 
 
       
395P04 LT505 36.93 223.2 260.13 
 
       
395P05 LT506 36.93 532.04 568.97 
 
       
395P06 LT507 36.93 223.2 260.13 
 
LT508 36.93 316.96 353.89 
 
LT509 36.93 247.03 283.96 
 
       
395P07 LT510 38.41 267.5 305.91 
 
LT511 38.41 278.09 316.50 
 
       
395P08 LT512 36.93 592.08 629.01 
 
       
395P09 LT513 36.93 223.2 260.13 
 
       
395P11 LT514 36.93 131.44 168.37 
 
       
395P12 LT515 36.93 223.2 260.13 
 
       
395P13 LT516 36.93 223.2 260.13 
 
LT517 36.93 223.2 260.13 
 
       
395P14 LT518 36.93 317.39 354.32 
 
LT519 38.41 232.13 270.54 
 
LT520 38.41 498.79 537.20 
 
LT521 38.41 291.58 329.99 
 
       
395P16 LT522 36.93 623.47 660.40 
 
LT523 36.93 280.37 317.30 
 
       
369P17 LT524 38.41 341.84 380.25 
 
       
395P18 LT525 36.93 223.2 260.13 
 
LT526 36.93 440.28 477.21 
 
       
395P19 LT527 36.93 247.03 283.96 
 
       
395P20 LT528 36.93 291.22 328.15 
 
LT529 36.93 315.05 351.98 
 
       
395P21 LT530 36.93 341.22 378.15 
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LT531 36.93 317.39 354.32 
 
       
395P22 LT532 36.93 479.38 516.31 
 
       
395P23 LT533 36.93 223.2 260.13 
 
       
369P24 LT534 36.93 510.64 547.57 
 
       
395P25 LT535 36.93 351.4 388.33 
 
LT536 36.93 288.26 325.19 
 
       
395P28 LT537 36.93 223.2 260.13 
 
       
395P29 LT538 38.41 232.13 270.54 
 
       
395P30 LT539 36.93 356.27 393.20 
 
LT540 36.93 233.38 270.31 
 
       
395P31 LT541 36.93 579.7 616.63 
 
       
395P32 LT542 38.41 354.96 393.37 
 
       
395P33 LT543 
   
 
       
395P36 LT544 36.93 291.22 328.15 
 
LT545 36.93 521.86 558.79 
 
       
Total   1636.76 14776.35 16413.11 
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8.7.3 Antibiotic Utilization plus NHLS Laboratory Tests Cost Calculation    
Table 41: Total Cost of Antibiotics Administered plus NHLS Laboratory Tests 
Conducted that Isolated MRSA per Patient in the Orthopaedic Ward in 2013 
Patient 
Number 
Total Cost (R) 
Antibiotic 
Utilization 
Laboratory 
Test 
Antibiotic Plus 
Laboratory Test 
        
369P03 2418.56 1665.04 4083.60 
        
369P09 978.58 612.11 1590.69 
        
369P12 11926.85 656.30 12583.15 
        
369P15 1246.66 260.13 1506.79 
        
369P06 3851.81 648.46 4500.27 
        
369P08 4338.20 2965.91 7304.11 
        
369P13 307.18 260.13 567.31 
        
369P14 1431.67 0.00 1431.67 
        
369P02 2228.84 260.13 2488.97 
        
369P04  1201.56 260.13 1461.69 
        
369P16 470.36 270.54 740.90 
        
369P05 1011.25 805.36 1816.61 
        
369P10 2512.50 578.10 3090.60 
        
369P07 2684.58 692.64 3377.22 
        
369P01 4209.32 3184.23 7393.55 
        
369P11 5987.08 1624.91 7611.99 
        
Total  46804.99 14744.12 61549.11 
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Table 42: Total Cost of Antibiotics Administered plus NHLS Laboratory Tests 
Conducted that Isolated MRSA per Patient in the Vascular Ward in 2013 
Patient 
Number 
Total Cost (R) 
Antibiotic 
Utilization 
Laboratory 
Test 
Antibiotic Plus 
Laboratory Test 
        
395P02 15092.31 1106.87 16199.18 
        
395P03 933.66 706.30 1639.96 
        
395P04 1511.40 260.13 1771.53 
        
395P05 4156.8 568.97 4725.77 
        
395P06 5921.98 897.98 6819.96 
        
395P07 1439.20 622.41 2061.61 
        
395P08 1200.00 629.01 1829.01 
        
395P09 8669.95 260.13 8930.08 
        
395P11 1830.24 168.37 1998.61 
        
395P12 51.45 260.13 311.58 
        
395P13 233.62 520.26 753.88 
        
395P14 1231.32 1492.05 2723.37 
        
395P16 1809.55 977.70 2787.25 
        
395P17 225.36 380.25 605.61 
        
395P18 1657.75 737.34 2395.09 
        
395P19 704.47 283.96 988.43 
        
395P20 8.00 680.13 688.13 
        
395P21 6270.04 732.47 7002.51 
        
395P22 1055.16 516.31 1571.47 
        
395P23 3544.29 260.13 3804.42 
        
395P24 394.416 547.57 941.99 
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395P25 3916.214 713.52 4629.73 
        
395P28 375.67 260.13 635.80 
        
395P29 508.20 270.54 778.74 
        
395P30 4381.70 663.51 5045.21 
        
395P31 16.25 616.63 632.88 
        
395P32 1001.6 393.37 1394.97 
        
395P33 45.06 0.00 45.06 
        
395P36 1368.58 886.94 2255.52 
    
Total  69554.23 16413.11 85967.34 
 
 
 166 
 
APPENDIX 8 
8.8 Decision-Tree-Analytic Models in Rollback  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Rollback of Actual Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in 
the Orthopaedic Ward  
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Figure 38: Rollback of Equal Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in 
the Orthopaedic Ward  
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Figure 39: Rollback of Actual Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in 
the Vascular Ward  
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Figure 40: Rollback of Equal Decision-Tree-Analytic Model Showing the Management Pathways for a Patient with a Suspected Infection in 
the Vascular Ward 
 170 
 
APPENDIX 9 
8.9 Threshold Analysis  
Table 43: Threshold Analysis for the Actual Decision-Tree-Analytic Model in the Orthopaedic Ward 
Variable 
Variable 
Value (R)  
Strategy 1 Strategy 2 
Expected 
Value (R) 
cSpecimenM 76.41 Empiric Antibiotic & Specimen For MCS Specimen For Xpert MRSA 1178.32 
cSpecimenCS 718.89 Empiric Antibiotic & Specimen For MCS Specimen For Xpert MRSA 1102.60 
cDailyMrsaSpecificAntibiotic 412.83 Specimen For Xpert MRSA Empiric Antibiotic & Specimen For MCS 1304.53 
cDailyEmpiricAntibiotic 57.83 Empiric Antibiotic & Specimen For MCS Specimen For Xpert MRSA 1149.20 
cXpertMRSA 332.76 Specimen For Xpert MRSA Empiric Antibiotic & Specimen For MCS 1203.56 
 
Table 44: Threshold Analysis for the Actual Decision-Tree-Analytic Model in the Vascular Ward 
Variable 
Variable 
Value (R) 
Strategy 1 Strategy 2 
Expected 
Value (R) 
cDailyEmpiricAntibiotic 214.63 Empiric Antibiotic & Specimen For MCS Specimen For MCS 851.43 
cDailyMrsaSpecificAntibiotic 26.33 Specimen For MCS Empiric Antibiotic & Specimen For MCS 790.85 
cDailyOtherAntibiotic 153.22 Specimen For MCS Empiric Antibiotic & Specimen For MCS 790.85 
cXpertMRSA 233.67 Specimen For Xpert MRSA Empiric Antibiotic & Specimen For MCS 790.85 
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Table 45: Threshold Analysis for the Equal Decision-Tree-Analytic Model in the Orthopaedic Ward 
Variable 
Variable 
Value (R) 
Strategy 1 Strategy 2 
Expected 
Value (R) 
pSpecimenSentMCS 0.97 Empiric Antibiotic Specimen For MCS 675.78 
 
Table 46: Threshold Analysis for the Equal Decision-Tree-Analytic Model in the Vascular Ward 
Variable 
Variable 
Value (R) 
Strategy 1 Strategy 2 
Expected 
Value (R) 
cDailyEmpiricAntibiotic 359.62 Empiric Antibiotic Specimen For MCS 572.28 
pMrsaIsolated 0.19 Specimen For MCS Empiric Antibiotic 256.98 
pSpecimenSentMCS 0.75 Empiric Antibiotic Specimen For MCS 453.19 
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